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I N T R O D U C T I O N 
The most widely used therapies for cancer in addition to surgery are chemotherapy 
and radiotherapy. Over the past decades, cancer therapy has evolved from these non-
targeted approaches to cancer specific strategies, including immunotherapy. The term 
‘immunotherapy’ encompasses a wide variety of strategies, which can be categorized into 
‘passive’ or ‘active’ therapies, based on their capacity to induce immunological memory. 
Passive immunotherapy uses mainly monoclonal antibodies (mAbs) to directly target 
antigens on specific cell surfaces, including cancer cells. In 1997, the CD20-targeting mAb 
rituximab was the first mAb to be approved by the U.S. Food and Drug Administration 
(FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic 
for treatment, and antibody therapy has become well-established in the treatment of 
cancer, especially in hematological malignancies. The field of antibody therapy is still 
continuously evolving, and numerous innovative antibody-based therapies are under 
(pre)clinical investigation. 
A N T I B O DY  T H E R A P Y
Naturally, antibodies are produced by B-cells as a polyclonal population, with high 
specificity for their distinct target antigen and epitope. Antibodies thereby play various 
important roles in our immune system. The field of therapeutic Abs commenced in 1975, 
when the development of the mouse hybridoma technology enabled the production 
of large amounts of murine monoclonal Abs (1). However, murine mAbs elicited an 
immunogenic response in human patients. To reduce this immunogenicity, chimeric 
mAbs, consisting of a constant human domain fused to a variable mouse domain were 
developed (2). The development of advanced design technologies such as human 
antibody-gene expression libraries and transgenic animals allowed the engineering of 
humanized (the hypervariable region of a murine antibody grafted in a human antibody) 
and fully human mAbs (3). For application in the clinic, mAbs generally require additional 
engineering to improve their affinity, limit any biophysical liabilities, and to increase their 
half-life. The clinical success of mAbs as cancer therapeutics lies in their ability to induce 
various cytotoxic machineries against specific targets. These cytotoxic machineries 
include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular 
phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), which are all 
mediated via the fragment crystallizable (Fc) domain of mAbs, and direct anti-tumor 
cytotoxicity. The therapeutic potential of mAbs is being exploited by the development of 
strategies to engineer the antibody Fc region in order to increase these Fc-tail mediated 
effector functions and induce tumor cytotoxicity more effectively. In addition, antibody-
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based products are developed that take advantage of specific antigen binding properties 
of antibodies to precisely target cytotoxic cells or toxic agents to cancerous cells, such 
as bispecific antibodies, antibody drug conjugates and chimeric antigen receptors 
(CARs). In this thesis the focus will be on two specific antibody engineering strategies: 
Fc-engineered mAbs and bispecific antibodies. 
A N T I B O DY  S T R U C T U R E
Antibodies are mono- or polymers of immunoglobulins (Ig) consisting of two identical 
pairs of heavy (H) and light (L) chains, which are linked through non-covalent 
interactions and disulfide bonds to form a Y-shaped structure (4). All H and L light chains 
contain a single variable domain (V
L
), which also consists of hypervariable regions. 
The combination of the (hyper) variable regions of the H and L chains determines 
the antigen specificity and affinity of an antibody. The L chains contain a single constant 
(C
L
) domain to make a stable link with the H chain. The number of constant domains 
of H chain (C
H
) is dependent on the isotype of the antibody: IgA, IgD and IgG contain 
three (C
H
1-3), and IgE and IgM contain four constant domains (C
H
1-4) C domains. The first 
C
H
 is linked with C
L
 to the variable regions, which together form the fragment antigen 









a flexible hinge region and constitute the Fc region (Figure 1A). 
F C - E F F E C TO R  F U N C T I O N S
Upon antigen engagement, IgG antibodies can induce direct anti-tumor effects via 
triggering of the cell death signaling pathways and via blockade of essential receptor 
systems, as well as indirect anti-tumor effects via their Fc-mediated effector functions, by 
engaging other immune cells or killer mechanisms. The Fc- mediated effector functions 
ADCC, ADCP, and CDC, have been shown to be crucial for the therapeutic efficacy of most 
clinically-approved antibodies (Figure 1B). There are four IgG subclasses (IgG1-IgG4), 
which differ in structure and function. IgG1 and IgG3 induce the strongest Fc-effector 
functions (5). However, since IgG1 has the longest half-life and is more stable than IgG3 
(6), most therapeutic antibodies with Fc-mediated functions are of IgG1 isotype. 
ADCC/ADCP
The IgG1-induced ADCC and ADCP response is mediated via binding to Fc gamma 
receptors (FcγR), which are expressed on innate effector cells, including monocytes, 
monocyte-derived cells, basophils, mast cells and natural killer (NK) cells. The FcγR family 
consists of the activating FcγRI (CD64), FcγRIIa (CD32a), FcγRIIIa (CD16a), and FcγRIIIb 















































































































































































































































































































































































































































































































































the most potent inducers of ADCC. NK cells as well as monocytes and macrophages 
express FcγRIIIa, however, only NK cells exclusively express FcγRIIIa (7). Triggering of 
FcγRIIIa induces phosphorylation of immunoreceptor tyrosine-based activation motifs 
(ITAMs), which activates a downstream signaling cascade resulting in the release of 
cytotoxic granules containing perforin and granzyme in the immune synapse formed 
between the NK cell and the target cell, leading to target cell death (8). In contrast to 
NK cells, the phagocytic monocytes, neutrophils and macrophages co-express activating 
and inhibitory FcγRs. ADCP can be induced by various activating FcγRs including FcγRIIIa 
(CD16a), FcγRIIa (CD32A), and FcγRIIIb (CD16b), which all signal via ITAMs, and may be 
inhibited by FcγRIIb (CD32b), which signals via immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs). The balance of activating and inhibitory signaling dictates ADCP induction, 
which occurs via internalization and degradation of the antibody-opsonized target by 
the phagocyte (9). 
Both FcγRIIa and FcγRIIIa are known to exist as two allotypic variants, which exert 
different affinities for IgG1. These FcyR polymorphisms are associated with clinical 
response for several clinical-approved mAbs including the anti-CD20 antibody 
rituximab, the anti-HER2 antibody trastuzumab, and the anti- epidermal growth 
factor receptor (EGFR) antibody cetuximab. A higher response rate was observed in 
patients carrying the FcγRIIa-131 H/H and the FcγRIIIa-158 V/V compared to the 131R 
and 158F carriers (10-12).
CDC
Therapeutic IgG1 antibodies can activate the classical pathway of the complement system 
by binding of the Fc region to the complement protein C1q, which initiates a cascade of 
proteolytic cleavage steps. This results in formation of the membrane attack complex 
(MAC), consisting of the complement products C5b to C9. The MAC generates pores 
in the cell membrane which initiates target cell lysis, termed complement-dependent 
cytotoxicity (CDC) (13). Similar to FcγRII-III, the affinity of C1q for IgG-Fc is low and binding 
is dependent on multivalent IgG-antigen immune complexes to provide sufficient avidity 
(14-16). The ability of IgG1 antibodies to activate the complement pathway is highly 
dependent on antigen density, size and fluidity (17-19). High-resolution crystallography 
studies have recently revealed that, dependent on such factors, specific non-covalent 
interactions between IgG Fc-domains induce ordered hexamer formation (mAb 
hexamerization) on the cell surface that provides a docking platform for the six-globular 
headed C1q molecule, and thereby efficiently activate the complement pathway (20). 
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F C - E N G I N E E R I N G  TO  E N H A N C E  F C - E F F E C TO R 
F U N C T I O N S
The hinge and the proximal C
H
2 regions of the Fc-tail are considered critical for Fc-
interaction with FcγRs and C1q. The interface of these regions contains the binding sites 




domain allows engagement of FcγR or C1q. 
In addition, the C
H
2 domains are post-translationally modified by asparagine(N)297-
linked glycosylation, and glycosylation and the specific glycan composition contribute 
to the stability and the dynamics of the C
H
2 domains (21-23). Glycan components include 
core units of N-acetylglucosamine (GlcNAc) and mannose, with additional variations in 
galactose, bisecting GlcNAc, fucose and sialic acid. 
Detailed understanding of Fc-interactions with C1q and FcγR opened up opportunities 
to modulate C1q- and FcγR- binding by Fc-engineering. In order to enhance ADCC, ADCP 
and CDC, studies have employed site-directed mutagenesis (sequence variations), Fc-
glycosylation modification (glycoengineering), and avidity modulation, which will be 
outlined below. 
Enhancing ADCC
Glycoengineering to enhance FcγR affinity
Fc glycosylation is required for binding the low affinity FcγR (24, 25). Hence, altering 
the specific composition of the Fc glycan can modulate the affinity for FcγR. The removal 
of core fucose (afucosylation) has been shown to highly increase FcγRIIIa binding affinity 
and consequently increase ADCC (26, 27) (Figure 2A). This effect has been attributed to 
an interaction between the Fc-glycan and the N-glycan attached to Asn 162 of the FcγRIIIa 
(28-31). Afucosylation is widely accepted as an effective approach to increase the potency 
of IgG1 antibodies to induce ADCC. 
Site directed mutagenesis to enhance FcγR affinity
FcγRs interact with IgGs via residues Leu234–Ser239 on the lower hinge of the Fc and 
residues Asp265–Glu269, Asn297–Thr299 on the C
H
2 domain of the Fc tail (32, 33). 
Numerous positions within or in close proximity of this binding region can be mutated 
to improve FcγR binding affinity: S298A/E333A/K334A, S239D/I332E, and P247I/A339Q were 
shown to enhance binding affinity for FcγRIIIa, including the lower-affinity polymorphic 
variant (F158) of FcγRIIIa, and induce higher ADCC levels (34-36).
Structural analyses of the Fc-FcγR interaction have revealed that the Fc binding to 
FcγR is asymmetrical: the receptor binds to different residues on each Fc-domain. Hence, 
applying mutations to Fc regions asymmetrically (Fc-heterodimers) also improved C
H
2 
domain stability and consequently the FcγRIIIa binding as compared to a symmetrical-
mutated Fc-variant (37, 38).  
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Figure 2. Fc-engineering strategies to enhance Fc-effector functions. (A) The biantennary 
complex glycan structure of the most frequent variants for the N-glycan of therapeutic IgG (G0F, 
G1F, G2F and fully processed). Glycoengineering strategies focus on afucosylation for enhanced 
ADCC and galactosylation for enhanced CDC . (B) ADCC/ADCP (left) and CDC (right) enhancing 
point mutations depicted in the crystal structure of the Fc region (PDB:3DO3). The ADCC-enhancing 
mutations S298A/E333A/K334A, S239D/I3332E and P247I/A339Q are depicted in magenta, the ADCP-
enhancing mutations F234L/R292P/Y300L/V305I/P396L, A330L and G236A are shown in blue. A330L 
and G236A were added to the ADCC-enhancing mutations S239D/I332E to decrease the mutation-
related increase in affinity to the inhibitory receptor FcγRIIb. The CDC-enhancing mutations E345G 
and E430G, which induce Fc:Fc interactions and subsequent mAb hexamerization (see E), are 
shown in orange and K326W/E333S and S267E/H268E/S324T, which enhance C1q binding affinity, 
are shown in pink. (C) Schematic representation of three Fc-multimerization strategies which are 
aimed to enhance ADCC and ADCP. (D) Cross-isotype antibody generated by replacing the C
H
2 and 
part of the C
H
3 domains of an IgG1 antibody with the corresponding regions of an IgG3 antibody, to 
increase the CDC response. (E) Schematic representation of mAb hexamerization which facilitates 
C1q binding and enhances CDC, and can occur upon antigen binding by IgG1 antibodies naturally or 




In comparison to affinity modulation, avidity modulation is a less established but more 
straightforward approach. Fc duplication (or tandem-Fc) or multiplication, whereby 
multiple Fcs are linked within one IgG1 molecule, has been shown to augment FcγR binding 
avidity and increase ADCC and ADCP (39-42) (Figure 2C). A theoretical safety concern for 
Fc-multiplication strategies is the fact that natural antibody oligomerization may result 
in unwanted immune activation (43). However, studies have reported minimal in vitro 
aggregation and no in vivo adverse events so far (40, 42). 
Enhancing ADCP
Glycoengineering to enhance FcγR affinity
Strategies enhancing ADCC via increased affinity for FcγRIIIa on NK cells can also enhance 
ADCP via increased antibody binding to monocytes and macrophages, since these cells also 
express FcγRIIIa. ADCP induced by neutrophils can be improved as well since neutrophils 
express FcγRIIIb, which shares 97% sequence homology with FcγRIIIa. It has indeed been 
demonstrated that afucosylated mAbs can induce higher levels of ADCP (44, 45). 
Site directed mutagenesis to enhance FcγR affinity
Different than ADCC, ADCP induction is highly dependent on the balance of binding to 
the activating receptors versus the inhibitory receptor FcγRIIb. Since the activating FcγRIIa 
shares 90% similarities with the inhibitory FcγRIIb (46), increasing FcγRIIa-binding may 
increase FcγRIIb binding as a consequence, with a negative impact on ADCP induction as 
a result. An unwanted increase in FcγRIIb binding was indeed observed after employing 
the ADCC-enhancing mutations S239D/I332E (35). Creating mutation A330L and/or G236A 
was required in the combination of S239D/I332E to enhance ADCP (47, 48). Alternatively, 
selectively increasing FcγRIIa binding was achieved by mutations F243L/R292P/Y300L/
V305I/P396L and G236A (47, 49)(Figure 2B). 
Fc-multimerization
Fc-multimerization strategies are not FcγR-specific. Therefore such strategies will enhance 
the binding of mAbs to other low affinity FcγRs, including to the inhibitory FcγRIIb. 
Nonetheless, it appeared possible to increase FcγRIIa binding and ADCP by Fc-multimers 
(40, 50). However, since binding to the inhibitory FcγRIIb was also increased (40), Fc-
multimerization strategies presumably require further Fc-engineering to optimally 




Glycoengineering to enhance C1q binding affinity
Whereas afucosylation significantly enhances ADCC and ADCP by facilitating 
the interaction with the FcγRIIIa glycan, it minimally affects CDC (51). Instead, galactose is 
the key glycan for C1q binding. Numerous studies demonstrated enhanced C1q binding 
and CDC by Fc-galactosylation (51-54) (Figure 2A). Molecular interactions between 
galactose and amino acid residues on the C
H
2 domains possibly increase C1q binding 
affinity (55). It has also been suggested that Fc-glycosylation modulates Fc:Fc interactions 
and thereby affects not the affinity but avidity of C1q binding (56). 
Site directed mutagenesis to enhance C1q binding affinity
The first structural analysis studies revealed that the residues D270, K322, P329 and P331 
of the C
H
2 domain were critical for the interaction with C1q (57, 58). More recently, it has 
been shown that there are two main interaction sites: residues 266-272 and 294-300 on 
one C
H
2 domain and residues 325-331 on the other (59). Mutations in residues located on 
or in proximity of these binding sites significantly affected C1q binding: the double mutant 
K326W/E333S and triple mutant S267E/H268E/S324T enhanced C1q binding and CDC (60, 
61) (Figure 2B). The hinge region also plays a role in complement activation, because this 
region affects the flexibility of the Fc tail, thereby determining the ability to fix C1q. Indeed 
certain mutations in the upper hinge region could enhance C1q binding and CDC (62). 
Cross-Isotype antibodies
Although both IgG1 and IgG3 can effectively activate complement, IgG3 antibodies can 
bind C1q more effectively (63). Therefore, cross-isotype antibodies have been generated 




3 domains of an IgG1 antibody with the corresponding regions 
of an IgG3 antibody, which increased the CDC response (64) (Figure 2D). 
B I S P E C I F I C  A N T I B O D I E S 
Antibodies are bivalent but monospecific molecules: their two Fab-arms bind to 
the same epitope on an antigen. Bispecific antibodies (bsAbs) were developed to allow 
the targeting of two different epitopes by one antibody construct. The majority of these 
bsAbs are designed as T-cell engagers. By directing one antigen-binding site to the CD3 
receptor on T-cells and another antigen-binding site to a tumor-associated antigen, 
bsAbs can redirect the cytotoxic T-cells to the tumor cell to induce T-cell mediated 
cytotoxicity. Although it is possible to produce bsAbs in one expression cell line using 
biochemical techniques (i.e. reduction and oxidation), the 4 heavy and light chains from 
the two different antibodies associate in random combinations, and thus a poor yield of 
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the desired functional bsAb product is obtained (65). Several engineering technologies 
have been developed to overcome this so-called chain-association issue, resulting in 
many different bsAb formats. These formats can be categorized into fragment-based 
bsAbs and Fc-retained bsAbs. 
Fragment-based bispecific antibodies
Fragment-based bsAbs completely bypass the chain-association issue as they are 
composed only of antigen-binding fragments and lack the Fc-region. The variable 
domains of one heavy and one light chain of an antibody are linked together into one 
single-chain variable fragment (scFv) (66), and crosslinked with another scFv to form 
the fragment-based bsAb. Multiple scFvs can be combined to increase the number of 
binding sites for each antigen and increase the binding avidity. The clinically most-
advanced fragment-based bsAb formats are the bispecific T-cell engager (BiTE), 
the dual-affinity re-targeting proteins (DARTs) and tandem diabodies (TandAbs) 
(67-69) (Figure 3). 
Fc-retained bispecific antibodies
A disadvantage of the fragment-based bsAb formats is the shortened half-life, as this will 
require a higher dosing frequency, which results from the missing Fc region. To retain 
the Fc-region while still circumventing the chain-association issues, various asymmetric 
and symmetric bsAb formats were developed. The clinically most-advanced asymmetric 
bsAb formats include the Triomab and knobs-into-holes (KiH)/CrossMab,which both 
enforce correct chain pairing. The Triomab format enforces correct chain pairing by 
combining full-size IgG-like half antibodies of two different species. For the knobs-into-
holes (KiH) approach the CH3 domains of the heavy chains are asymmetrically engineered 
to create a ‘knob’ in one chain while a ‘hole’ is generated in the other chain, allowing 
heterodimerization of two different heavy chains (70, 71). Light chain mispairing however 
still occurred with this technology, which led to the development of the CrossMab format 
as addition to the KiH platform. Correct chain pairing is enforced by exchanging the light 
and heavy chain domains of one fab arm (72). Numerous symmetrical bsAb formats 
have also been developed. To generate symmetrical bsAb formats while circumventing 
the chain-associate issue, the two desired Fab arms are engineered into a single 
polypeptide chain or heavy/light chain pair, allowing one single Fab-arm to bind to two 
antigens simultaneously. The clinically most advanced symmetric bsAb formats include 
two-in-one or dual-action-Fab (DAF) and Dual Variable Domain (DVD) (73, 74) (Figure 3).
For Fc-retained T-cell engaging bsAbs the Fc-tail is often modified to abrogate Fc-
effector functions. To silence Fc effector functions similar but opposed strategies can be 




























































































































































































B - C E L L  M A L I G N A N C I E S
The term B-cell malignancies comprises a heterogeneous group of diseases, including 
the B-cell proliferative disorders  B-cell Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (B-NHL), B-cell chronic lymphocytic leukemia (B-CLL) and the plasma cell 
proliferative disorder multiple myeloma (MM), of which our focus will be on B-NHL, 
B-CLL and MM.  At present, the World Health Organization (WHO) classification of 
haematological malignancies recognizes around 100 subtypes of NHL based on clinical, 
histologic, immunophenotypic, and genetic features (75). The most common B-NHL 
subtypes include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle 
cell lymphoma (MCL), marginal zone lymphoma (MZL) and Burkitt lymphoma (BL), which 
all have specific tumor characteristics and differ in aggressiveness and incidence. B-CLL is 
classified as a leukemia as the malignant B cells are predominantly present in the peripheral 
blood. Multiple myeloma (MM) is a malignancy of plasma cells that accumulate in 
the bone marrow. In these B-cell malignancies a wide variety of disease-associated targets 
are available, including various lineage specific surface molecules, which allow for tumor 
cell targeting by mAbs. Below we have summarized the Fc-engineered and bispecific 
antibodies that are in clinical development for treatment of B-cell malignancies.
B-CLL and B-NHL
The CD20-targeting chimeric mAb rituximab was the first mAb to be approved by 
the FDA for cancer therapy in 1997 and targeting CD20 is currently still part of the first-
line of immune-chemotherapy regimens for patients with B-NHL and B-CLL, as it has 
proven to prolong overall survival significantly in DLBCL, FL and CLL (76-78). CD20 is 
expressed on almost all healthy and malignant B-cells, but is not expressed by precursor 
B-cells and plasma cells, making it a suitable therapeutic target for B-cell malignancies 
(79). Although rituximab is capable of both ADCC/ADCP and CDC induction, multiple 
antibody engineering strategies have been explored to enhance the effector functions 
of CD20-targeting mAbs. The FDA-approved second generation CD20-targeting mAb 
ofatumumab binds to a different CD20 epitope than rituximab, and allows binding closer to 
the cell membrane which enhances CDC (80). The FDA-approved third generation CD20-
targeting mAb obinutuzumab (GA101) is glycoengineered (afucosylated) and thereby 
enhances ADCC (81). In addition, other Fc-engineered CD20-targeting antibodies are 
evaluated in clinical trials including the glycoengineered ublituximab and the Fc-mutated 
ocaratuzumab (AME-133v; LY2469298), PRO131921 (RhuMAb v114), and ocrelizumab, which 
were all designed to enhance ADCC (82-87). CD20 is also explored as target in the context 
of bsAbs, and various CD20-targeting bsAb formats are being developed (88-92). 
However, many patients still demonstrate or develop resistance against CD20-targeting 
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therapies (93, 94), and several other targets are currently being investigated for targeting 
by Fc-engineered antibodies or bispecific T-cell engagers including CD37, CD19, BAFF-R, 
CD22, CD25 and CD79b.
Similar to CD20, CD37 is expressed on all mature B-cells, but absent or expressed at 
very low levels on stem cells, precursor B-cells and plasma cells (95, 96). Several CD37-
targeting therapeutics are clinically evaluated for B-NHL and CLL, including several 
immunoconjugates but also the Fc-engineered antibody BI 836826 (Mab 37.1) that induces 
higher levels of ADCC (97, 98). 
CD19 expression is restricted to the B-cell lineage but is in contrast to CD20 also 
expressed on precursor B-cells. CD19 is highly expressed in B-NHL and several leukemia’s, 
including CLL and ALL. Unmodified CD19 targeting antibodies induce limited ADCC/ADCP 
and CDC, partly because they are rapidly internalized (99). CD19 is therefore mostly used 
as target for ADCs or T-cell engagers, such as bsAbs or chimeric antigen receptor (CAR) 
T-cells. The success of CD19 targeting bsAbs is demonstrated by the FDA approval of 
blinatumomab, a CD19/CD3 BiTe format, for the treatment of B-cell acute lymphoblastic 
leukemia (ALL). Blinatumomab and novel CD19xCD3 bispecific antibodies with extended 
half-life are now investigated in CLL and B-NHL (100-102). In addition to CD19-targeting 
bsAbs, some Fc-engineered CD19-targeting antibodies are also clinically evaluated. 
The CD19-targeting afucosylated mAbs inebilizumab (MEDI-551) and MDX-1342 and the Fc-
mutated (S239D/I332E) mAb tafasitamab (MOR208; XmAb5575) all enhance ADCC levels in 
vitro relative to native CD19 mAbs (103-105). Tafasitamab has been granted accelerated 
FDA approval in combination with lenalidomide for patients with relapsed DLBCL.
B cell–activating factor (BAFF) is an immunomodulatory cytokine which regulates B- 
cell survival and activation. BAFF can bind to three receptors although only one of them 
binds BAFF with high specificity: the BAFF-receptor (BAFF-R) (106). BAFF-R is expressed 
on almost all normal and malignant B-cells, but not on pre-B-cells, and is therefore 
considered an appropriate target for B-CLL and B-NHL. Ianalumab (VAY736; B-1239) is 
a BAFF-R targeting glycoengineered (afucosylated) ADCC-enhancing antibody currently 
in clinical evaluation for CLL (107, 108). 
CD22, CD25, and CD79b are also clinically evaluated as target, either by naked 
mAbs, immunotoxins and antibody-drug conjugates, however not by Fc-engineered or 
bispecific antibody formats (109, 110). 
MM
The CD38-targeting mAb daratumumab highly improved treatment outcome of MM 
patients since its registration in 2019. CD38 is an attractive target for MM due to its high and 
uniform expression on MM cells, while its expression on myeloid and lymphoid cells and in 
non-hematopoietic tissue is relatively low. Daratumumab induces MM-cell cytotoxicity via 
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ADCC, ADCP and CDC, in addition to direct cell death (111). A second CD38-targeting mAb, 
isatuximab, has recently also been approved by the FDA and two other CD38-targeting 
unmodified mAbs, TAK-097 and MOR202, are currently under clinical evaluation. CD38 is 
also the target of various CD3-redirecting bispecific antibodies, including AMG424, which 
is currently tested in phase I, and GBR1342, which was granted orphan drug designation by 
the FDA. Other potential targets for MM include CD19, SLAMF7, BCMA and GPRC5D. 
While CD19 is generally considered to be absent on plasma cells, it has been shown 
that some MM cells express CD19 at extremely low density which sufficed for targeting by 
CAR T-cell therapy (112). Consequently, blinatumomab and Fc-engineered CD19-targeting 
mAbs are also being investigated for treatment of MM. 
B-cell maturation antigen (BCMA; CD269; TNFRSF17) plays a significant role in 
the differentiation of B-cells to plasma cells and is required for plasma cell longevity (113). 
BCMA expression is specific for plasma cells, and MM cells even overexpress BCMA (114). 
Multiple T-cell engagers targeting BCMA are currently being clinically evaluated including 
various formats of BCMA targeting bispecific antibodies. While BCMA-targeting CAR-T 
cell therapy is expected to receive approval for clinical application soon, most BCMA-
targeting CD3-redirecting bsAbs are in phase I clinical trial evaluation (115). In addition to 
T-cell engagers, the glycoengineered (afucosylated) BCMA-targeting ADCC-enhancing 
mAb SEA-BCMA is currently evaluated in a phase 1 safety study (116).  
The function of the G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) 
in MM is poorly characterized. Still, it is considered an appropriate target for MM 
due a high expression on MM cells, lower expression on B-cells, and no expression on 
other hematopoietic cells (117). The GPRC5D expression on normal tissue is limited to 
hard-keratinized structures, such as nails (118). Currently, one GPRC5D-targeting CD3-
redirecting bsAb is tested in phase 2 clinical trials. 
FcRL5 (CD307) expression is restricted to the B-cell lineage where it regulates 
B-cell receptor (BCR) signaling (119). The first bsAb targeting FcRL5 is currently being 
investigated in a phase 1 dose escalation study. 
The clinically-approved mAb elotuzumab targets CD319 (or SLAMF7), an immune 
regulatory protein of the signaling lymphocyte activation molecule (SLAM) family (120). 
SLAMF7 is expressed on several lymphocytes but overexpressed on plasma cells (121). 
Several CD319-targeting CAR T-cells are currently in clinical evaluation, but CD319-
targeting bsAbs have not yet entered clinical trials. 
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T H E  D U O B O DY  A N D  H E X A B O DY  T E C H N O LO G Y 
TO  TA R G E T  B - C E L L  M A L I G N A N C Y  A S S O C I AT E D 
A N T I G E N S
Despite the vast increase of Fc-engineered and bispecific antibodies as well as other novel 
targeted therapies into clinical development and application there is still a high unmet 
clinical need for patients with B-NHL and CLL and patients with MM. CD20-targeting 
antibodies have drastically changed the survival rates of patients with B-NHL and CLL. 
However, there are still limited treatment options for patients that relapse from or are 
refractory to CD20-targeting therapies. For MM many new treatments have become 
available over the last decades, including proteasome inhibitors, immunomodulatory 
drugs and antibody-based therapies. Still, MM remains an incurable disease for most 
patients and especially relapsed or refractory patients with high-risk cytogenetics have 
a poor prognosis. To offer better or alternative treatment options for these patients, novel 
antibody engineering technologies are being explored. In this thesis we focus on two 
novel engineering strategies: the DuoBody platform as bispecific antibody technology 
and HexaBody platform as novel Fc-engineering strategy. 
DuoBody Technology
The DuoBody Technology is a relatively novel asymmetric bsAb format and entails 
a controlled fab-arm exchange, which mimics the naturally occurring fab-arm exchange 
for IgG4 antibodies. The controlled fab-arm exchange is achieved for IgG1 by engineering 
two different IgG1 antibodies with single matched point mutations at the CH3:CH3 
interface. When subjected to reducing conditions the IgG1 molecules form half-molecules 
and subsequently re-associate in the desired bispecific format (122, 123) (Figure 3B). 
The DuoBody format is unique compared to the other bsAb formats especially in light of 
its easy production and manufacturing protocols, which are similar to that of conventional 
IgG antibodies.
The HexaBody Technology
The HexaBody Technology has been designed in order to facilitate C1q binding and 
increase CDC level. It is based on the finding that antibody hexamers facilitate C1q 
binding, the essential first step in complement pathway activation. With the HexaBody 





3 interface that stimulate the Fc:Fc interactions between antibodies and facilitate 
the natural concept of antibody hexamerization, leading to superior C1q binding and 
enhanced CDC (20, 124) (Figure 2B,E). Since Fc-hexamerization by these specific point-
mutations only occurs upon antigen binding on the cell surface, antibodies generated by 
the HexaBody platform retain the pharmacokinetics of conventional IgG1 antibodies.
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S C O P E  O F  T H I S  T H E S I S
In this thesis we describe the therapeutic potential of antibodies generated by 
the DuoBody and HexaBody platform for specific B-cell malignancies, including B-cell 
chronic lymphocytic leukemia (B-CLL), B-cell non-hodgkin lymphoma (B-NHL) and 
multiple myeloma (MM). We studied the mechanisms of action of these antibodies and 
their preclinical efficacy, and strived to fulfill the unmet clinical needs in B-cell malignancies 
by focusing on the efficacy in samples from relapsed/refractory patients. We also aimed 
to increase the probability of clinical success of these antibodies, by seeking for specific 
characteristics of patient, tumor or effector cells that could predict their efficacy. 
In chapter 2 we focused on the DuoBody-platform to redirect CD3+ T-cells to CD20+ 
B-NHL cells and explored the efficacy of this DuoBody-CD3xCD20 or ‘’epcoritamab’’ in 
B-NHL patient samples. We examined the sensitivity of cells from patients with different 
B-NHL subtypes, also in relapsed/refractory setting, and evaluated tumor- and T-cell 
characteristics that could predict sensitivity to epcoritamab.
In chapter 3 we examined whether antibodies targeting CD20 and CD37 that harbored 
the E430G HexaBody mutation could induce complement-dependent cytotoxicity in 
malignant B-cells, either as single HexaBodies or in combination. 
In chapter 4 we further explored CD37 as target for CLL and B-NHL. 
In part I we tested a panel of CD37-targeting E430G-harboring mAbs, either as single 
mAb, in combination or as biparatopic antibodies, and selected DuoHexaBody-CD37 as 
most promising candidate. 
In part II we investigated the preclinical efficacy of DuoHexaBody-CD37 in a wide 
range of CLL and B-NHL newly diagnosed and relapsed or refractory patient samples. 
While the HexaBody platform was originally designed to induce complement pathway 
activation, the antibody hexamerization that is enhanced by this technology can be 
employed for other pathways that benefit from this clustering. One of these pathways is 
the extrinsic apoptotic pathway, which becomes activated once death receptors cluster on 
the cell surface. In chapter 5 we studied HexaBody-DR5/DR5: a combination of two death 
receptor 5 targeting IgG1 antibodies that both harbor the HexaBody mutation to induce 
apoptotic pathway activation via receptor clustering. We investigated the mechanism of 
action and preclinical efficacy of HexaBody-DR5/DR5 in multiple myeloma. 
Chapter 6 summarizes and discusses the most important results of this thesis.  
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Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody 
redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical 
efficacy of epcoritamab against primary tumor cells present in the lymph node 
biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. 
In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent 
activity against primary tumor cells, irrespective of prior treatments, including 
CD20 mAbs. Median lysis  of 65%, 74% and 84% were achieved in diffuse large 
B-cell lymphoma (n=16), follicular lymphoma (n=15) and mantle cell lymphoma 
(n=8), respectively. Furthermore, in this allogeneic setting, we discovered that 
the capacity of B-cell tumors to activate T-cells was heterogeneous and showed 
an inverse association with their surface expression levels of the immune 
checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous 
setting, when lymph node (LN)-residing T-cells were the only source of effector 
cells, the epcoritamab-dependent cytotoxicity strongly correlated with local 
effector cell-to-target cell ratios. Further analyses revealed that LN-residing- 
or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor 
T-cells equally mediated epcoritamab-dependent cytotoxicity. These results 
show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/




I N T R O D U C T I O N
The B-cell specific marker CD20, which is expressed on all mature B-cells, but absent 
on hematopoietic stem cells, pro-B-cells and plasma cells (1), is an attractive target for 
the treatment of B-cell malignancies, including B-cell non-Hodgkin lymphomas (B-NHL). 
Consequently, over the past decades, several CD20-targeting monoclonal antibodies 
(mAbs), including rituximab and subsequent-generation CD20-mAbs, have been 
successfully applied for the treatment of B-NHL, often in combination with chemotherapy 
(2). Nonetheless, a high incidence of disease relapse occurs after treatment with currently 
available CD20-targeting mAbs, urging the development of more innovative and powerful 
therapies targeting CD20. While conventional mAbs can eliminate target cells via several 
mechanisms, they do not exploit the powerful cytotoxic machinery of T-cells, which can 
induce long-term remissions in several hematopoietic cancers and solid tumors, provided 
that they are efficiently and specifically targeted to tumor cells (3, 4). Hence, major efforts 
are devoted to developing efficient chimeric antigen receptors (CARs) and T-cell engagers 
targeting CD20 (5-11). Epcoritamab (DuoBody®-CD3xCD20, GEN3013) is a novel full-length 
IgG1 bispecific antibody (bsAb) redirecting CD3+ T-cells to CD20 expressing cells (7, 12, 
13). In an initial study, we have shown that epcoritamab induces potent T-cell-mediated 
cytotoxicity towards B-cell NHL cell lines in vitro and in vivo (7). In the dose-escalation part 
of an ongoing first-in-human clinical trial, epcoritamab showed a favorable safety profile 
and preliminary efficacy data indicate encouraging anti-tumor activity as a single agent, 
including complete responses, in patients with R/R DLBCL or FL (14).
Here, we investigated the preclinical activity of epcoritamab using primary tumor 
cells obtained from lymph node (LN) or bone marrow (BM) biopsies samples of patients 
with diffuse large B-cell lymphoma (DLBCL; n=16), follicular lymphoma (FL; n=15) and 
mantle cell lymphoma (MCL; n=8). The patients were newly diagnosed (ND) or relapsed/
refractory (RR) to conventional treatment regimens, including anti-CD20 mAbs. We 
investigated (i) the intrinsic sensitivity of tumor cells to epcoritamab-dependent T-cell-
mediated cytotoxicity and the capacity of tumor cells to activate T-cells, ii) whether type 
of malignancy and prior exposure to CD20-targeted therapy influenced their sensitivity, 




M AT E R I A L  A N D  M E T H O D S 
Cell lines
B-NHL cell lines (Daudi; ATCC and WSU-DLCL2; DSMZ) were cultured in RPMI-1640 
(Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen) 
and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA, USA). Cell lines were 
authenticated by STR-profiling and tested for mycoplasma contamination.
Patient samples
Single cell suspensions from LN biopsies were isolated by mechanical disruption as 
described in supplemental files. Mononuclear cells of BM (BMMCs) or PB (PBMCs) were 
isolated by Ficoll density-gradient centrifugation. Cells were either used directly or 
cryopreserved in liquid nitrogen until further use. This type of study does not require 
approval from an ethics committee. All patient material and clinical data were collected 
according to the code of conduct for medical research developed by The Council of 
the Federation of Medical Scientific Societies (FEDERA). 
Phenotyping by Flow cytometry
Multicolor flow cytometry was used to identify CD19+ and/or CD20+ B-cells, CD3+CD4+ and 
CD3+CD8+ conventional T-cells and CD3+CD4+CD25+CD127low/- regulatory T-cells. Malignant 
B-NHL cells were identified within the total B-cell population on light chain restriction 
and on tumor-specific combinations with CD markers such as CD5 and CD10 when 
relevant. When indicated, CD20 expression was quantified on malignant B-cells using 
an indirect immunofluorescence assay (QIFIKIT®, Agilent Technologies, Santa Clara, CA, 
USA). Additionally, cell suspensions were phenotyped for immune checkpoint ligands 
and receptors, including programmed death-ligand 1 (PD-L1), HLA-DR, herpesvirus entry 
mediator (HVEM), programmed cell death protein 1 (PD-1), T-cell immunoglobulin and 
mucin domain-containing protein 3 (TIM-3), lymphocyte-activation gene 3 (LAG-3) and B- 
and T-lymphocyte attenuator (BTLA). Further details are provided in supplemental files. 
Cytotoxicity assays
Violet tracer (Thermo Fisher, Waltham, MA, USA) labeled target cells were pre-incubated 
with serial dilutions of antibodies for 15 minutes in 96-well u bottom plates and then 
cultured for 24 hours without additional effector cells or with effector cells at a fixed (10:1) 
T-cell to target (E:T) cell ratio. Effector cells were allogeneic or autologous effector PBMCs 
or, from specified samples, CD3+ lymph node-residing T-cells, isolated using magnetic-
activated-cell sorting (MACS) following the manufacturer’s instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Viable target cells were identified with multi-color flow 
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cytometry. Data were analyzed using FACS DIVA software. Cytotoxicity was calculated only 
if >500 viable target cells were counted in untreated wells and with the following formula: 
Further details are described in supplemental files.  
The concentration of granzyme B released in cell-free supernatants of cytotoxicity 
assays was measured by a sandwich ELISA kit (Mabtech, Nacka Strand, Sweden) following 
manufacturer’s protocol. 
Multiplexed immunofluorescence (mIF)
Multiplexed immunofluorescence was performed on 4 µm-thick formalin-fixed, 
paraffin-embedded whole tissue sections using the Opal 7-color fluorescence 
immunohistochemistry kit (Akoya biosciences, Menlo Park, CA, USA). Further details are 
provided in supplemental files.
Statistics
Dose-response curves were generated and half maximal effective concentration (EC
50
) 
values calculated using non-linear regression analysis (sigmoidal dose-response) 
(Graphpad Prism 8.2). Comparisons between variables were performed using Mann-
Whitney U-test, Wilcoxon matched-pairs signed rank test or unpaired t-test for analysis 
of two groups, and Kruskal-Wallis with Dunn’s multiple comparions test for analysis of 
multiple groups. Two-sided P values < 0.05 were considered statistically significant.
R E S U LT S
Epcoritamab induces potent cytotoxicity in the presence of healthy donor PBMCs
To determine the sensitivity of B-NHL cells to epcoritamab, independent of interpatient 
variation in effector T-cell frequency or function, malignant cells obtained from B-NHL 
patients were exposed to epcoritamab in the presence of PBMCs of a single healthy 
donor as a source of effector cells at a fixed 10:1 effector (T-cell) to target (malignant cell) 
ratio. At a concentration of 30 ng/mL, epcoritamab mediated effective and comparable 
levels of cytotoxicity in DLBCL (median 65%; range 0-93%; n=16), FL (median 69%; range 
42-87%; n=15), and MCL (median 84%; range 61-96%; n=8) samples. In 37/39 samples 
the EC
50













samples,  CD3+  lymph  node‐residing  T‐cells,  isolated  using magnetic‐activated‐cell  sorting 97 
(MACS)  following  the  manufacturer’s  instructions  (Miltenyi  Biotec,  Bergisch  Gladbach, 98 
Germany). Viable  target  cells were  identified with multi‐color  flow  cytometry. Data were 99 
analyzed using FACS DIVA software. Cytotoxicity was calculated only if >500 viable target cells 100 
were counted in untreated wells and with the following formula:  101 
% 𝑐𝑐�𝑛𝑛𝑜𝑜𝑛𝑛𝑜𝑜�𝑛𝑛𝑐𝑐𝑛𝑛𝑛𝑛� � �100 � % 𝑛𝑛𝑛𝑛𝑛𝑛�𝑛𝑛𝑠𝑠𝑛𝑛𝑛𝑛�� 102 







Figure 1. Epcoritamab mediates comparable levels of cytotoxicity in various B-NHL subtypes 
and in ND and RR samples, including samples from patients who received prior CD20-antibody 
containing treatment. (A) Percentages cytotoxicity mediated by epcoritamab and CD3xCtrl 
(30 ng/mL) and (B) EC
50
 values (ng/mL), shown for samples with clear dose-response curves, for 
cytotoxicity in the presence of allogeneic PBMCs (E:T ratio 10:1) in ND and RR DLBCL (n=16), FL (n=15) and 
MCL (n=8) samples (median ± interquartile range), including patients who relapsed from or were refractory to 
CD20 therapy (  and  , respectively). Statistical analysis was performed with Kruskal-Wallis and Dunn’s multiple 
comparisons test to compare epcoritamab with CD3xCtrl for each indication (*p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001) and epcoritamab-dependent cytotoxicity between subtypes (ns (C) CD20 expression (antibody 
molecules per cell) on tumor cells in samples from B-NHL patients unexposed to prior CD20 therapy correlated 
to epcoritamab-dependent cytotoxicity (30 ng/mL) (Spearman’s; ns). (D) Time between last CD20-therapy 
and moment of lymph node biopsy (months) of patients previously treated with CD20-antibody containing 
treatment (n=8) correlated to cytotoxicity mediated by epcoritamab (30 ng/mL) (Spearman’s; r=0.78, *p=0.03).
significant differences between DLBCL, FL and MCL in this cohort (median; range: 0.32; 
0.04-3.7ng/mL in DLBCL, 0.42; 0.11-2.1 ng/mL in FL, and 0.89; 0.20-4.0 ng/mL in MCL) 
(Figure 1A-B). Epcoritamab was effective in samples from ND patients (median 73%; range 
0-96%; n=24) as well as in samples from RR patients (median 73%; range 42-95%; n=15). 
Importantly, even if patients received prior CD20-targeted therapy, i.e. rituximab and/or 
obinutuzumab, epcoritamab mediated effective cytotoxicity (median 74%; range 42-95%; 
n=10) (Figure 1A-B). CD20 expression levels on tumor cells in CD20-naïve patient samples 
did not correlate with epcoritamab-dependent cytotoxicity (Figure 1C). The relation 
between target expression and cytotoxicity was not explored for R/R patient samples, as 
target expression could not be reliably quantified due to potential residual membrane-
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Figure 2. T-cell activation by epcoritamab does not correlate strongly with cytotoxic 
activity. (A) Gating of CD4+ and CD8+ cells and example of a flow histogram for CD69 positivity and 
(B) percentages of CD69-positive CD4+ and CD8+ allogeneic T-cells after treatment of B-NHL samples with 
epcoritamab and CD3xCtrl (30 ng/mL) (median ±interquartile range). (C) Granzyme B levels (pg/mL) in 
supernatants of coculture of B-NHL sample and allogeneic T-cells stimulated with epcoritamab and CD3xCtrl 
(30 ng/mL) (median ±interquartile range). (D,E) Correlation between percentage CD69-positive (CD4+ and 
CD8+) allogeneic T-cells (D) or granzyme B release (pg/mL) (E), and cytotoxicity induced by epcoritamab (30 
ng/mL) (Spearman’s; ns and r=0.35; *p=0.04, respectively). All samples from different B-NHL subtypes and from 
ND and RR are plotted together. 
bound CD20 mAbs (rituximab or obinutuzumab). In CD20 mAb-exposed patient 
samples, sensitivity to epcoritamab correlated with the elapsed time between the last 
CD20-therapy and the LN biopsy (range: 2 weeks – 5 years; r=0.78; *p=0.03; Figure 1D). 
However, most relevant for clinical application is the observation that epcoritamab could 
induce 42% cytotoxicity in an FL sample that was collected only two weeks after the last 
anti-CD20 therapy. 
T-cell activation by epcoritamab does not correlate strongly with cytotoxicity of 
B-NHL cells
While epcoritamab consistently mediated cytotoxicity in B-NHL cells, we observed 
considerable heterogeneity in epcoritamab-induced T-cell activation, as assessed by 
the induction of CD69 (%) on CD4+ and CD8+ T-cells, and in total granzyme B release 
(Figure 2A-C). Although we observed a significant correlation between T-cell activation 
and granzyme B production (Supplemental figure 1), there was no significant correlation 
between T-cell activation and killing of malignant cells. A weak but significant correlation 
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was observed between granzyme B levels and epcoritamab-dependent cytotoxicity 
(r=0.35, *p=0.04) (Figure D-E). Remarkably, although in some samples very high levels of 
granzyme B release were observed, the cytotoxicity was relatively low. This suggests that 
tumor cell-intrinsic resistance mechanisms may play a role in sensitivity to epcoritamab-
dependent cytotoxicity. We observed resistance to epcoritamab-dependent cytotoxicity, 
despite high T-cell activation, for 1 ND DLBCL sample. 
T-cell activation in presence of epcoritamab shows an inverse association with 
tumor cell HVEM expression levels 
To understand the differences in capacity of B-NHL cells to activate healthy donor 
T-cells in the presence of epcoritamab, we investigated the association between B-NHL 
subtype, treatment status, and CD20 expression level and between expression of ligands 
of the immune checkpoint molecules PD-1, LAG3 and BTLA: PD-L1, HLA-DR and HVEM 
(tumor necrosis factor receptor superfamily member [TNFRSF]14), with allogeneic T-cell 
activation. No association between T-cell activation and B-NHL subtype or treatment 
status was observed (Supplemental figure 2), nor between T-cell activation and tumor 
expression of CD20, PD-L1 or HLA-DR (Supplemental figure 3). Activation of allogeneic 
CD4+ and CD8+ T-cells was highest in patients that showed low expression of HVEM (i.e. 
comparable to healthy donor B cells) on B-NHL cells (Figure 3A). T cell activation was 
significantly lower in patients that showed higher tumor HVEM expression, potentially 
indicating tumor cell-mediated immune suppression in these samples. However, no 
relation between HVEM expression and epcoritamab-dependent cytotoxicity was 
observed (Figure 3B). 
Figure 3. Lower T-cell activation by epcoritamab in presence of tumor cells with high 
expression of the immune regulatory molecule HVEM. (A) CD69-positive CD4+ and CD8+ allogeneic 
T-cells after treatment of B-NHL samples with epcoritamab (30 ng/mL) and CD3xCtrl (30 ng/mL) in samples 
with low or high tumor HVEM expression levels (Mann-Whitney U-test; ***p<0.001, **p<0.01). (B) Epcoritamab-
dependent cytotoxicity (30ng/mL) in B-NHL samples with low and high tumor cell HVEM expression (Mann-
Whitney U-test; ns). HVEM expression on healthy donor B-cells was used as cut-off value to stratify between 
low and high expression. Data are shown as median ±interquartile range. All samples from different B-NHL 
subtypes and from ND and RR are plotted together.
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B-NHL LN T-cells induce epcoritamab-dependent cytotoxic activity 
After determining the intrinsic sensitivity of B-NHL cells to epcoritamab-dependent 
cytotoxicity, we assessed the anti-tumor activity of epcoritamab in B-NHL samples 
in the autologous setting, without addition of PBMCs, thus exclusively depending on 
lymph node-residing autologous T-cells. In this setting, we observed low to moderate 
levels of cytotoxicity in DLBCL (median 20%; range 0-46%; n=15), FL (median 17%; range 
0-46%; n=15) and MCL (median 0%; range 0-11%; n=8) (Figure 4A), which were overall 
lower response levels than in the allogeneic setting. To understand the lower levels of 
cytotoxicity in the autologous setting, we analyzed the phenotype and frequency of 
T-cells derived from B-NHL patient samples. The samples from FL patients contained 
significantly higher CD4:CD8 T-cell ratios compared to samples from DLBCL and MCL 
patients (Figure 4B), but not specifically higher frequencies of CD4+ regulatory T-cells 
(Supplemental figure 4). Both PD-1 bright and dim CD4+ T-cell populations were observed 
in FL samples (Figure 4C), consistent with the reported presence of PD-1 bright follicular 
CD4+ T-helper cells (15). Nonetheless, the phenotypic differences among B-NHL 
subtypes showed no association with the observed cytotoxicity levels. However, we 
observed a strong correlation between the frequency of total CD3+ T-cells present in 
the single cell suspensions and epcoritamab-dependent cytotoxicity (r=0.63; ****p<0.0001) 
(Figure 4D). This correlation was less profound, but still significant, in the case of 
CD3+CD8+ cytotoxic T-cells and CD3+CD4+ T-helper cells (r=0.46; **p=0.004 and r=0.57; 
***p=0.0002, respectively) (Supplemental figure 5). To confirm that the T-cell content of 
single cell suspensions used in experiments depicted in Figure 4A-D was representative 
for the intact LN biopsies, we performed multiplexed immunofluorescence (mIF) analyses. 
Here, similar numbers of CD4+ and CD8+ T-cells were found in matched FFPE LN biopsies 
(n=23) (Supplemental figure 6).
We next studied whether CD3+ T-cells in the B-NHL microenvironment showed 
any deficiencies in their capacity to induce epcoritamab-dependent kill of B-NHL 
cells, by comparing MACS sorted T-cells from four DLBCL, five FL LN biopsies and four 
healthy donor PBMCs. T-cells from B-NHL LN biopsies mediated comparable levels of 
epcoritamab-dependent cytotoxicity as T cells-cell from healthy individuals against two 
different B-NHL cell lines (Daudi and WSU-DLCL2 ) at three different E:T ratios (Figure 4E). 
These results indicated the sufficient capacity of T cells derived from B-NHL biopsies to 
mediate epcoritamab-dependent cytotoxicity. 
B-NHL peripheral blood T-cells induce epcoritamab-dependent cytotoxicity
The presence of low T-cell numbers in the tumor microenvironment of B-NHL patients 
suggested that the efficacy of epcoritamab in vivo might depend on infiltration of 


























































































































































































































































































































































































































































































































































































































































































































































































































































































blood T-cells from B-NHL patients were capable of mediating epcoritamab-dependent 
cytotoxicity. In all available samples (n=5), patient-derived PBMCs showed comparable 
capacity to induce epcoritamab-dependent cytotoxicity as healthy donor PBMCs (median 
of 54% versus 66% cytotoxicity (p=ns), respectively) (Figure 5A-B). All together, these 
results indicate that there were no apparent intrinsic dysfunctions in peripheral blood 
and LN-derived T-cells from B-NHL patients which could negatively affect the efficacy of 
epcoritamab in the clinical setting.
D I S C U S S I O N
In this study, we evaluated the preclinical efficacy of epcoritamab, a novel full-length IgG1 
CD3 bsAb that triggers T-cell-mediated cytotoxicity of CD20-positive tumor cells (7). 
First, using T-cells from a single healthy donor as effector cells, we explored the intrinsic 
sensitivity of tumor cells from different B-NHL subtypes to epcoritamab and their capacity 
to activate T-cells. We demonstrate that epcoritamab mediated high levels of cytotoxicity 
against tumor cells from patients with B-NHL (DLBCL, FL and MCL). We observed some 
heterogeneity in the level of epcoritamab-dependent cytotoxicity, which could not be 
explained by CD20 expression levels or B-NHL subtype. Importantly, epcoritamab was 
equally effective in samples from ND patients and from RR patients, including patients 
who relapsed from or were refractory to prior anti-CD20-therapy. In RR patients there 
was a weak but significant correlation between epcoritamab-dependent cytotoxicity 
and the time elapsed since the last anti-CD20-treatment was given to the patients. It is 
known that anti-CD20 mAbs can be present in the circulation for long periods of time, 
and therefore could compete with epcoritamab for antigen binding (16, 17). However, 
largely ruling out this possibility, it has recently been shown that the potency of 
Figure 5. The intrinsic capacity of T-cells from peripheral blood of B-NHL patients to induce 
cytotoxicity is comparable to that of healthy donor T-cells. (A) Dose-response of and (B) 
maximal cytotoxicity induced by epcoritamab in B-NHL cells in the presence of allogeneic healthy 
donor PBMCs or autologous B-NHL patient PBMCs in a 10:1 E:T ratio (n=5; Wilcoxon matched-pairs 
signed rank test; ns).
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epcoritamab in vivo is not affected by a large excess of rituximab in the circulation (7). 
Another explanation for the observed correlation could be the CD20 mAb induced CD20 
down-modulation, although CD20 expression after CD20 mAb treatment was reported 
to be fairly stable in the majority of lymphoma patients (18-20). CD20 expression levels 
could however not be reliably assessed in this study, due to competition of the detection 
antibody with potential residual membrane-bound CD20 mAb. Nevertheless, we still 
observed a substantial response of 42% to epcoritamab in a sample that was collected 
only 2 weeks after last exposure to CD20-treatment, indicating that epcoritamab can be 
effective even if it is administered shortly after discontinuing treatment with a CD20 mAb. 
Another interesting observation in our study is the heterogeneity in the level of 
activation in allogeneic T cells after exposure to B-NHL in the presence of epcoritamab. 
As one single donor was used in the experiments, differences may not be attributed to 
intrinsic differences in the allogeneic T cell population. Conversely, this approach did 
allow to investigate intrinsic differences in B-NHL studied. PD-L1 or HLA-DR expression 
in B-NHL did not show a correlation with T-cell activation. Interestingly, we observed an 
inverse association of T-cell activation levels with expression of the immune checkpoint 
molecule HVEM on tumor cells. Hence, this observation indicates that immune 
checkpoint pathways may play a role in modulation of T-cell functionality. Furthermore, 
the lack of a strong correlation between T-cell activation and granzyme B release with 
epcoritamab-dependent cytotoxicity indicates the involvement of yet unknown intrinsic 
resistance mechanisms in B-NHL cells against the cytotoxic activity of T-cells. Remarkably, 
these resistance mechanisms are especially visible when CD20 expression levels are 
relatively lower, which suggests that higher target expression can overcome these 
resistance mechanisms. These observations warrant further investigation. It would be 
interesting to investigate the possibility of increasing the level of target expression or 
T-cell activation to potentially overcome the intrinsic resistance.
In this study we also performed a detailed analysis of the B-NHL patients’ own 
T-cells to gain deeper insight into their capacity to mediate epcoritamab-dependent 
cytotoxicity. Without the addition of PBMCs, we observed that epcoritamab-dependent 
cytotoxicity correlated significantly with the local frequency of CD3+ T-cells in the LN. 
T-cells residing in LN showed no functional deficiencies, as evidenced by the fact that 
they were capable of inducing sufficient levels of epcoritamab-dependent cytotoxicity 
especially at effector to target ratios higher than 3:1. In addition, autologous peripheral 
blood T-cells from B-NHL patients as well as from healthy individuals induced comparable 
levels of tumor cell kill in the presence of epcoritamab. Thus, T-cells present in the LN 
tumor microenvironment, as well as T-cells isolated from the peripheral blood of B-NHL 
patients possess adequate capacity to mediate epcoritamab-dependent cytotoxicity. Our 
results suggest that the recruitment of sufficient peripheral blood T cells into the LN will 
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be required for optimal clinical efficacy of epcoritamab. Alternatively, local expansion of 
tumor-resident T cells may contribute to anti-tumor activity in patients.
In conclusion, we have demonstrated induction of effective T-cell-mediated 
cytotoxicity by epcoritamab against primary B-NHL cells and thereby provide preclinical 
proof-of-concept for the treatment of B-NHL patients with epcoritamab, including 
patients who relapsed after prior CD20-mAb containing treatment. Moreover, we show 
that peripheral blood or tumor-resident T cells from B-NHL patients show excellent 
capacity to induce T-cell-mediated cytotoxicity in presence of epcoritamab. These data 
support the single-agent activity of epcoritamab demonstrated in the ongoing first 
in human trial (NCT03625037, (14)) in patients with relapsed, progressive or refractory 
B-cell lymphoma, and warrant further investigation of specific biomarkers that may be 
correlated with response to epcoritamab.
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S U P P L E M E N TA L  I N F O R M AT I O N 
Lymph node (LN) suspension cells
LN biopsies were mechanically disrupted into small fragments and cultured in RPMI 1640 
+ 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) in a fully humidified incubator 
at 37˚C, 5% CO
2 
for 16 hours. The supernatant was filtered using a 70 µM Easy Strainer 
(Greiner Bio-one, Alphen aan den Rijn, the Netherlands) to collect the malignant B-cells, 
T-cells and other cells diffused out of the biopsy fragments.  
Normalization of flow-based phenotyping
Median fluorescence intensity (MFI) values were normalized to expression levels on B – 
and T-cells of a single healthy donor whose PBMCs were measured parallel to each B-NHL 
sample, to minimize inter-experimental variations. The expression levels on B- and T-cells 
of this healthy donor were also used as cut-off value to stratify between low and high 
expression levels on B-NHL cells. PD-1 expression was defined as dim and bright if two 
clear separate populations were observed.
Flow cytometry-based cytotoxicity assays
In the flow cytometry-based cytotoxicity assays violet tracer-negative allogeneic CD3+ 
donor T-cells or violet tracer-positive CD3+ patient T-cells were examined for expression 
of the T-cell activation marker CD69. 
All antibodies and markers used in flow cytometry-based B- and T-cell phenotyping 
and cytotoxicity assays are depicted in Table 1.
Multiplexed immunofluorescence (mIF)
Slides were deparaffinized and rehydrated, followed by a blocking step for endogenous 




/methanol and fixation with 10% neutral buffered formalin 
(Leica Biosystems, Nußloch, Germany). Slides were washed in Milli-Q water and 0.05% 
Tween20 in 1x Tris-Buffered Saline (TBS-T). Antigen retrieval was done by placing 
the slides in 0.05% ProClin300 (Sigma-Aldrich, Saint Louis, MO, USA)/Tris–EDTA buffer pH 
9.0 in a microwave at 100% power until boiling point, followed by 15 min at 30% power. 
Slides were cooled in Milli-Q water, washed in 1x TBS-T and blocked with Antibody Diluent 
(Agilent Technologies, Santa Clara, CA, USA). The slides were then incubated with primary 
antibody diluted in Normal Antibody Diluent, followed by incubation with the broad 
spectrum horseradish peroxidase (HRP) from the SuperPicture Polymer Detection Kit 
(Life Technologies, Carlsbad, CA, USA). Next, the slides were incubated with Opal TSA 
fluorochromes (Akoya biosciences, Menlo Park, CA, USA) diluted in amplification buffer 
(Akoya biosciences). The primary and secondary antibody complex was stripped by 
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Table 1. Antibodies used in flow cytometry for tumor and T-cell phenotyping and cytotoxicity assays
Target Label Assay Company
CD20 V450 Tumor phenotyping BD Horizon
CD19 PC7 Tumor phenotyping Beckman Coulter
CD45 Krome Orange Tumor phenotyping 
Cytotoxicity 
Beckman Coulter
Kappa PE Tumor phenotyping DAKO
Lambda FITC Tumor phenotyping Emelca Bioscience
CD274 BV786 Tumor phenotyping BD 
HLA-DR APC-H7 Tumor phenotyping BD 
CD270 BV711 Tumor phenotyping BD 
CD5 APC Tumor phenotyping BD 
CD10 APC Tumor phenotyping BioLegend
Live/dead BUV455 Tumor phenotyping Invitrogen
CD3 BUV395 T-cell phenotyping BD 
CD4 APC-H7 T-cell phenotyping   
Cytotoxicity 
BD 
CD8 PC7 T-cell phenotyping BD 
CD279 BV605 T-cell phenotyping BioLegend
CD25 FITC T-cell phenotyping BioLegend
CD366 PE T-cell phenotyping BD 
CD272 V450 T-cell phenotyping BD 
CD127 PE-CF594 T-cell phenotyping BD 
CD223 APC T-cell phenotyping BD 
CD197 BV786 T-cell phenotyping BD 
CD45RA AF700 T-cell phenotyping BD 
7-AAD T-cell phenotyping Cytotoxicity BD 
CD2 BV786 Cytotoxicity BD 
CD8 APC R700 Cytotoxicity BD 
CD19 BUV737 Cytotoxicity BD 
CD25 PE Cytotoxicity DAKO
CD69 FITC Cytotoxicity BioLegend
CD, cluster of differentiation; V, violet; PC7, phycoerythrin cyanin 7; PE, phycoerythrin; FITC, fluorescein 
isothiocyanate; BV, briljant violet; HLA, human leukocyte antigen; APC, allophycocyanin; H7, cyanine 7 (Cy7); BUV, 
briljant ultraviolet; AF, alexa fluor; 7-AAD, 7-amino-actinomycin D 
microwave treatment with 0.05% ProClin300/Tris–EDTA buffer at pH 9.0. The combination 
of primary antibody and fluorescent dyes is indicated in table 2, in order of staining. Finally, 
DAPI working solution (Akoya biosciences) was applied and the slides were mounted with 
Prolong Diamond Anti-fade mounting medium (#P36965; Life Technologies).
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Table 2. Antibodies used in multiplexed immunofluorescence
Marker Clone (Company) Dilution Opal fluorophore
PD-1 EH33 (Cell signaling) 1:500 Opal520
CD8 C8/144B (Agilent) 1:1000 Opal620
CD3 CD3 (Agilent) 1:500 Opal690
PD-L1 22C3 (Agilent) 1:100 Opal650
PAX5 24/PAX-5 (BD Biosciences) 1:100 Opal570
CD163 10D6 (Novocastra) 1:500 Opal540
PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PAX5, paired box 5
Image acquisition and quantification
Stained slides were scanned using the Vectra Polaris Automated Quantitative Pathology 
Imaging System (Akoya biosciences). For each sample, representative tumor regions 
were selected and six 2x2 fields of view were acquired at 40x resolution. After image 
capture, the images were spectrally unmixed and analyzed, using supervised machine 
learning algorithms within Inform 2.4.1. (Akoya biosciences). In brief, individual cells were 
located and segmented to be able to perform analysis on a per-cell basis. Cells were 
then assigned into four different phenotype categories: “T-cell”, “tumor”, “macrophage” 
or “other”, based on the size of the cells and positivity of markers in the panel. In 
the training phase, cells representative for each category were manually selected after 
which the algorithm predicts the phenotype for all remaining cells. To improve accuracy, 
phenotypes were checked and adjusted when necessary. The training was applied to 
all six images of each sample. Thresholds for positive staining were determined for 
all markers. Data was exported and custom R scripts were used to further stratify cells 
within the phenotype categories, based on thresholds of positivity. Specifically for T-cells: 
T-helper cells (CD3+CD8-PD1- and CD3+CD8-PD1+) and cytotoxic T-cells (CD3+CD8+PD1- and 
CD3+CD8+PD1+). For tumor, macrophages and other, cells were further stratified into 
PD-L1 negative and PD-L1 positive. Phenotypes were then summarized per sample using 
the phenoptr R package (1). 
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Supplemental figure 2. Epcoritamab induces similar levels of allogeneic T-cell activation in 
the presence of different subtypes of ND and RR B-NHL. (A,B) CD69 positive CD4+ and CD8+ 
allogeneic T-cells upon epcoritamab treatment (30 ng/mL) in the presence of B-NHL samples for 
different subtypes and for ND and RR. Data are shown as median ± interquartile range.
Supplemental figure 1. T-cell activation correlates with release of granzyme B. Spearman’s 
correlation of epcoritamab-mediated (30 ng/mL) CD69 positivity on CD4+ and CD8+ allogeneic 
T-cells and granzyme B release (pg/mL) by these T-cells in the presence of B-NHL cells 
(****p<0.0001). 
S U P P L E M E N TA L  F I G U R E S
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Supplemental figure 5. Epcoritamab-dependent cytotoxicity correlates with both CD4:Target 
and CD8:Target ratios. Spearman’s correlation of epcoritamab-dependent cytotoxicity (30 ng/mL) 
in B-NHL samples with the ratios of CD8+ T-cells to target cell (left) and CD4+ T helper cells to target 
cell (right) (r=0.46; **p=0.004 and r=0.57; ***p=0.0002, respectively). 
Supplemental figure 4. Comparable frequencies of regulatory T-cells in different B-NHL 
subtypes. Percentage of CD25+CD127low/- regulatory T-cells in the CD4+ T-cell population in DLBCL, 
FL and MCL samples. Data are shown as median ± interquartile range (Kruskal-Wallis with Dunn’s 
multiple comparisons test; ns).  
Supplemental figure 3. (A-C) CD69-positive allogeneic CD4+ and CD8+ T-cells induced by 
epcoritamab (30 ng/mL) in B-NHL samples with low and high tumor cell CD20 (A), PD-L1 (B) and 
HLA-DR expression (C) (Mann-Whitney U-test; ns). Median CD20 expression (antibody molecules 
per cell), defined on samples of ND patients, was used to stratify between low and high CD20 
expressing ND samples. PD-L1 and HLA-DR expression on healthy donor B-cells was used as cut-off 




R E F E R E N C E S
1. Johnson KS. Phenoptr:inForm Helper Functions. R package version 0.2.5. 2020.
Supplemental figure 6. T-cell content of single cell suspensions is representative for intact 
LN biopsies. Spearman’s correlation of flow cytometry-based T-cell frequencies in lymph node 
suspension cells with multiplexed immunofluorescence (mIF)-based T-cell frequencies in lymph 
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A B S T R AC T
CD20 monoclonal antibody therapies have significantly improved the outlook 
for patients with B-cell malignancies. However many patients acquire resistance, 
demonstrating the need for new and improved drugs. We previously demonstrated 
that the natural process of antibody hexamer formation on targeted cells allows 
for optimal induction of complement-dependent cytotoxicity. Complement-
dependent cytotoxicity can be potentiated by introducing a single point mutation 
such as E430G in the IgG Fc domain that enhances intermolecular Fc-Fc interactions 
between cell-bound IgG molecules, thereby facilitating IgG hexamer formation. 
Antibodies specific for CD37, a target that is abundantly expressed on healthy 
and malignant B cells, are generally poor inducers of complement-dependent 
cytotoxicity. Here we demonstrate that introduction of the hexamerization-
enhancing mutation E430G in CD37-specific antibodies facilitates highly potent 
complement-dependent cytotoxicity in chronic lymphocytic leukemia cells ex vivo. 
Strikingly, we observed that combinations of hexamerization-enhanced CD20 and 
CD37 antibodies cooperated in C1q binding and induced superior and synergistic 
complement-dependent cytotoxicity in patient-derived cancer cells compared 
to the single agents. Furthermore, CD20 and CD37 antibodies colocalized on 
the cell membrane, an effect that was potentiated by the hexamerization-
enhancing mutation. Moreover, upon cell surface binding, CD20 and CD37 
antibodies were shown to form mixed hexameric antibody complexes consisting 
of both antibodies each bound to their own cognate target, so-called hetero-
hexamers. These findings give novel insights into the mechanisms of synergy in 
antibody-mediated complement-dependent cytotoxicity and provide a rationale 
to explore Fc-engineering and antibody hetero-hexamerization as a tool to 
enhance the cooperativity and therapeutic efficacy of antibody combinations. 
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I N T R O D U C T I O N
Monoclonal antibodies (mAbs) have become the backbone of treatment regimens for 
several cancer indications. The chimeric immunoglobulin (Ig)G1 CD20 mAb rituximab 
was the first mAb approved for clinical use in cancer therapy. CD20 is expressed on more 
than 90% of mature B cells and rituximab is widely used to treat B-cell malignancies (1-3). 
However, many patients do not experience complete remission or acquire resistance to 
rituximab treatment, thereby demonstrating the need for improved mAb therapeutics or 
alternative tumor-targeting strategies (4-6).
mAbs employ various mechanisms to eliminate cancer cells, such as induction of 
programmed cell death or Fc-mediated effector functions, including antibody-dependent 
cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and 
complement-dependent cytotoxicity (CDC), which can be increased by Fc engineering 
(7). ADCC and ADCP, for example, can be enhanced by improving FcγR binding through 
Fc glyco-engineering or amino acid modifications (8-11). Likewise, C1q binding and CDC 
can be increased by amino acid substitutions in Fc domains (12, 13). CDC is initiated when 
membrane-bound antibodies bind the hexavalent C1q molecule, which together with C1r 
and C1s forms the C1 complex, the first component of the classical complement pathway. 
C1 activation triggers an enzymatic cascade that leads to covalent attachment of opsonins 
to target cells, and the generation of potent chemo attractants, anaphylatoxins and 
membrane attack complexes (MACs) (14). IgG antibodies bound to cell surface antigens 
assemble into ordered hexamers, providing high avidity docking sites to which C1 binds 
and is activated (15). IgG hexamer formation and complement activation can be enhanced 
by single point mutations in IgG Fc domains, such as E430G, which increase interactions 
between Fc domains of cell-bound IgG (16). The hexamerization-enhanced (Hx) CD20-
targeting mAb 7D8 displayed strongly enhanced CDC of B cells from patients with chronic 
lymphocytic leukemia (CLL), which often demonstrate complement resistance due to low 
CD20 and high membrane complement regulatory protein (mCRP) expression (16-18). 
In polyclonal antibody responses, antibodies against distinct epitopes or antigens are 
thought to cooperate resulting in increased effector functions against target cells. This 
increase can be mimicked in mAb combinations or cocktails. For example, monoclonal 
EGFR antibodies do not induce CDC in vitro, but combinations of mAbs against multiple 
EGFR epitopes induced potent CDC (19, 20). 
CD37, which is abundantly expressed on B cells, represents a promising therapeutic 
target for the treatment of B-cell malignancies (21, 22). Currently known CD37 mAbs in 
clinical development however, are generally poor inducers of CDC (23-27). Here we show 
that introducing Hx mutations into CD37 mAbs strongly potentiated CDC of CLL cells, and 
that combinations of CD20 and CD37 targeting mAbs could further enhance CDC of tumor 
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cell lines and primary patient cells. We investigated the mechanism behind the synergistic 
CDC activity of CD20 and CD37 mAbs, and found that the mAb combinations activate 
complement cooperatively. The two mAbs formed mixed hexameric antibody complexes 
consisting of both antibodies each bound to their cognate targets, which we termed 
hetero-hexamers. The concept of hetero-hexamer formation and the use of Fc-Fc 
interaction enhancing mutations could serve as a tool to enhance cooperativity, and 
thereby the tumor killing capacity, of mAb combinations. 
M E T H O D S
Cells
Daudi, Raji and WIL2-S B-lymphoma cell lines were obtained from the American Type 
Culture Collection (ATCC no. CCL-213, CCL-86 and CRL-8885 respectively). All primary 
patient cells used in this study were obtained after written and informed consent and 
stored using protocols approved by the institutional review boards in accordance with 
the declaration of Helsinki (see Online Supplementary Methods).
Antibodies and reagents
mAbs IgG1-CD20-7D8, IgG1-CD20-11B8, IgG1-CD37 clone 37.3 and IgG1-gp120 were 
recombinantly produced at Genmab (18, 28-30). The HIV-1 gp120 mAb b12 was used to 
determine assay background signal. Mutations to enhance or inhibit Fc-Fc interactions 
were introduced in expression vectors encoding the antibody heavy chain by gene 
synthesis (GeneArt). Rituximab (MabThera®), ofatumumab (Arzerra®) and obinutuzumab 
(Gazyvaro®) were obtained from the pharmacy (UMC Utrecht). See Online Supplementary 
Methods for details on reagents used.
CDC assays
CDC assays with CLL patient cells were performed with human complement as described 
(31). CDC assays with B-lymphoma cell lines and patient-derived B-lymphoma cells 
were performed using 100,000 target cells incubated (45 minutes at 37˚C) with a mAb 
concentration series and pooled normal human serum (NHS, 20% final concentration) 
as a complement source. Killing was calculated as the percentage of propidium idodide 
(PI) or 7-AAD positive cells determined by flow cytometry. See Online Supplementary 
Methods for details on cell markers used to define cell populations. 
Expression analysis
Expression levels of cellular markers were determined using an indirect 
immunofluorescence assay (QIFIKIT®, Agilent Technologies) according to 
the manufacturer‘s instructions (see online Supplementary Methods). 
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C1q binding and CDC efficacy
Daudi cells (3 x 106 cells/mL) were incubated with 10 µg/mL mAb and a concentration 
series of purified human C1q for 45 minutes at 37˚C. After washing, cells were incubated 
with FITC-labeled rabbit anti-human C1q antibody for 30 minutes at 4˚C and analyzed on 
a FACS Canto II flow cytometer (BD Biosciences, CA, USA). The efficiency of C1q binding 
and subsequent CDC was assessed as described above using fixed mAb concentrations, 
a concentration series of purified C1q and 20% C1q depleted serum. 
Confocal microscopy 
Raji cells were opsonized with A488 labeled Hx-CD20-7D8 and A594 labeled Hx-CD37 mAbs 
(2.5 µg/mL final concentrations), and incubated for 15 minutes at room temperature. After 
washing, cells were placed on a poly-D lysine-coated slide and images were captured with 
a Zeiss AxioObserver LSM 700 microscope using plan-Apochromat 63X/1.40 Oil DIC M27 
objective lenses and acquired/processed using Zen software. 
Förster Resonance Energy Transfer (FRET) analysis
Proximity-induced FRET was determined by measuring energy transfer between cells 
incubated with A555-conjugated donor and A647-conjugated acceptor mAbs using flow 
cytometry (see Online Supplementary Methods). The dynamic range of FRET analysis by 
flow cytometry was determined using control mAbs, as specified in Supplementary Figure 1.
Data processing and statistical analyses
All values are expressed as the mean ± standard deviation of at least two independent 
experiments. Graphs were generated and analyzed using GraphPad Prism 7.0 (CA, 
USA). Differences between two groups were analyzed using paired Student’s t-test with 
two-tailed 95% confidence intervals and between more groups by paired or unpaired 
one-way ANOVA followed by a Tukey post-hoc multiple comparisons test. Significant 
differences are indicated as: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. See Online 
Supplementary Methods for details on synergy and colocalization analysis.
R E S U LT S
Hexamerization-enhancing mutations in CD20 and CD37 mAbs substantially 
enhance CDC of CLL B cells
We previously reported increased CDC with engineered mAbs containing Hx mutations 
in the Fc domain (15, 16). We therefore investigated whether introducing the Hx 
mutation E430G into the CD37 chimeric IgG1 mAb 37.3 could potentiate CDC in B cells 
isolated from CLL patients and compared this to the CD20 mAb IgG1-CD20-7D8 with 
and without a Hx mutation. Wild-type (WT) IgG1-CD20-7D8 promoted considerable 
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Figure 1. Hexamerization-enhancing mutations in CD20 and CD37 mAbs substantially 
enhance CDC of CLL B cells. (A-B) CDC of B cells obtained from patient A with CLL. Cells were 
opsonized with different concentrations of CD20 mAb 7D8 as wild type (IgG1-CD20-7D8) or with 
a hexamerization-enhancing mutation (Hx-CD20-7D8) (A); or CD37 mAb 37.3 as wild type (IgG1-
CD37) or with a hexamerization-enhancing mutation (Hx-CD37) (B) in the presence of 50% pooled 
normal human serum (NHS), heat-inactivated (HI) NHS, NHS + EDTA or medium. Representative 
examples of three replicate experiments are shown. (C-E) CDC of B cells obtained from 12 different 
CLL patients (patient B-M). CLL B cells were opsonized with 16 µg/mL (C), 2 µg/mL (D) or 0.25 µg/mL 
(E) Hx-CD20-7D8 or Hx-CD37. The dashed line represents 95% cell lysis. CDC induction is expressed 
as the percentage lysis determined by the fraction of TO-PRO-3 positive cells and data shown are 
mean and standard deviation (SD) of duplicate measurements. 
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CDC of CLL B cells and CDC was increased by the E430G mutation (Figure 1A). While WT 
IgG1-CD37 efficiently binds to CLL B cells, it was ineffective at inducing CDC (Figure 1B; 
Supplementary Figure 2), in contrast to Hx-CD37 (Figure 1B). For both Hx-CD20-7D8 
and Hx-CD37, high levels of cell killing largely required active complement, since CDC 
was almost absent in heat-inactivated NHS, NHS supplemented with EDTA or medium 
alone (Figure 1 A-B). Background killing of cells from patient A mediated by Hx-CD37 in 
the absence of complement was slightly higher than expected. However, in C1q-depleted 
serum, background killing was 16%, compared to 6% for cells reacted with Hx-CD20-7D8. 
Background killing in C1q-depleted serum for 6 other CLL patient samples averaged 13% 
and 14% for cells reacted with Hx-CD20-7D8 and Hx-CD37, respectively. Reaction in NHS 
increased CDC to averages of 91% and 95%, respectively. Introduction of the Hx mutation 
E430G into CD20 and CD37 mAbs did not affect pharmacokinetic profiles and binding to 
FcRn (data not shown) (16). At the highest concentration (16 µg/mL) Hx-CD37 induced 
≥ 95% CDC of tumor B cells for 9 out of 12 patients (Figure 1C). At concentrations of 
0.25 and 2 µg/mL, Hx-CD37 generally demonstrated higher potency than Hx-CD20-7D8 
(Figure 1D-E), which may be explained by higher expression levels of CD37 (approximately 
2-fold) in the majority of CLL samples (Supplementary Figure 3A-B).
CD20 and CD37 mAbs synergistically induce CDC of malignant B cells
We investigated the CDC activity of combinations of WT CD20 and WT CD37 mAbs, using 
two different CD20 mAbs. The ability to activate complement represents a key distinction 
between type I CD20 mAbs which mediate strong CDC and type II CD20 mAbs, which only 
mediate weak CDC (32). The effect of combining WT type I CD20 mAb 7D8 or WT type II 
CD20 mAb 11B8 with WT CD37 mAb on CDC was assessed using Daudi cells. As expected, 
WT IgG1-CD20-7D8 showed potent CDC activity (96.6% cell lysis), whereas WT IgG1-CD37 
did not induce CDC (Figure 2A). The combination of WT IgG1-CD20-7D8 and WT IgG1-CD37 
did not demonstrate enhanced CDC. However, while neither WT IgG1-CD20-11B8 nor 
WT IgG1-CD37 induced CDC as single agents, the combination promoted strong lysis of 
approximately 60% (Figure 2B). Minimal cell lysis was observed in experiments with heat-
inactivated serum, indicating that that cell killing was largely dependent on complement 
(Supplementary Figure 4).
We additionally examined whether combinations of CD20 and CD37 mAbs with Hx 
mutations also showed cooperativity in CDC by testing mAb combinations using a full 
dose-response matrix (8x8 serial dilution grid) based on the EC50 values of the single 
mAbs. Surprisingly, both Hx-CD20-7D8 and Hx-CD20-11B8 in combination with Hx-CD37 
showed enhanced CDC of Daudi cells compared to the single agents (Figure 2C, 
Supplementary Figure 5A). We next assessed whether the observed combination effect 
was synergistic using the Loewe additivity-based combination index (CI) score calculated 
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by CompuSyn, whereby effects were categorized as synergistic (CI < 1), additive (CI = 1) 
or antagonistic (CI > 1) (33). The Loewe additivity-based model assumes synergy when 
the effect of a drug combination is higher than the effect of a drug combined with itself, 
and takes into account both the potency and the shape of the dose-effect curve of each 
drug in the dose-response matrix. Synergy was observed for both Hx-CD20-7D8 and Hx-
CD20-11B8 when combined with Hx-CD37, with average CI values of 0.37 and 0.31 (effective 
dose - ED95), respectively (Figure 2D, Supplementary Figure 5B, Supplementary Table 1). 
At the lower tested mAb concentrations, synergy was more profound (lower CI values) for 
combinations of Hx-CD37 with type II CD20 mAb-derived Hx-CD20-11B8 than with type I 
CD20 mAb-derived Hx-CD20-7D8. 
In addition to Daudi cells, we used two other B-cell lines expressing various levels of 
CD20 and CD37 to further examine the cooperativity in CDC between combinations of 
Hx-CD37 with Hx-CD20 mAbs or with clinically validated CD20 mAbs. Across all B-cell 
lines tested, enhanced CDC activity was observed for combinations of Hx-CD37 with 
Hx-CD20 mAbs, as well as for combinations of Hx-CD37 with ofatumumab, rituximab 
and obinutuzumab (Figure 2E). Even in WIL2-S cells expressing low levels of CD37, 
a combination of Hx-CD37 with obinutuzumab induced 72% lysis, whereas the single 
agents induced only 5% and 10% lysis respectively. Despite high single agent activity of 
Hx-CD37 and Hx-CD20 mAbs at 10 µg/mL (per mAb) in Daudi cells, the cooperativity 
between Hx-CD37 and Hx-CD20 mAbs became apparent at the lower mAb concentrations. 
Enhanced binding and use of C1q by combinations of hexamerization-enhanced 
CD20 and CD37 mAbs
We hypothesized that the observed synergy in CDC between Hx-CD20 and Hx-CD37 
mAbs resulted from more efficient use of complement proteins, starting with binding of 
C1q. Therefore, we determined whether combinations of Hx-CD20 and Hx-CD37 differed 
in their C1q binding capacity. We incubated Daudi cells with fixed mAb concentrations 
and titrated C1q, and measured C1q binding and the concentration of C1q required to 
induce CDC, referred to here as CDC efficacy. Hx-CD20-7D8 already induced efficient 
C1q binding as a single agent, while Hx-CD37 showed limited C1q binding (Figure 3A). 
Combinations of Hx-CD20-7D8 and Hx-CD37 did not significantly increase C1q binding. 
However, the combination showed higher CDC efficacy as demonstrated by the lower 
EC50 value in the C1q dose-response curves compared to the single mAbs (0.03 µg/mL 
for the combination versus 0.12 µg/mL for Hx-CD20-7D8 and 0.34 µg/mL for Hx-CD20-
11B8) (Figure 3B). In contrast to the results with the type I CD20 mAb-derived variant, 
combining type II CD20 mAb-derived Hx-CD20-11B8 with Hx-CD37 resulted in increased 
C1q binding compared to the single mAbs, as well as increased CDC efficacy (Figure 3C-D). 
Collectively, these data suggest that combinations of both type I and type II CD20 mAb-





Figure 2. CD20 and CD37 mAbs synergistically induce CDC of malignant B cells. (A-B) CDC on 
Daudi cells opsonized with 30 µg/mL WT type I CD20 mAb 7D8 (IgG1-CD20-7D8) (A) or type II CD20 
mAb 11B8 (IgG1-CD20-11B8) (B), CD37 mAb 37.3 (IgG1-CD37), or a combination thereof (15 + 15 µg/
mL) in the presence of 20% NHS. CDC induction is expressed as the percentage lysis determined 
by the fraction of propidium iodide (PI)-positive cells. Data shown are mean and SD of triplicate 
measurements. (C) 8 x 8 CDC dose response matrix plot for the combination of hexamerization-
enhanced CD37 mAb Hx-CD37 (0-0.8 µg/mL) with hexamerization-enhanced CD20 mAb Hx-
CD20-11B8 (0-8 µg/mL), tested on Daudi cells and categorized as a color gradient from green 
(0% lysis) to yellow (50% lysis) to red (100% lysis). HIV gp120-specific mAb b12 (IgG1-gp120) was 
used as a negative control human mAb. (D) Loewe additivity-based Combination index (CI) values 
calculated by CompuSyn for the CDC dose response matrix as described in (C) and categorized 
as synergistic (<1, red), additive (1, white) and antagonistic (>1, blue). Representative examples of 
two replicate experiments are shown. (E) CDC and CD37 expression analysis on Daudi, Raji and 
WIL2-S cells. For the CDC assay, cells were opsonized with Hx-CD37 (10 µg/mL), different CD20 mAb 
variants (10 µg/mL) or combinations thereof (10 + 10 µg/mL). Data show the mean of nine replicates 
collected from three independent experiments. Expression levels were determined using QIFIKIT 
analysis. The number of antibody molecules per cell was calculated from the antibody-binding 
capacity (mean fluorescence intensity - MFI) normalized to a calibration curve, according to 
the manufacturer’s guidelines. Expression data show the mean of four replicates collected from 
two independent experiments.
CD20 and CD37 mAbs colocalize on B cells
Confocal microscopy was used to determine whether the CD20- and CD37-specific 
antibodies associate on the cell surface upon target binding. Cell-bound Hx variants 
of CD20 mAb 7D8 and CD37 mAb 37.3 were detected using A488 and A594 fluorescent 
labeling, respectively, and antibody colocalization was quantified by calculating spatial 
overlap (Manders’ coefficients) between the two fluorescent labels. The merged A488/
A594 image showed that membrane-bound Hx-CD20 and Hx-CD37 mAbs indeed 
colocalized on the surface of Raji cells (Figure 4A), which was confirmed by quantitative 
analysis, giving Manders’ Coefficients of M1=0.805 (fraction of image 1 overlapping image 
2) and M2=0.751 (fraction of image 2 overlapping image 1).
Colocalization of cell-bound CD20 and CD37 mAbs was further examined by directly 
assessing molecular proximity using fluorescence resonance energy transfer (FRET) 
analysis. We examined FRET on Daudi cells between WT and Hx variants of CD20 and 
CD37 mAbs alone and in combination. Consistent with its CDC activity (Figure 2A), WT 
IgG1-CD20-7D8 induced high FRET, which suggests antibody hexamer formation (Figure 
4B). WT IgG1-CD20-11B8 did not demonstrate proximity-induced FRET (Figure 4C), 
and WT IgG1-CD37 induced approximately 15% FRET (Figure 4B-C). Introducing a Hx 
mutation resulted in increased FRET levels for each of the single agents, indicating that 
enhancing Fc-Fc interactions increases mAb colocalization at the cell surface (P<0.0001, 


























































































































































































































































































































































































































shown), thereby excluding the possibility that increased FRET would be due to more 
mAbs being available on the cell surface. Combinations of WT IgG1-CD20-7D8 and WT 
IgG1-CD37 induced approximately 30% FRET, which was increased compared to the WT 
IgG1-CD37 single mAb (P<0.0001, Figure 4B). Combinations of WT IgG1-CD20-11B8 and WT 
IgG1-CD37 substantially increased FRET compared to each single mAb (P< 0.0001, Figure 
4C), consistent with the enhanced CDC induction (Figure 2B). Combinations of Hx-CD20-
7D8 or Hx-CD20-11B8 with Hx-CD37 further enhanced FRET compared to the FRET levels 
induced by the WT mAb combinations (P<0.0001, Figure 4D-E). These results confirm that 
CD20 and CD37 IgG1 mAbs bind in close proximity on the cell membrane, which can be 
enhanced by introducing the E430G mutation.
Hexamerization-enhanced CD20 and CD37 mAbs cooperate in CDC through Fc-
mediated clustering in hetero-hexamers 
Both enhancing Fc-Fc interactions in the CD20 or CD37 mAbs and combining the two B-cell 
target mAbs resulted in enhanced mAb colocalization. Together with the dependency of 
CDC on the formation of hexameric IgG complexes on the cell surface (15), this suggests 
that the CD20 and CD37 mAbs might not only form hexamers composed of mAbs 
bound to identical surface targets, but may cooperate by also forming mixed hexameric 
complexes of mAbs bound to either target, referred to here as hetero-hexamers. 
The contribution of Fc-Fc interactions between Hx-CD20-11B8 and Hx-CD37 to the CDC 
activity of the mAb combination was examined by the introduction of the complementary 
Fc-Fc interface mutations K439E and S440K. K439E and S440K suppress Fc-Fc interactions 
between antibody molecules containing the same mutation, whereas Fc-Fc interactions 
are restored in K439K and S440K antibody mixtures 15). The capacity of Hx-CD20-11B8 
and Hx-CD37 variants with K439E and S440K mutations to induce CDC was tested using 
Daudi and WIL2-S cells.
The CDC activity of Hx-CD20-11B8 was completely inhibited by introducing either 
the K439E or S440K Fc-Fc inhibiting mutation using Daudi and WIL2-S cells (Figure 5A-B). 
CDC activity was restored when Fc-Fc inhibition was neutralized by mixing the two CD20 
mAbs. Similar results were observed for Hx-CD37 on Daudi cells, while on WIL2-S cells, 
Hx-CD37 did not induce CDC, most likely due to low CD37 expression (Figure 5C-D). 
Combining Hx-CD20-11B8 and Hx-CD37 mAbs harboring the same Fc-Fc inhibiting 
mutation (K439E or S440K) strongly reduced CDC activity on Daudi and WIL2-S cells 
(Figure 5E-F). However, CDC of both cell lines was restored by mixing Hx-CD20-11B8 and 
Hx-CD37, each carrying one of the complementary mutations K439E or S440K. These data 
suggest that Hx-CD20-11B8 and Hx-CD37 can indeed form hetero-hexameric complexes, 





Next, the effect of the Fc-Fc interaction-inhibiting mutations on colocalization of 
Hx-CD20-11B8 and Hx-CD37 mAbs on the cell membrane of Daudi cells was evaluated 
using FRET analysis. mAb combinations with Hx-CD20-11B8 and Hx-CD37 variants, both 
harboring the same Fc-Fc inhibiting mutation (K439E or S440K) showed reduced FRET 
on Daudi cells (Figure 5G; Supplementary Figure 6). FRET levels were restored when Fc-Fc 
inhibition was neutralized by combining Hx-CD20-11B8 and Hx-CD37 mAbs, each having 
one of the complementary mutations K439E or S440K. Thus, donor- and acceptor-labeled 
Hx-CD20-11B8 and Hx-CD37 mAb variants come together in close proximity on the cell 
membrane of Daudi cells, which appears to be, at least in part, mediated by the Fc domain.
Combinations of hexamerization-enhanced CD20 and CD37 mAbs induce superior 
ex vivo CDC of tumor cells obtained from patients with B-cell malignancies
We next examined the capacity of combinations of Hx-CD20 and Hx-CD37 mAbs to induce 
CDC ex vivo in tumor cells obtained from patients with B-cell malignancies. First, the CDC 
activity of Hx-CD20-7D8, Hx-CD37 or combinations was evaluated using tumor cells 
obtained from 15 patients diagnosed with CLL. Both Hx-CD20-7D8 and Hx-CD37 induced 
substantial CDC of CLL tumor cells from all 15 tested donors (Figure 6A), in accordance with 
Figure 1. Hx-CD37 was more effective in CDC than Hx-CD20-7D8, which may be explained 
by higher expression CD37 on CLL cells (P< 0.05, Supplementary Figure 3A-B). Importantly, 
significantly increased CDC levels were observed in 9 out of 15 tested CLL donors upon 
treatment with the combination of Hx-CD20-7D8 and Hx-CD37. Even at modest total 
concentrations of Hx-CD20-7D8 and Hx-CD37 (£ 1.25 µg/mL for each mAb), >90% CDC 
Figure 4. CD20 and CD37 mAbs colocalize on B cells. (A) Confocal fluorescence microscopy 
analysis to detect colocalization of cell-bound CD20 and CD37 mAbs. Raji cells were opsonized 
with hexamerization-enhanced A488-conjugated CD20 mAb 7D8-derived Hx-CD20-7D8 (image 1, 
green) and hexamerization-enhanced A594-conjugated CD37 mAb 37.3-derived Hx-CD37 (image 
2, red), and incubated for 15 minutes at room temperature. Images were captured in PBS imaging 
medium at ambient temperature using a Zeiss AxioObserver LSM 700 microscope with Plan-
Apochromat 63X/1.40 Oil DIC M27 objective lenses and acquired/processed using Zen software. 
Two excitation lasers were used at 488 and 555 nm. In the merged image, overlap of red and green 
produces orange or yellow. A representative example of two replicate experiments is shown. (B-C) 
FRET analysis to detect the molecular proximity of (B) WT type I CD20 mAb 7D8 (IgG1-CD20-7D8) or 
(C) WT type II CD20 mAb 11B8 (IgG1-CD20-11B8), WT CD37 mAb 37.3 (IgG1-CD37) or a combination 
thereof on the cell membrane of Daudi cells. (D-E) FRET analysis to detect the molecular proximity 
of hexamerization enhanced variants of (D) type I CD20 mAb 7D8-derived Hx-CD20-7D8 or (E) type 
II CD20 mAb 11B8-derived Hx-CD20-11B8, CD37 mAb 37.3-derived Hx-CD37 or a combination thereof 
on the cell membrane of Daudi cells. Daudi cells were opsonized with 10 µg/mL A555-conjugated- 
and 10 µg/mL A647-conjugated antibody variants for 15 minutes at 37˚C. FRET was calculated 
from MFI values as determined by flow cytometry. Data shown are mean and SD of six replicates 





of B cells was induced in 12 out of the 15 tested CLL donors (Figure 6A). Enhanced CDC by 
the mAb combination was observed over a range of mAb concentrations and at different 
mAb ratio’s, and was more apparent at lower mAb concentrations as illustrated for one 
representative donor (Figure 6B). Next, we evaluated the cytotoxic capacity of Hx-CD20-
11B8, Hx-CD37, and the combination thereof using tumor cells of 10 patients diagnosed 
with different B-cell lymphomas, including B-NHL (NOS), FL, MZL and MCL. While for 
the single agents a large variation in CDC efficacy was observed between the donors, 
the combination of Hx-CD20-11B8 and Hx-CD37 consistently showed enhanced CDC 
activity compared to the single mAbs (Figure 6C). Representative figures from each tested 
lymphoma subtype show that combinations of Hx-CD20-11B8 and Hx-CD37 at the tested 
1:1 ratio may enhance CDC, even when CDC induced by the individual mAbs was low or 
absent (Figure 6D). Furthermore, analysis of CD20 and CD37 target expression levels on 
primary B cells from 24 CLL patients and 10 patients with different NHL subtypes illustrated 
a large diversity in target expression levels and ratios (Supplementary Figure 3A-C). These 
results suggest that combinations of Hx-CD20 and Hx-CD37 mAbs may generally increase 
the therapeutic potential of CDC-inducing mAbs in B-cell malignancies accross different 
target expression levels and ratios.
D I S C U S S I O N
Improving therapeutic efficacy against (heterogeneous) tumors has been the focus of 
intense preclinical and clinical development. We previously showed that the therapeutic 
potential of IgG1 mAbs can be enhanced by introducing mutations that improve 
hexamerization by Fc-mediated clustering and thereby increase CDC activity (15, 16). 
In the present study, we introduced a Hx mutation, E430G, into CD20 and CD37 mAbs 
Figure 5. Hexamerization-enhanced CD20 and CD37 mAbs cooperate in CDC through Fc-
mediated clustering in hetero-hexamers. The effect of introducing Fc-Fc inhibiting mutations 
S440K and K439E on the CDC induction of hexamerization-enhanced type II CD20 mAb 11B8-
derived Hx-CD20-11B8 on Daudi cells (A) and WIL2-S cells (B), hexamerization-enhanced CD37 
mAb 37.3-derived Hx-CD37 on Daudi (C) and WIL2-S cells (D) and the mAb combinations thereof on 
Daudi (E) and WIL2-S cells (F). Cells were opsonized with concentration series of Hx-CD20-11B8 and 
Hx-CD37 variants in the presence of 20% NHS. CDC induction is expressed as the percentage lysis 
determined by the fraction of PI-positive cells. Representative examples of two (WIL-2S) and three 
replicates (Daudi) are shown. (G) The effect of introducing Fc-Fc inhibiting mutations S440K and 
K439E on the molecular proximity of Hx-CD20-11B8 and Hx-CD37 variants on the cell membrane 
of Daudi cells. Daudi cells were incubated with 10 µg/mL A555-conjugated Hx-CD20-11B8 variants 
and 10 µg/mL A647-conjugated Hx-CD37 variants for 15 minutes at 37˚C. FRET was calculated from 
the MFI values as determined by flow cytometry. Data shown are mean and SD of six replicates 
collected from three independent experiments. 
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Figure 6. Combinations of hexamerization-enhanced CD20 and CD37 mAbs induce superior ex 
vivo CDC of tumor cells obtained from patients with B-cell malignancies. (A) B cells obtained 
from 15 patients diagnosed with CLL were opsonized with fixed concentrations of hexamerization-
enhanced type I CD20 mAb 7D8-derived Hx-CD20-7D8 or hexamerization-enhanced CD37 
mAb 37.3-derived Hx-CD37 (open symbols: 2.5 µg/mL, closed symbols: 2 µg/mL; each presented 
as 100%), or 1:1 mixtures thereof (open symbols: 0.625 µg/mL of each mAb, closed symbols: 0.5 
µg/mL of each mAb; each represented as 50%) in the presence of 50% NHS. CDC induction is 
presented as the percentage lysis determined by the fraction of TO-PRO-3 positive cells. (B) B 
cells of a representative CLL patient sample (patient G) were opsonized with different total mAb 
concentrations of Hx-CD20-7D8 or Hx-CD37 (single agents indicated as 100%) and combinations 
thereof at different antibody ratios (indicated as 75%:25%, 50%:50% and 25%:75%) in the presence 
of 50% NHS. CDC induction is presented as the percentage lysis determined by the fraction 
of TO-PRO-3 positive cells. Data shown are mean and SD of duplicate measurements. (C) B cells 
obtained from 10 patients diagnosed with different B-cell malignancies (B-NHL (NOS), FL, MZL and 
MCL) were opsonized with 10 µg/mL of hexamerization-enhanced type II CD20 mAb 11B8-derived 
Hx-CD20-11B8 or Hx-CD37, and the combination thereof (5 + 5 µg/mL) in the presence of 20% NHS. 
CDC induction is presented as the percentage lysis determined by the fraction of 7-AAD positive 
B-lymphoma cells. (D) CDC assay with B-cell patient samples representative for B-NHL (NOS), FL, 
MZL and MCL as described in (C). Data shown are mean and SD of duplicate measurements. 
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and observed an impressive increase in CDC activity in primary CLL samples. Moreover, 
combinations of CD20 and CD37 mAbs showed enhanced and synergistic CDC 
activity, including combinations of Hx-CD37 mAbs with the approved mAbs rituximab, 
ofatumumab and obinutuzumab. With several CD20 and CD37 mAbs approved or in clinical 
development, it is attractive to study the mechanism behind the cooperativity between 
mAbs targeting these two antigens (34, 35). It was recently reported that expression levels 
of CD20 and CD37 mRNA and protein are correlated on lymphoma B cells (36). Here, using 
confocal microscopy and FRET analysis we show that CD20 and CD37 mAbs colocalize on 
surfaces of B cells and that enhancing Fc-Fc interactions increases mAb colocalization. 
The observed synergistic CDC activity of CD20 and CD37 mAbs was supported by 
increased C1q binding and increased CDC efficacy, as illustrated by enhanced CDC at 
relatively low C1q concentrations. Synergy in complement activation was most evident for 
CD37 mAbs in combination with type II CD20 mAbs, than with type I CD20 mAbs which are 
already effective at clustering as WT mAbs.
De Winde et al (37) recently suggested that the organization of the B-cell plasma 
membrane is shaped by dynamic protein-protein interactions and that this organization 
might be altered by targeted mAb therapies. It has previously been described that 
membrane proteins can cluster into lipid rafts or tetraspanin enriched microdomains 
(TEMs), enabling efficient signal transduction (38, 39). We hypothesized that 
the synergistic interactions in CDC between CD20 and CD37 mAbs could be driven by 
clustering of both target-bound mAbs into oligomeric complexes. By introducing Fc-Fc 
inhibiting mutations we were able to demonstrate that CD20 and CD37 mAbs do not only 
permit the formation of homo-hexamers consisting of mAbs bound to either single target 
separately, but also allow the formation of hetero-hexamers composed of alternating 
CD20 and CD37 mAbs, each bound to their own cognate target, explaining the synergistic 
effects. As proposed in Figure 7, other hetero-hexamer variants may occur, although 
the presence of such alternative variants remains to be demonstrated.  We therefore 
propose a model for Fc-mediated clustering of synergistic mAb combinations on 
malignant B cells (Figure 7). Upon binding of mAbs targeting two different co-expressed 
antigens on the plasma membrane that (are able to) colocalize, hetero-hexameric 
complexes are formed, providing a docking site for C1q binding and CDC induction. 
Introducing hexamerization-enhancing mutations can increase Fc-mediated clustering of 
mAbs into both homo- and hetero-hexameric complexes, thereby increasing the number 
of hexamers and further potentiating CDC. Increasing the therapeutic potency of 
mAb combinations, driven by hetero-hexamerization, could be of clinical relevance 
as illustrated by a combination of Hx-CD20 and Hx-CD37 mAbs that showed strong 
CDC of tumor B cells obtained from patients with different B-cell malignancies. Hicks 





antibody-drug conjugate in clinical development, was potentiated in combination with 
rituximab in vivo in B-NHL xenograft models, which was associated with increased CD37 
internalization rates. Other mechanisms of synergy between CD20 and CD37 have also 
been reported, such as upregulation of CD20 expression in Daudi cells after treatment 
with the radiolabeled anti-CD37 mAb 177Lu–lilotomab (41).
The concept of antibody hetero-hexamer formation may hold relevance for a broader 
range of targets and effector mechanisms. An emerging therapeutic approach is 
the development of designer polyclonals, consisting of multiple mAbs in one product of 
which several are in clinical development, such as MM-151, targeting three epitopes on 
EGFR and Sym013, a mixture of six mAbs targeting all three HER family members (EGFR, 
HER2 and HER3) (42, 43). One could speculate that enhancing Fc-mediated antibody 
clustering involving different co-expressing targets on hematologic or solid tumors may 
induce synergystic efficacy, providing a rationale for application in designer polyclonals. 
Whether effector mechanisms other than CDC, such as ADCC or ADCP are also enhanced 
by combinations of CD20 and CD37 mAbs remains to be elucidated. One may speculate 
that the engagement of two mAbs binding co-expressed targets allows for higher total 
antibody binding on the cell surface, allowing more efficient engagement of FcγRs on 
effector cells.
In the present work, we have demonstrated that synergy in CDC induced by 
combinations of CD20 and CD37 mAbs is likely driven by Fc-mediated clustering 
into hetero-hexameric antibody complexes on the cell surface. Enhancing hetero-
hexamerization between mAb combinations using Fc engineering represents a powerful 
tool to increase the therapeutic efficacy of mAb combinations directed against 
hematologic tumor targets, as well as other tumor targets.
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Figure 7. Model for Fc-mediated clustering of CD20 and CD37 mAbs in hetero-hexamers upon 
binding to the cell surface. (A) mAbs naturally cluster into hexameric complexes upon antibody 
binding to a cognate antigen on a target cell, thereby providing a docking site for C1q binding 
and CDC induction. (B) Upon binding of mAbs targeting two different co-expressed antigens on 
the plasma membrane that (are able to) colocalize, hetero-hexameric antibody complexes are 
formed consisting of both mAbs, providing a docking site for C1q binding and CDC induction. 
Introducing hexamerization-enhancing mutations can increase Fc-mediated clustering of mAbs, 
both into homo- and hetero-hexameric antibody complexes on the cell surface, thereby increasing 
the number of C1q docking sites and further potentiating CDC.
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S U P P L E M E N TA L  M AT E R I A L S  A N D  M E T H O D S
Cells
CLL cells were purified from the blood of newly diagnosed CLL patients (University of 
Rochester), in accordance with standard protocols (University of Rochester Institutional 
Review Board) (1). Bone marrow mononuclear cells (BMNCs), peripheral blood 
mononuclear cells (PBMCs) and lymph node suspension cells from patients with B-cell 
non-Hodgkin lymphoma (B-NHL, not otherwise specified (NOS)), follicular lymphoma 
(FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) were obtained 
from the Amsterdam University Medical Center (Amsterdam, The Netherlands) after 
written informed consent and stored using protocols approved by the Privacy Review 
Board of the Netherlands Cancer Registry in accordance with the declaration of Helsinki. 
BMNCs and PBMCs were isolated by density-gradient centrifugation (Ficoll-Paque PLUS, 
GE Healthcare) from bone marrow aspirates or peripheral blood samples of lymphoma 
patients. Lymph node suspension cells were obtained by mechanical dissociation held 
overnight at 37˚C and filtered using cell strainers. Cells were used in experiments directly 
or stored in liquid nitrogen until further use.
Reagents
Fluorescein isothiocyanate (FITC) conjugated rabbit anti-human C1q (Dako) was used for 
flow cytometry experiments. C1q depleted serum and purified human C1q were obtained 
from Quidel. Mouse anti-human IgM antibody HB57 and mouse anti-human IgG1 mAb 
HB43 were used as described (2, 3). Pooled normal human serum (NHS; AB positive) was 
obtained from Sanquin (Amsterdam, The Netherlands). mAbs labeled with Alexa dyes 
(A488, A555, A594, A647) were reacted with N-hydroxysuccinimidyl–esters following 
manufacturer’s instructions (Molecular Probes).
Cell markers flow cytometry
Cell markers used to define cell populations from patients with B-cell lymphoma: CD45-KO 
(Beckman Coulter), CD19-PC7 (Beckman Coulter), CD3-V450 (BD), CD5-APC (BD), CD5-PE 
(Dako), CD10-APC-H7 (BD), CD10-PE (Dako), CD23-FITC (Biolegend), kappa-APC-H7 (BD), 
kappa-PE (Dako) and lambda-FITC (Emelca Bioscience). Within the CD45+ cell population, 
B cells were identified as CD3-CD19+ cells. Malignant cells were identified based on clonality 
by kappa/lambda staining (B-NHL (NOS), MZL). Tumor specific markers were used (when 




Expression levels of cellular markers were determined using an indirect 
immunofluorescence assay (QIFIKIT®, Agilent Technologies) according to 
the manufacturer’s instructions. Briefly, cells were labeled with primary mouse mAbs and 
incubated, in parallel with QIFIKIT® beads containing a defined number of mAb molecules, 
with FITC-labeled Polyclonal Goat Anti-Mouse Immunoglobulins F(ab‘)2. The number 
of antibody molecules per cell was determined by extrapolating the measured mean 
fluorescence intensity (MFI) to the calibration curve generated by plotting the MFI of 
the individual bead populations against the number of mAb molecules per bead.
Förster Resonance Energy Transfer (FRET) analysis
500,000 Daudi cells/well were incubated with 10 µg/mL A555-conjugated donor mAbs and/
or 10 µg/mL A647-conjugated acceptor mAbs in 10 mL of RPMI/0.2% BSA in 96-well round-
bottom plates for 15 minutes at 37°C. Cells were washed twice, pelleted by centrifugation 
(3 minutes, 300xg) and resuspended in 200 µL PBST. Mean fluorescence intensities (MFI) 
were determined by flow cytometry (FACS Canto ll) by recording 10,000 events at 585/42 
nm (FL2, donor A488) and ≥670 nm (FL3), both excited at 488 nm, and at 660/20 nm 
(FL4, acceptor A647), excited at 635 nm. Unquenched donor fluorescence intensity was 
determined with cells incubated with A555-conjugated donor mAbs, and non-enhanced 
acceptor intensity was determined with cells incubated with A647-conjugated acceptor 
mAbs. Proximity-induced FRET was determined by measuring energy transfer between 
cells incubated with A555-conjugated donor and A647-conjugated acceptor mAbs. MFI 
values allowed calculation of FRET according to the following equation:
Energy transfer (ET) = FL3(D, A) − FL2(D, A)/a − FL4(D, A)/b, wherein a = FL2(D)/FL3(D), 
b = FL4(A)/FL3(A), D is donor, A is acceptor and FLn (D, A) = donor + acceptor (4).
ET values obtained were normalized:
Normalized energy transfer (%) = 100 * ET/FL3(D, A).
Synergy and colocalization analyses
Synergy between combinations of mAbs was determined using Loewe additivity-based 
combination index (CI) scores calculated by CompuSyn software (ComboSyn Inc., Paramus, 
NJ), whereby effects were categorized as additive (CI = 1), synergistic (CI < 1) or antagonistic 
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(CI > 1).5 In brief, synergistic lysis exceeds the level of one mAb plus the predicted fractional 
lysis induced by the other mAb on the remainder of the cell population.
mAb colocalization was quantified by calculating spatial overlap (Manders’ 
coefficients) between images of cell-bound A488-labeled Hx-CD20-7D8 and cell-bound 
A594-labeled Hx-CD37 using the colocalization plugin in ImageJ (6, 7).
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S U P P L E M E N TA L  F I G U R E S
Supplementary Figure 1. Evaluation of the dynamic range of fluorescence resonance energy 
transfer (FRET) detection determined by flow cytometry using control mAbs. Daudi cells were 
incubated with 10 µg/mL of A555- or A647-conjugated CD20 mAb 7D8 (IgG1-CD20-7D8) and washed, 
followed by 10 µg/mL A555- or A647-conjugated mouse-anti-human IgG1 mAb HB43 (IgG1-HB43; 
positive control) or mouse-anti-human IgM mAb HB57 (IgG1-HB57; negative control) for 15 minutes 
at 37˚C. FRET was calculated from MFI values as determined by flow cytometry. Data shown are 
mean and SD of six replicates collected from three independent experiments. IgG1-HB43 was used 
as a positive control for proximity-induced FRET by virtue of its ability to directly bind, and thus 
colocalize with a human IgG1 mAb, such as the WT CD20 mAb 7D8 on the cell surface. As binding 
of A555- or A647-conjugated HB43 requires a cell surface-bound IgG1 mAb, unconjugated IgG1-
CD20-7D8 was used for primary binding in the single stainings (calculating the unquenched donor 
and non-enhanced acceptor fluorescence intensities) and A555- or A647-conjugated IgG1-CD20-
7D8 mAb was used for primary binding in the combination stainings (calculating energy transfer 
efficiency). Using the same setup, IgG1-HB57 was used as a negative control for proximity-induced 
FRET. HB57 is a murine mAb that binds membrane-bound human IgM (B-cell receptor) on Daudi 
cells, and was expected to poorly colocalize with the human antibody IgG1-CD20-7D8. Conjugated 
IgG1-CD20-7D8 and IgG1-HB43 efficiently colocalized with an energy transfer efficiency of 90%, 
while IgG1-CD20-7D8 and IgG1-HB57 poorly colocalized with ~10% energy transfer efficiency. These 




Supplementary Figure 2. Binding of CD20 and CD37 mAbs to tumor B cells obtained from 
a patient diagnosed with CLL (patient A). Antibody binding on primary CLL B cells was 
analyzed using 16 µg/mL WT CD37 mAb 37.3 (IgG1-CD37) and its hexamerization-enhanced variant 
Hx-CD37 (A) or WT CD20 mAb 7D8 (IgG1-CD20-7D8) and its hexamerization-enhanced variant 
Hx-CD20-7D8 (B) in the presence NHS, HI-NHS, NHS + EDTA or medium. Binding was detected 
using A488-conjugated mouse anti-human IgG1 Fc mAb HB43 and mean fluorescence intensities 
were converted to molecules of equivalent soluble fluorochrome (MESF) using calibrated beads 
(Spherotech). Representative examples of three replicate experiments are shown.
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Supplementary Figure 3. CD20 and CD37 target expression levels on tumor B cells obtained 
from patients with B-cell malignancies. (A) CD20 and CD37 expression. Binding was detected 
using an A488-conjugated mouse anti-human IgG1 Fc mAb HB43 and mean fluorescence intensities 
were converted to molecules of equivalent soluble fluorochrome (MESF) using calibrated beads 
(Spherotech). (B) Correlation analysis of CD20 and CD37 expression levels on tumor B cells from 24 
CLL patient samples described in (A). The Pearson’s correlation coefficient (r and R2) was calculated 
using GraphPad Prism software. (C) CD20 and CD37 expression levels on tumor B cells of 2 B-NHL 
(NOS), 3 FL, 2 MZL and 3 MCL patient samples. Expression levels were determined using a human 
IgG calibrator kit (Agilent Technologies). The number of antibody molecules per cell was calculated 
from the antibody-binding capacity (mean fluorescence intensity) normalized to a calibration 
curve, according to the manufacturer’s guidelines. Significant differences are indicated as *p < 0.05 
and ****p < 0.0001. 
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Supplementary Figure 4. Minimal cell lysis observed in assays with heat-inactivated serum 
indicates that cell killing is complement dependent. Daudi cells opsonized with 30 µg/mL WT 
type I CD20 mAb 7D8 (IgG1-CD20-7D8) (A) or WT type II CD20 mAb 11B8 (IgG1-CD20-11B8) (B), 
anti-CD37 mAb 37.3 (IgG1-CD37), or a combination thereof (15 + 15 µg/mL) for 45 minutes at 37ºC 
in the presence of 20% heat-inactivated NHS. HIV gp120-specific mAb b12 (IgG1-gp120) was used 
as a negative control human mAb. Cell kill is expressed as the percentage lysis determined by 
the fraction of PI-positive cells. Representative examples of two replicates are shown.
Supplementary Figure 5. (A) 8 x 8 CDC dose response matrix plot for the combination of 
hexamerization-enhanced CD37 mAb Hx-CD37 (0-0.8 µg/mL) with hexamerization-enhanced 
CD20 mAb Hx-CD20-7D8 (0-0.8 µg/mL) tested on Daudi cells and categorized as a color gradient 
from green (0% lysis) to yellow (50% lysis) to red (100% lysis). HIV gp120-specific mAb b12 (IgG1-
gp120) was used as a negative control human mAb. (B) Loewe additivity-based Combination index 
(CI) values calculated by CompuSyn for the CDC dose response matrix as described in (A) and 
categorized as synergistic (<1, red), additive (1, white) and antagonistic (>1, blue). Representative 
examples of two replicate experiments are shown. CDC induction is expressed as the percentage 
lysis determined by the fraction of PI-positive cells.
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Supplementary Figure 6. The effect of introducing Fc-Fc inhibiting mutations S440K and 
K439E on the molecular proximity of hexamerization-enhanced CD20 and CD37 mAbs on 
the cell membrane of Daudi cells. Daudi cells were incubated with 10 µg/mL A555-conjugated 
hexamerization-enhanced CD37 mAb 37.3 (Hx-CD37) variants and 10 µg/mL A647-conjugated 
hexamerization-enhanced CD20 mAb 11B8 (Hx-CD20-11B8) variants for 15 minutes at 37˚C. FRET 
was calculated from MFI values as determined by flow cytometry. Data shown are mean and SD of 
six replicates collected from three independent experiments. 
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S U P P L E M E N TA L  TA B L E S
Supplementary Table 1. Average Loewe-additivity-based combination index (CI) values calculated 
by CompuSyn at different effective doses of a CDC dose-response matrix using combinations of 
hexamerization-enhanced CD20 mAb Hx-CD20-7D8 or Hx-CD20-11B8 with hexamerization-enhanced 
CD37 mAb Hx-CD37. 
CI values* at different effective doses (ED): 
Antibody Combination ED50 ED75 ED90 ED95
Hx-CD20-7D8 + Hx-CD37 0.96 0.66 0.47 0.37
Hx-CD20-11B8 + Hx-CD37 0.72 0.52 0.39 0.31
*CI values can be categorized as synergistic (<1), additive (=1) and non-synergistic (>1).
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Tetraspanin CD37 has recently received renewed interest as a therapeutic target 
for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is 
a powerful Fc-mediated effector function for killing hematological cancer cells, 
CD37-specific antibodies are generally poor inducers of CDC. To enhance CDC, 
the E430G mutation was introduced into humanized CD37 monoclonal IgG1 
antibodies to drive more efficient IgG hexamer formation through intermolecular 
Fc-Fc interactions after cell surface antigen binding. DuoHexaBody-CD37, 
a bispecific CD37 antibody with the E430G hexamerization-enhancing mutation 
targeting two non-overlapping epitopes on CD37 (biparatopic), demonstrated 
potent and superior CDC activity compared to other CD37 antibody variants 
evaluated, in particular ex vivo in patient-derived chronic lymphocytic leukemia 
cells. The superior CDC potency was attributed to enhanced IgG hexamerization 
mediated by the E430G mutation in combination with dual epitope targeting. 
The mechanism of action of DuoHexaBody-CD37 was shown to be multifaceted, 
as it was additionally capable of inducing efficient antibody-dependent cellular 
cytotoxicity and antibody-dependent cellular phagocytosis in vitro. Finally, potent 
anti-tumor activity in vivo was observed in cell line- and patient-derived xenograft 
models from different B-cell malignancy subtypes. These encouraging preclinical 
results suggest that DuoHexaBody-CD37 (GEN3009) may serve as a potential 
therapeutic antibody for the treatment of human B-cell malignancies.
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B-cell malignancies comprise a heterogeneous group of lymphoproliferative disorders 
including non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). In 
addition to chemotherapy and small molecule inhibitors, immunotherapy with anti-CD20 
monoclonal antibodies (mAbs) such as rituximab, ofatumumab and obinutuzumab, has 
significantly improved the outlook for patients with B-NHL and CLL (1-3). However, many 
patients eventually relapse and become resistant to treatment, creating an unmet need 
for alternative therapeutic strategies. In recent years, the tetraspanin plasma membrane 
protein CD37 has gained renewed interest as a promising therapeutic target for B-cell 
malignancies (4-7). CD37 is selectively expressed on mature B cells and has limited or 
no expression on other hematopoietic cells such as T cells and NK cells, granulocytes, 
monocytes and dendritic cells (8-10).
CD37 is involved in the spatial organization of the B-cell plasma membrane by forming 
tetraspanin-enriched micro domains (TEMs) through lateral associations with interaction 
partners, such as other tetraspanins or integrins (11, 12). CD37 is signaling-competent as 
it contains intracellular functional ITIM-like and ITAM-like motifs that play a role in pro-
survival and pro-apoptotic signaling via the PI3K/AKT pathway. In addition, it controls IL-6 
receptor signaling through interaction with SOCS3 (12, 13). 
In cancer, CD37 is highly expressed on malignant B cells in a variety of B-cell lymphomas 
and leukemias, including NHL and CLL (14, 15). To date, multiple CD37-targeting agents 
have shown preclinical or clinical efficacy (5-7), including antibody drug conjugates 
(16, 17), a small modular immuno-pharmaceutical protein (SMIP) (18), an antibody with 
enhanced antibody-dependent cellular cytotoxicity (ADCC) capacity (19), a radiolabeled 
antibody (20) and chimeric antigen receptor (CAR) T cells (21). The effector mechanisms 
of these agents include direct cytotoxicity mediated through conjugated cytotoxic or 
radioactive payloads, classical FcγR-mediated effector functions such as ADCC, and 
T-cell mediated cytotoxicity. Interestingly, CD37 antibody-based therapeutics currently 
in (pre-)clinical development are poor inducers of complement-dependent cytotoxicity 
(CDC) (5-7), another powerful Fc-mediated effector mechanism for killing hematological 
cancer cells (22, 23).
We have previously reported that activation of the classical complement pathway by 
IgG antibodies depends on IgG hexamer formation upon binding to membrane bound 
antigens. IgG hexamers, which form through intermolecular Fc-Fc interactions, provide an 
optimal docking site for hexavalent C1q (24-26). Activation of C1 triggers the complement 
cascade involving a series of proteolytic events leading to formation of membrane 
attack complexes that eventually kill target cells via disruption of their cell membrane. 
Introduction of a single point mutation, such as E430G, in the IgG Fc domain increases IgG 
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hexamer formation and enhances CDC activity (27, 28). We combined this approach with 
the bispecific antibody technology DuoBody® to generate an obligate bispecific antibody 
for which potency was further increased compared to combinations of the parent 
molecules. Obligate bispecific antibodies represent a novel and most promising concept 
in current therapeutic antibody drug development (29, 30). 
We hereby report the generation of a panel of CD37-targeting mAbs with an E430G 
hexamerization-enhancing mutation and characterized the preclinical mechanism 
of action and anti-tumor activity of the single mAbs, mAb combinations and CD37 
biparatopic (bispecific) antibodies. It was demonstrated that CDC efficacy by single 
CD37-targeting mAbs was enhanced by combining two non-cross-blocking mAbs, which 
was most evident in the context of a biparatopic antibody variant, DuoHexaBody-CD37. 
DuoHexaBody-CD37 also induced potent FcgR-mediated effector functions, including 
ADCC and antibody-dependent cellular phagocytosis (ADCP). In addition, DuoHexaBody-
CD37 showed significant anti-tumor efficacy in vivo in human cell line- and patient-
derived xenograft models, indicating that DuoHexaBody-CD37 may serve as a promising 
novel therapeutic antibody for treatment of human B-cell malignancies.
M AT E R I A L S  A N D  M E T H O D S
Antibodies
Anti-CD37 antibodies were generated through immunization (MAB Discovery GmbH, 
Germany) of rabbits with a mixture of HEK293F cells expressing human (sequence no. 
NP_001765) or cynomolgus monkey (Macaca fascicularis, sequence no. XP_005589942) 
CD37 or a mixture of Fc-fusion proteins containing the large extracellular loop of 
human or cynomolgus monkey CD37. CD37 antibodies were produced recombinantly 
as chimeric human IgG1s containing the hexamerization-enhancing mutation E430G 
(HexaBody® molecules (27)) and F405L or K409R mutations for bispecific antibody 
generation by controlled Fab-arm exchange (cFAE; DuoBody technology (30, 31)) as 
appropriate. Humanized antibody sequences were generated using CDR-grafting in 
optimized human germ-line variable region sequences at Abzena (Cambridge, UK). 
The anti-HIV-1 gp120 mAb IgG1-b12 was used as an negative control antibody (IgG1-ctrl) 
(32). Rituximab (MabThera®), ofatumumab (Arzerra®) and obinutuzumab (Gazyva®) were 
commercially obtained. 
Cell lines, patients, donors and reagents
Details on cell lines used in this study are summarized in Online Supplementary Table S1. All 
primary patient cells were obtained after written and informed consent and stored using 
protocols approved by institutional review boards in accordance with the declaration 
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of Helsinki (see Online Supplementary Information). Blood samples and buffy coats 
from healthy human donors were obtained from the University Medical Center Utrecht 
(Utrecht, The Netherlands) and Sanquin (Amsterdam, The Netherlands), respectively. 
Pooled normal human serum (NHS; AB positive) was obtained from Sanquin. Details on 
antibodies/reagents used to define cell subsets within samples used for flow cytometry 
are provided in Online Supplementary Tables S2-S5.
Antibody binding assays
Antibody binding was assessed using target cells incubated with antibody for 30 minutes 
at 4°C. After washing, cells were incubated with R-Phycoerythrin (PE)-conjugated goat-
anti-human IgG F(ab’)2 (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) 
for 30 minutes at 4°C. Cells were washed and binding was analyzed by determining 
the geometric mean fluorescent intensity (gMFI) of the PE signal using flow cytometry. 
For binding competition assays, target cells were incubated with primary unlabeled 
antibodies (final concentration 20 µg/ml) for 15 minutes at room temperature. Next, 
Alexa Fluor 488 (A488)-labelled antibodies (by reaction with N-hydroxysuccinimidyl-
esters following manufacturer’s instructions [Molecular Probes, Eugene, OR, USA]) were 
added to cells at final concentration of 2 µg/ml, followed by incubation for 15 minutes 
at room temperature. Cells were washed and gMFI of the A488 signal was determined 
by flow cytometry.
Alanine scanning
A CD37 single residue alanine library was generated (GeneArt, Regensburg, Germany) in 
which all amino acid residues in the extracellular domains of human CD37 (UniProt P11049) 
were individually mutated to alanine, except for cysteines. The library was used to map 
amino acids in the extracellular loops of human CD37 involved in binding of mAbs Hx-
CD37-010 and Hx-CD37-016 (details summarized in Online Supplementary Information).
CDC assays
CDC assays were performed as described using tumor cells incubated with 
antibody for 45 minutes at 37°C in the presence of NHS (20% final concentration) as 
a complement source (33). 
Expression analysis
Expression levels of cellular markers were determined as described (33) using an indirect 




ADCC and ADCP assays
Activation of FcγRIIIa- (H-131) and FcγRIIIa-mediated (V-158) intracellular signaling 
was quantified using Luminescent Reporter Bioassays (Promega, Madison, WI, USA), 
according to the manufacturer’s recommendations. Chromium-51 (Cr51) release ADCC 
assays were performed as described (34) and summarized in Online Supplementary 
Information. ADCP assays were performed using tumor cells labeled with calcein AM 
(Life Technologies, Carlsbad, CA, USA) or pHRodoTM Red AM Intracellular pH Indicator 
(ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer’s 
instructions and opsonized with antibodies for 15 minutes at 37°C. Human monocyte-
derived macrophages (h-MDM, isolation and culturing detailed in Online Supplementary 
Information) were added at effector to target (E:T) ratios of 2:1 or 1:1 and incubated for 4 
hours at 37°C/5%CO
2
. During incubation, images were captured using an IncuCyte S3 Live 
Cell Analysis System with a 10x objective lense and acquired/processed using IncuCyte 
S3 software. Alternatively, tumor cells and h-MDM were stained for surface markers after 
incubation using fluorochrome-conjugated antibodies for 30 minutes at 4°C, fixed using 
4% paraformaldehyde (ChemCruz, Dallas, TX, USA) and analyzed by flow cytometry. 
CD11b+/calcein AM+/CD19- cells were defined as h-MDM that phagocytosed Daudi cells. 
CD11b-/calcein AM+ cells were defined as non-phagocytosed Daudi cells remaining after 
co-culture, used to determine target cell depletion. 
Whole blood assays
Binding and cytotoxicity assays were performed with heparin- and hirudin-treated blood 
samples from healthy human donors, respectively. For cytotoxicity, blood samples 
were incubated with antibody for 4 hours at 37°C. Next, red blood cells were lysed and 
samples were stained for 30 minutes at 4°C with fluorochrome-labeled lineage-specific 
antibodies and TO-PRO-3 to characterize cell subsets and dead or dying cells respectively. 
For binding, red blood cells were first lysed and subsequently incubated with designated 
antibody mixtures. Binding was assessed by flow cytometry and expressed as the gMFI of 
AF488 fluorescence intensity for viable cell subsets. Depletion was determined as: 
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Animal studies 
Cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) studies were conducted 
following protocols approved by institutional ethical committees, as provided in Online 
Supplementary Information and Supplementary Table S6. In vivo pharmacokinetic analysis 
was performed as described27.  
 
Data processing  
Flow cytometry data were analyzed using FlowJo V10 software. Graphs were plotted and 
analyzed using GraphPad Prism 8.0. Dose-response curves were generated using best-fit 
values of non-linear dose-response fits using log-transformed concentrations. All data shown 
are representative of at least two independent replicate experiments. Statistical differences in 
median animal tumor volumes were compared between treatment groups on the last day all 
groups were complete. In case of equal variance between groups (Bartlett’s test) the 
parametric One Way ANOVA Uncorrected Fisher’s LSD test (Daudi-Luc) was used. In case of 
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Flow cytometry data were analyzed using FlowJo V10 software. Graphs were plotted and 
analyzed using GraphPad Prism 8.0. Dose-response curves were generated using best-fit 
values of non-linear dose-response fits using log-transformed concentrations. All data 
shown are representative of at least two independent replicate experiments. Statistical 
differences in median animal tumor volumes were compared between treatment groups 
on the last day all groups were complete. In case of equal variance between groups 
(Bartlett’s test) the parametric One Way ANOVA Uncorrected Fisher’s LSD test (Daudi-
Luc) was used. In case of unequal variance between groups (Bartlett’s test) the non-
parametric Mann-Whitney test (JVM-3, DOHH-2, NHL PDX) was used.
R E S U LT S
Generation of CD37 mAbs and analysis of their binding characteristics
Rabbits were immunized with CD37 antigen to generate a diverse panel of mAbs 
recognizing human CD37. After humanization using CDR-grafting, antibodies were 
expressed in a human IgG1 backbnone with and without the E430G hexamerization-
enhancing mutation (Hx) and binding to CD37 on human tumor cells was assessed using 
Daudi cells. Four humanized CD37 mAbs were selected for further studies based on 
specific and efficient target binding (EC
50
 < 0.1 µg/ml), CDR sequence diversity and cross-
reactivity with human and cynomolgus monkey CD37. Hx-CD37-004, Hx-CD37-005, Hx-
CD37-010 and Hx-CD37-016, and corresponding wild-type (WT) IgG1 variants showed 
dose-dependent binding to Daudi cells (Figure 1A) with EC
50
 values ranging from 0.42 - 
0.92 µg/ml. Comparable binding of WT anti-CD37 mAbs indicated that binding was not 
affected by the E430G mutation. We next performed cross-block binding experiments 
on Raji cells to examine cross-competition between the four humanized CD37 mAbs. Hx-
CD37-004 competed with CD37-016 for binding, and Hx-CD37-005 competed with Hx-
CD37-010 for binding to CD37 (Figure 1B). The mutually competing antibodies Hx-CD37-
004 and Hx-CD37-016 were able to simultaneously bind to CD37 with one of the other 
mutually competing antibodies Hx-CD37-005 or Hx-CD37-010, thereby indicating that 
the four antibodies represent two different cross-blocking groups. 
We selected one mAb candidate from each cross-blocking group, Hx-CD37-010 and 
Hx-CD37-016, and used alanine scanning analysis to map epitopes within the extracellular 
loops of human CD37. A library with alanine substitutions at all extracellular residues of 
human CD37, except for cysteines, was generated. Alanine mutants were expressed 
individually in HEK293F™ cells and binding of Hx-CD37-010 and Hx-CD37-016 was 
determined by flow cytometry. Loss of Hx-CD37-010 binding to human CD37 was observed 
with alanine substitutions at position Y182, D189, T191, I192, D194, K195, V196, I197 and P199, 
while for Hx-CD37-016, loss of antibody binding was observed with alanine substitutions 
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Figure 1. Binding characteristics of CD37 panel mAbs. (A) Binding of WT (IgG1) and 
hexamerization-enhanced (Hx) antibody variants of the CD37 panel to Daudi cells. Antibody 
binding was assessed by flow cytometry and is expressed as the gMFI of the PE signal from 
a secondary IgG detection antibody. (B) Binding competition between Hx-CD37 panel antibodies 
was assessed on Raji cells by pre-incubating cells with 20 µg/ml unlabeled Hx-CD37 panel antibodies 
(primary binding) followed by incubation with A488-labeled antibodies (2 µg/ml). Relative binding 
in presence of competing antibody was plotted (% relative binding = [gMFI A488 in presence of 
competing antibody]/[gMFI A488 in absence of competing antibody]*100). Data represents 
the mean and standard deviation (SD) of triplicate measurements. (C) Mapping of amino acids 
in the extracellular loops of human CD37 involved in binding of Hx-CD37-010 or Hx-CD37-016 
as determined by alanine scanning. A z-score (fold change in binding compared to binding of 
a control antibody) for each mutant position was calculated and plotted. Z-scores < 0 indicate loss 
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at position E124, F162, Q163, V164, L165 and H175 (Figure 1C). These results showed that 
residues identified to be crucial for binding of Hx-CD37-010 are distinct from residues 
crucial for binding of Hx-CD37-016. Together, the binding analyses demonstrate that Hx-
CD37-010 and Hx-CD37-016 bind different residues within the second extracellular domain 
(EC2) of human CD37 (Figure 1D).
CDC activity of CD37 mAbs is potentiated by enhanced hexamerization and dual 
epitope targeting
We previously reported that CDC by CD37 mAbs is potentiated by introducing 
the hexamerization-enhancing mutation E430G in the IgG Fc domain(33) and therefore 
investigated the potency of the novel CD37 mAbs to induce CDC in vitro. Whereas 
WT IgG1-CD37 antibodies were inactive, hexamerization-enhanced variants induced 
dose-dependent and potent CDC in Daudi cells (EC
50
 ranging from 0.15 - 0.75 µg/ml) 
(Figure 2A). In addition, introduction of the E430G mutation unlocked CDC activity of 
the CD37 mAbs in Raji cells (EC
50
 ranging from 0.29 - 0.77 µg/ml), which are expected 
to be less sensitive to CDC due to higher expression of complement regulatory protein 
CD59 (Figure 2B) (35). An alternative way to enhance CDC is by dual epitope targeting 
using non-cross-blocking antibody combinations, as has been previously reported for 
a number of cell surface antigens, for example EGFR (36). Also here, the WT IgG1-CD37 
mAbs did not induce CDC as single agents, whereas combinations of non-cross-blocking 
WT IgG1-CD37-010 and IgG1-CD37-016 potentiated CDC to 65% maximum lysis in Raji cells 
(Figure 2C). Interestingly, while hexamerization-enhanced variants of these non-cross-
blocking CD37 mAbs individually induced 50% maximum lysis in Raji cells, CDC-mediated 
lysis was strongly enhanced in the combination (87% maximum lysis) (Figure 2D), thereby 
clearly outperforming combinations of the WT non-cross-blocking CD37 mAbs. These 
results were confirmed with combinations of the other CD37-specific non-cross-blocking 
mAbs (data not shown). In contrast, combinations of Hx-CD37 mAbs that compete for 
CD37 binding did not show enhanced CDC activity compared to single antibodies, 
of binding of Hx-CD37-016 in comparison to Hx-CD37-010 while z-scores > 0 indicate loss of binding 
of Hx-CD37-010 in comparison to Hx-CD37-016. Amino acid residues where the z-score was higher 
than 1.5 (Hx-CD37-010) or lower than –1.5 (Hx-CD37-016), indicated by the horizontal dotted lines, 
were considered as ‘loss of binding mutants’. The number above the x-axis refers to amino acid 
positions in full length human CD37. EC1 = small extracellular loop, EC2 = large extracellular loop 
of CD37, respectively. (D) Amino acid residues involved in Hx-CD37-010 (blue) and Hx-CD37-016 
(purple) binding to CD37 are depicted in a graphical representation based on UniProtKB P11049. 
The extracellular domain of CD37 contains six cysteines (Cys, C), which are indicated in red; these 
form intramolecular disulphide bonds and contribute to the conformation of the tetraspanin. 
The asparagine residues (Asn, N) in the N-glycosylation site consensus sequence Asn-Xxx-Ser 
(NXS) are indicated in red. 
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Figure 2. CDC activity of CD37 mAbs is potentiated by enhanced hexamerization and dual 
epitope targeting. (A-B) CDC in Daudi (A) and Raji (B) cells opsonized with WT (IgG1) or 
hexamerization-enhanced (Hx) variants of CD37 mAbs. (C-D) CDC in Raji cells opsonized with 
combinations of non-cross-blocking IgG1-CD37 (C) or Hx-CD37 (D) mAbs. (E) CDC in Raji 
cells opsonized with combinations of cross-blocking Hx-CD37 mAbs. The indicated antibody 
concentrations represent the total antibody concentration used. CDC induction was assessed in 




including the combination of Hx-CD37-005 and Hx-CD37-010 (Figure 2E) and the mixture 
of Hx-CD37-004 and Hx-CD37-016 (data not shown). These results indicate that CDC 
activity of the CD37 mAbs is potentiated by enhanced hexamerization through the E430G 
mutation and by dual epitope targeting.
A biparatopic hexamerization-enhanced CD37 antibody variant, DuoHexaBody-
CD37, induces superior CDC activity in vitro and ex vivo 
We next explored the possibility of combining enhanced hexamerization with dual epitope 
targeting in a bispecific antibody. A biparatopic CD37 mAb variant, DuoHexaBody-CD37, 
was generated through controlled Fab-arm exchange between Hx-CD37-010 and Hx-
CD37-016 (30, 31). The CDC activity of DuoHexaBody-CD37 was compared to that of single 
mAbs and mAb combinations in samples from untreated CLL patients and a CLL patient 
relapsed/refractory to rituximab, ibrutinib and idelalisib. Strikingly, DuoHexaBody-CD37 
induced superior CDC activity in all patient-derived CLL samples compared to either 
the single mAbs or the combination, which was most apparent in the refractory CLL 
sample (Figure 3A-D). Consistent with results in tumor cell lines, the mAb combination 
showed enhanced CDC compared to the single mAbs. Comparison of DuoHexaBody-
CD37 with the approved CD20 antibodies rituximab, ofatumumab and obinutuzumab 
demonstrated superior CDC in all patient samples tested. None of the approved CD20 
antibodies induced CDC in the refractory CLL sample (Figure 3A) while in untreated CLL 
samples, only ofatumumab induced CDC at concentrations of 10 mg/ml (Figure 3C-D) 
and 100 mg/ml (Figure 3B).
The capacity of DuoHexaBody-CD37 to induce CDC in malignant B-cells was 
further confirmed in CDC assays in vitro using 16 tumor cell lines with varying CD37 
expression levels, derived from different B-cell lymphoma subtypes (Figure 3E). 
DuoHexaBody-CD37 induced potent CDC in 8 of the 16 cell lines tested, with generally 
higher levels of tumor cell lysis observed in cell lines with CD37 expression levels above 
100 000 copies/cell (Figure 3E, F). 
DuoHexaBody-CD37 induces efficient ADCC and ADCP in vitro
While the primary rationale behind the development of DuoHexaBody-CD37 was focused 
on maximizing its capacity to induce CDC, other Fc-mediated effector functions such as 
ADCC and ADCP, known to contribute to tumor cell kill, were also tested. The potential 
of DuoHexaBody-CD37 to induce ADCC and ADCP was first evaluated in FcγRIIIa (V-158) 
and FcγRIIa (H-131) reporter assays, respectively. When bound to Daudi target cells, 
DuoHexaBody-CD37 induced efficient, dose-dependent activation of FcγRIIIa and FcγRIIa 
signaling in transfected Jurkat effector T cells (Figure 4A, B). FcγRIIIa and FcγRIIa 





ADCC induction by DuoHexaBody-CD37 was further evaluated in a 51Cr release assay 
using Daudi cells as target cells and human PBMCs from 12 healthy human donors as 
effector cells (E:T ratio 100:1). DuoHexaBody-CD37 induced efficient, dose-dependent 
ADCC of Daudi cells (EC
50 
= 9.9 ± 10.0 ng/ml), which was comparable to the WT IgG1-CD37 
mAbs without the E430G and F405L/K409R mutations (Figure 4C, D).
Next, ADCP was assessed in a flow cytometry-based assay using calcein AM-labeled 
Daudi target cells and h-MDM as effector cells. DuoHexaBody-CD37 induced efficient 
phagocytosis of calcein AM-labeled Daudi target cells by h-MDM, as illustrated by a dose-
dependent increase in CD11b+/calcein AM+ double positive h-MDM (EC
50 
= 13.5 ± 13.1 ng/
ml), resulting in almost complete depletion of Daudi target cells (EC
50 
= 5.8 ± 2.3 ng/ml) 
(Figure 4E). DuoHexaBody-CD37-mediated ADCP was confirmed in an image-based assay 
using Daudi cells labeled with the pH-sensitive pHRodo dye that becomes increasingly 
fluorescent in the acidic lysosomal environment. Also here, DuoHexaBody-CD37 induced 
efficient engulfment and lysosomal degradation of Daudi cells by h-MDM (Figure 4F, 
G). Together, these data demonstrate that DuoHexaBody-CD37 induces efficient FcγR-
mediated immune effector functions to kill CD37-positive tumor cells.
DuoHexaBody-CD37 depletes B cells, but not other leukocyte populations in human 
whole blood
CD37 is reported to be highly expressed on mature B cells, with low expression levels on 
other leukocyte subsets (8-10). Since non-malignant B-cell depletion may be used as 
a safety- and pharmacodynamic biomarker when exploring B-cell targeting therapies, 
the ability of DuoHexaBody-CD37 to bind and deplete B cells versus other leukocyte 
Figure 3. A biparatopic hexamerization-enhanced CD37 antibody variant, DuoHexaBody-
CD37, induces superior CDC activity in vitro and ex vivo. (A-D) PBMCs (A-B) or purified B-cells 
(C-D) from 4 chronic lymphocytic leukemia (CLL) patients were used to determine CDC induction 
by DuoHexaBody-CD37, and Hx-CD37 antibody variants (Hx-CD37-010 and Hx-CD37-016) alone or 
in combination (1:1 equimolar mixture). CDC induction was assessed in the presence of 20% NHS. 
The percentage lysis was determined by the fraction of PI-positive (A-B) or 7AAD-positive cells 
(C-D). (E) 17 B-lymphoma cell lines and the Epstein-Barr virus (EBV)-positive B-lymphoblastic cell 
line WIL-2S were evaluated for CD37 molecule expression on the cell surface using quantitative 
flow cytometry. The dotted line indicates 100,000 CD37 surface molecules/cell. (F) The capacity 
of 10 µg/ml DuoHexaBody-CD37 to induce CDC in the presence of 20% NHS was tested in 16 cell 
lines also described in (E) and expressed as the percentage lysis determined by the fraction of PI-
positive cells. The cell lines are grouped per B-lymphoma subtype: mantle cell lymphoma (MCL), 
Burkitt’s lymphoma, diffuse large B-cell lymphoma (DLBCL) with activated B-cell (ABC) or germinal 
center B-cell (GCB) subtypes and an EBV-positive B-lymphoblastic cell line. Cell lines with >100,000 
CD37 molecules per cell are indicated by black bars, and those with <100,000 CD37 molecules per 
cell by white bars. Either four (E) or two (F) replicates were used per cell line (mean ± SD). 
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Figure 4. DuoHexaBody-CD37 induces efficient ADCC and ADCP in vitro. (A-B) FcγRIIIa (A) 
and FcγRIIa (B) crosslinking by DuoHexaBody-CD37 was analyzed in a bioluminescent Reporter 
Bioassay using Daudi target cells and engineered FcγRIIIa- or FcγRIIa-expressing Jurkat effector T 
cells that express luciferase upon FcγR crosslinking. Luciferase production is presented as relative 
luminescence units (RLU). Error bars represent the mean ± SD of duplicate measurements. (C) 
ADCC by 2 µg/ml DuoHexaBody-CD37 was evaluated in a classical 51Cr release assay using Daudi 
target cells and PBMCs from 12 healthy human donors as a source of effector cells (E:T of 100:1). 
The percentage lysis was calculated relative to a Triton X-100 control (100% lysis) and no antibody 
control (0% lysis). ****P<0.00001, paired T-test with two-tailed 95% confidence intervals. (D) Dose-
response ADCC (mean percentage lysis ± SD of 3 replicate samples) induced by DuoHexaBody-
CD37, WT IgG1-CD37-010 and WT IgG1-CD37-016 shown for one representative responsive donor 
as described in (C). Error bars represent the mean ± SD of triplicate measurements. (E) ADCP 
induced by DuoHexaBody-CD37 using Daudi target cells and monocyte-derived h-MDM from 
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subsets was evaluated in whole blood derived from six healthy human donors. The blood 
was hirudin anticoagulated to preserve complement activity. DuoHexaBody-CD37 showed 
efficient binding to CD19+ B cells, while low binding was observed to T cells, NK cells and 
neutrophils for all six healthy human donors tested (Figure 5A). DuoHexaBody-CD37 
showed potent depletion of the CD19+ B-cell population compared to the negative 
control, with 98% ± 1.3% depletion at 10 µg/ml and an average EC
50
 of 0.077 ± 0.039 µg/ml 
(Figure 5B). For the T cells, NK cells and neutrophils that showed low DuoHexaBody-
CD37 binding, no depletion was observed at saturating mAb concentrations of 
10 µg/ml (Figure 5C).
DuoHexaBody-CD37 shows anti-tumor activity in vivo in xenograft models
The anti-tumor activity of DuoHexaBody-CD37 in vivo was evaluated in CDX models 
obtained by intravenous or subcutaneous injection of B-cell lymphoma-derived 
Daudi-Luc and DOHH-2 cells and CLL-derived JVM-3 cells, that express moderate to 
high levels of CD37 (Figure 3E). First, we confirmed that DuoHexaBody-CD37 (which lacks 
cross-reactivity to murine CD37) has a normal clearance rate comparable to WT IgG1-ctrl 
in tumor-free mice, i.e. in the absence of target binding (data not shown). Next, SCID mice 
were injected with Daudi-luc, DOHH-2 or JVM-3 cells and treated with 0.1, 1, or 10 mg/kg 
DuoHexaBody-CD37 after tumors had established. Three weekly doses of DuoHexaBody-
CD37 resulted in significantly reduced tumor growth in the Daudi-Luc model at all tested 
dose levels as compared to the IgG1-ctrl, and at 1 and 10 mg/kg in the JVM-3 and DOHH-2 
models (Figure 6A).
The anti-tumor activity of DuoHexaBody-CD37 was also assessed in PDX models, 
which offer more reliable results for clinical outcomes because of their more conserved 
characteristics of the original tumor including heterogeneity, genetic and biological 
healthy human donors as a source of effector cells. Calcein AM-labeled Daudi cells opsonized 
with DuoHexaBody-CD37 were incubated with CD11b+ h-MDM at an E:T ratio of 2:1 and ADCP was 
analyzed by flow cytometry after a 4h co-culture. The amount of h-MDMs that phagocytosed 
Daudi cells is presented as % CD11b+/calcein AM+/CD19- double positive cells. CD19 was used to 
exclude macrophages with bound instead of phagocytosed tumor cells. The percentage CD11b-/
calcein AM+ cells was determined as an indicator of the amount of non-phagocytosed Daudi cells; 
presented here as a depleted cell fraction relative to a no antibody control sample. Data from one 
representative donor out of three is shown. (F) ADCP of pHRodo-labeled Daudi target cells by 
h-MDM induced by DuoHexaBody-CD37 over time at an E:T ratio of 1:1, shown for one out of three 
representative donors. Red fluoresence indicates phagocytosed Daudi target cells by h-MDM. 
ADCP was quantified by the total sum of the red fluorescent intensity in the image (RCUxµm2/
image) and presented as the mean ± SD of duplicate measurements. (G) Phase contrast- and red 
fluorescent images of DuoHexaBody-CD37-opsonized (1 µg/ml) pHRodo-labeled Daudi target cells 
co-cultured with h-MDM effector cells at 0 hrs and 4 hrs incubation as described in (F). 
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4 Figure 5. DuoHexaBody-CD37 depletes B cells, but not other leukocyte populations in human whole blood. Binding to- and depletion of different leukocyte cell subsets in human whole blood 
by DuoHexaBody-CD37 was assessed by flow cytometry using six healthy donors. (A) Binding of 
A488-labeled DuoHexaBody-CD37 (30 µg/ml) is expressed as the gMFI ± SD of the A488 signal. 
(B-C) Cell depletion induced by a concentration series (B, one representative donor) or 10 µg/
ml (C, six donors) DuoHexaBody-CD37 after a four hour incubation period presented as mean % 
depletion ± SD relative to a no antibody control sample. Leukocyte subsets were characterized as: B 
cells (CD19+), T cells (CD3+), NK cells (CD56+) and neutrophils (CD66+/CD16+).
complexity and molecular diversity (37). In a screening approach, we evaluated 
the anti-tumor efficacy induced by DuoHexaBody-CD37 using nine NHL PDX models in 
an experimental set up using a one mouse per group design. SCID mice were treated with 
two weekly doses of 5 mg/kg DuoHexaBody-CD37 or PBS after tumors had established, 
and the ratio between the relative tumor growth in the DuoHexaBody-CD37-treated 
mouse (ΔT) and the PBS control mouse (ΔC) was used to classify responders (ΔT/ΔC < 
10%) versus non-responders (ΔT/ΔC > 70%) and intermediates (10% ≤ ΔT/ΔC ≤ 70%). Three 
models were classified as responders, three as intermediates and three as non-responders 
(Figure 6B). From the three models that showed <10% relative tumor growth (i.e. tumor 
stasis or tumor regression), two models achieved complete tumor regression and did 
not grow out during the complete observation period (~60 days). Although CD37 mRNA 
expression was confirmed for all PDX models, variability between models was limited and 
could not be associated with response (data not shown). Follow-up cohort studies in two 
responding PDX models (Ly12638 and Ly13005) confirmed potent, dose-dependent anti-
tumor activity of DuoHexaBody-CD37 at doses as low as 1 mg/kg (Figure 6C). Collectively, 
these data indicate that DuoHexaBody-CD37 can mediate significant anti-tumor activity 
in both CDX and PDX in vivo models derived from different B-cell malignancy subtypes.
D I S C U S S I O N
The treatment landscape for B-cell malignancies has rapidly evolved since initial approval 





































































































































































































































































































































































































































































































































































































































































a number of alternative B-cell surface antigens have been evaluated for targeted mAb 
therapy including CD19, CD22, CD30, CD79b and CD37 (38). Similar to CD20, CD37 is 
highly expressed on tumor B cells across all major NHL and CLL subtypes. Although CD37 
has long been recognized as a potential target for treatment of B-cell malignancies, it 
has recently received renewed interest with various agents currently in (pre)-clinical 
development. While multiple effector mechanisms have been reported for these agents, 
they are generally poor in inducing CDC (5-7). 
Here, we introduce DuoHexaBody-CD37, a novel CD37-targeted agent generated 
using an innovative approach that combines DuoBody and HexaBody® antibody 
platform technologies. DuoHexaBody-CD37 is a biparatopic bispecific IgG1 antibody 
with a hexamerization-enhancing mutation that induces strong anti-tumor activity 
in preclinical models in vitro and in vivo through potent CDC, ADCC and ADCP 
(Figure 7). DuoHexaBody-CD37 exhibits highly potent CDC activity in vitro and ex vivo, 
which was superior to the parental WT or hexamerization-enhanced CD37 mAbs and to 
the combinations thereof. DuoHexaBody-CD37 not only outperformed all other CD37 
antibody variants evaluated in ex vivo CDC assays using primary CLL patient samples, but 
also outperformed approved CD20 mAbs rituximab, ofatumumab and obinutuzumab. 
We demonstrated that the superior CDC efficacy of DuoHexaBody-CD37 is caused by 
enhanced antibody hexamerization upon target binding and by dual epitope targeting 
inherent to binding two non-overlapping epitopes on CD37. Locally increasing the density 
of Fc-domains through dual epitope targeting can potentiate CDC (36) and may also 
favorably affect Fc-mediated antibody hexamerization, specifically in the context of 
the hexamerization-enhancing mutation. Consequently, the threshold for complement 
activation by DuoHexaBody-CD37 might be lower, which could result in enhanced anti-
tumor efficacy in clinical settings. This could be of specific interest for patients who no 
longer respond to CD20 mAb treatment regimens, where antigen expression, cell surface 
antigen distribution or expression of complement inhibitors might be limiting factors (22). 
While DuoHexaBody-CD37 was shown to bind two non-overlapping epitopes on CD37, 
the fine mechanism of target binding, either bivalent or monovalent, and subsequent 
oligomerization into hexameric complexes remains to be elucidated. IgG oligomerization 
on target surfaces was recently reported to occur via Fc-Fc interaction-mediated 
recruitment of IgG molecules directly from solution, but also through lateral diffusion on 
the cell  in case of preferentially monovalent binding IgG molecules (25). CD37 is thought 
specifically ΔT/ΔC, was used to categorize models as responders (ΔT/ΔC < 10%), intermediates (10% 
≤ ΔT/ΔC ≤ 70%), or non-responders (ΔT/ΔC > 70%). (C) PDX dose response using two responding 
NHL models as described in (B) with indicated doses of DuoHexaBody-CD37 or IgG1-ctrl (n=8 mice/
group). Average tumor size is shown ± SEM. * P<0.01, ** P<0.001, *** P<0.0001.
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to be highly mobile due to its role in protein trafficking and organization in the plasma 
membrane and the formation of TEMs (39). One could speculate that for DuoHexaBody-
CD37 specifically, dual epitope targeting may optimize Fc-tail configuration in the process 
of IgG hexamerization, which may be augmented by lateral diffusion. 
Besides inducing highly potent CDC, DuoHexaBody-CD37 was shown to efficiently 
engage with FcγRs in mediating ADCC and ADCP, indicating the mechanism of action 
of DuoHexaBody-CD37 is multifaceted. DuoHexaBody-CD37 compared favorably to 
rituximab in both FcγRIIIa and FcγRIIa crosslinking, in cell line models that showed 
comparable levels of CD20 and CD37 expression. Importantly, DuoHexaBody-CD37 
efficiently depleted peripheral blood B cells, but not other leukocyte populations 
from healthy human whole blood. Furthermore, in xenograft models in vivo, 
DuoHexaBody-CD37 induced significant inhibition of tumor growth in a CLL CDX model, 
2 NHL CDX models and 6 out of 9 NHL PDX models. Notably, mice are not considered 
a suitable species to assess CDC-dependent tumor cell kill in vivo, suggesting FcγR-
mediated effector functions may largely determine the observed anti-tumor activity 
(40). Further studies are required to understand the contribution of individual effector 
mechanisms in vivo. 
The current landscape of drug development in B-cell malignancies includes CD20-
targeting antibodies such as ofatumumab and the glycoengineered obinutuzumab, and 
small molecule inhibitors targeting Bruton’s tyrosine kinase, Bcl-2 and PI3K-δ such as 
ibrutinib, venetoclax and idelalisib, respectively3. These growing numbers of therapeutic 
agents might also provide opportunities for combination therapy with CD37-targeting 
antibodies. Combinations of DuoHexaBody-CD37 with anti-CD20 antibodies could be of 
particular interest, as we have previously shown enhanced CDC in CLL and B-NHL primary 
patient cells with combinations of CD20 and CD37 mAbs containing hexamerization-
enhancing mutations(33). Furthermore, CD37 has been reported to contain ITIM-like 
and ITAM-like regulatory motifs that regulate pro-survival and pro-apoptotic 
signaling processes via the PI3K/AKT pathway (13). We speculate that combinations of 
DuoHexaBody-CD37 with pro-apoptotic PI3K-δ-inhibitors such as idelalisib may work 
synergistically, however the role of DuoHexaBody-CD37 in apoptotic signaling via CD37 
remains to be elucidated.
In summary, we present here a novel therapeutic antibody that, for the first time, 
combines the proprietary DuoBody and HexaBody antibody platforms to create 
a biparatopic CD37 IgG1 antibody with enhanced Fc-mediated hexamerization upon target 
binding. The potent anti-tumor activity exhibited by DuoHexaBody-CD37 in preclinical 
B-cell malignancy models highlights its therapeutic potential. Preparations to evaluate 
the clinical safety and preliminary efficacy of DuoHexaBody-CD37 in a first-in-human 
clinical trial are currently ongoing.
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Figure 7. Mechanism of action of DuoHexaBody-CD37. (A) The biological process of 
DuoHexaBody-CD37 binding to CD37 receptors on the cell surface and the formation of hexameric 
antibody complexes, thereby providing an optimal docking site for C1q, the hexavalent first 
component of the complement system. Fc-Fc-mediated clustering of CD37 antibodies into 
hexameric complexes on the cell surface can be enhanced through the introduction of an E430G 
hexamerization-enhancing mutation and by dual epitope targeting. (B) DuoHexaBody-CD37 was 
shown to induce kill in malignant B cells by inducing highly potent CDC and through FcγR-mediated 
effector functions such as ADCC and ADCP.
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S U P P L E M E N TA L  M AT E R I A L S  A N D  M E T H O D S
Cells
The (origin of) cell lines used in this study are summarized in Supplementary Table 1. All cell 
lines were routinely tested for mycoplasma contamination and generally aliquoted and 
banked to allow in vitro assays to be performed from frozen cells instead of continuously 
cultured systems to ensure authenticity of the cell lines. Commercially available purified 
primary chronic lymphocytic leukemia (CLL) cells from newly diagnosed patients were 
obtained from AllCells (Alameda, CA USA) and CLL peripheral blood mononuclear cells 
(PBMCs) were obtained from the Amsterdam University Medical Center (Amsterdam, 
The Netherlands) after written informed consent and stored using protocols approved 
by the Privacy Review Board of the Netherlands Cancer Registry in accordance with 
the declaration of Helsinki. PBMCs were isolated by density-gradient centrifugation 
(Ficoll-Paque PLUS, GE Healthcare, Chicago, IL, USA) from peripheral blood samples of 
lymphoma patients. Cells were used in experiments directly or stored in liquid nitrogen 
until further use.
Antibodies 
Details on antibodies used to define cell subsets within flow cytometry-based CDC 
assays with primary CLL patient samples, ADCP assays and human whole blood assays are 
described in Supplementary Table 2-5.
Alanine scanning
A CD37 single residue alanine library (generated at GeneArt, Regensburg, Germany) 
was cloned into a pMAC expression vector and CD37 alanine mutants were expressed 
individually in FreeStyle HEK293F™ cells according to the manufacturer’s instructions 
(Thermo Fischer Scientific, Waltham, MA, USA). Antibody binding was determined as 
described in main text using 3 µg/ml AF488-conjugated monovalent binding variants (one 
irrelevant binding arm) of Hx-CD37-010 (bsIgG-CD37-010xctrl) and Hx-CD37-016 (bsIgG-
ctrlxCD37-016) and expressed as the gMFI of the ungated cell population. The two non-
cross-blocking test antibodies served as control antibodies for each other. To correct for 
expression differences between the different CD37 mutants, data were normalized against 
the gMFI of the control antibody, using the following equation (wherein ‘aa position’ 
refers to the particular position of the alanine substitution in the extracellular loop of 
the human CD37 mutant):
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Where μ and σ are the mean and SD of the normalized gMFI of all mutants. Z-scores < 0 are 
caused by loss of binding of bsIgG-ctrlxCD37-016 in comparison to bsIgG-CD37-010xctrl while 
z-scores > 0 are caused by loss of binding of bsIgG-CD37-010xctrl in comparison to bsIgG-
ctrlxCD37-016. Amino acid residues where the z-score was higher than 1.5 (bsHx-CD37-
010xctrl) or lower than –1.5 (bsHx-ctrlxCD37-016), indicated by the horizontal dotted lines, 
were considered as ‘loss of binding mutants’. 
ADCC assays 
Daudi target cells were labeled with 100 μCi 51Chromium (Amersham Biosciences, Uppsala, 
Sweden) and incubated with antibody concentration series and PBMCs from healthy human 
donors (isolated from buffy coats) as effector cells at a 100:1 effector to target ratio for four 
hours at 37°C. After incubation, the supernatant was transferred to Microscint-40 solution and 
released 51Chromium was counted in a scintillation counter (PerkinElmer, Waltham, MA, USA). 
Maximal and spontaneous lysis were determined using target cells incubated with 5% Triton 
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To express loss or of antibody binding, a z-score (fold change in binding compared to 
binding of a control antibody) was determined according to the following calculation:
Where µ and σ are the mean and SD of the normalized gMFI of all mutants. Z-scores 
< 0 are caused by loss of binding of bsIgG-ctrlxCD37-016 in comparison to bsIgG-CD37-
010xctrl while z-scores > 0 are caused by loss of binding of bsIgG-CD37-010xctrl in 
comparison to bsIgG-ctrlxCD37-016. Amino acid residues where the z-score was higher 
than 1.5 (bsHx-CD37-010xctrl) or lower than –1.5 (bsHx-ctrlxCD37-016), indicated by 
the horizontal dotted lines, were considered as ‘loss of binding mutants’.
ADCC assays
Daudi target cells were labeled with 100 µCi 51Chromium (Amersham Biosciences, 
Uppsala, Sweden) and incubated with antibody concentration series and PBMCs from 
healthy human donors (isolated from buffy coats) as effector cells at a 100:1 effector to 
target ratio for four hours at 37°C. After incubation, the supernatant was transferred to 
Microscint-40 solution and released 51Chromium was counted in a scintillation counter 
(PerkinElmer, Waltham, MA, USA). Maximal and spontaneous lysis were determined using 
target cells incubated with 5% Triton X-100 or medium without effector cells, respectively. 
Specific lysis was calculated as (wherein cpm is counts per minute): 
Isolation of monocytes and culturing human monocyte-derived macrophages 
(h-MDM)
PBMCs were isolated from a buffy coat from healthy donors (Sanquin) through 
centrifugation using LeucoSepTM-tubes (Greiner Bio-One, Alphen aan den Rijn, 
Netherlands) containing Lymphocyte Separation Medium (Corning). Human CD14+ 
monocytes were obtained from healthy donor PBMCs through positive isolation using 
CD14 MicroBeads (Miltenyi Biotec, Leiden, Netherlands) according to the manufacturer’s 
instructions. Monocytes were cultured in culture medium (CellGenix® GMP DC serum-
free medium with 50 ng/ml M-CSF) in Nunc™ dishes with UpCell™ surface (Thermo Fisher 
Scientific) at 37˚C/5%CO
2
 for 7-8 days to obtain human monocyte-derived macrophages 
(h-MDM). h-MDMs were characterized by flow cytometry for expression of myeloid- and 
macrophage-specific maturation markers (Supplementary Table 3). 
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expressed as the gMFI of the ungated cell population. The two non-cross-blocking test 
antibodies served as control antibodies for each other. To correct for expression differences 
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Where μ and σ are the mean and SD of the normalized gMFI of all mutants. Z-scores < 0 are 
caused by loss of binding of bsIgG-ctrlxCD37-016 in comparison to bsIgG-CD37-010xctrl while 
z-scores > 0 are caused by loss of binding of bsIgG-CD37-010xctrl in comparison to bsIgG-
ctrlxCD37-016. Amino acid residues where the z-score was higher than 1.5 (bsHx-CD37-
010xctrl) or lower than –1.5 (bsHx-ctrlxCD37-016), indicated by the horizontal dotted lines, 
were considered as ‘loss of binding mutants’. 
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Sweden) and incubated with antibody concentration series and PBMCs from healthy human 
donors (isolated from buffy coats) as effector cells at a 100:1 effector to target ratio for four 
hours at 37°C. After incubation, the supernatant was transferred to Microscint-40 solution and 
released 51Chromium was counted in a scintillation counter (PerkinElmer, Waltham, MA, USA). 
Maximal and spontaneous lysis were determined using target cells incubated with 5% Triton 
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cpm is counts per minute):  
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Isolation of monocytes and culturing human monocyte-derived macrophages (h-MDM) 
PBMCs were isolated from a buffy coat from healthy donors (Sanquin) through centrifugation 
using LeucoSepTM-tubes (Greiner Bio-One, Alphen aan den Rijn, Netherlands) containing 
Lymphocyte Separation Medium (Corning). Human CD14+ monocytes were obtained from 
healthy donor PBMCs through positive isolation using CD14 MicroBeads (Miltenyi Biotec, 
Leiden, Netherlands) according to the manufacturer’s instructions. Monocytes were cultured 
in culture edium (CellGenix® GMP DC serum-free medium with 50 ng/ml M-CSF) in Nunc™ 
dishes with UpCell™ surface (Thermo Fisher Scientific) at 37C/5%CO2 for 7-8 days to 
obtain human monocyte-derived macrophages (h-MDM). h-MDMs were characterized by 
flow cytometry for expression of myeloid- and macrophage-specific maturation markers 
(Supplementary Table 3). 
Animal husbandry 
In house animal experiments were performed in compliance with the Dutch animal protection 
law (WoD) translated from the directives (2010/63/EU) and, if applicable, the Code of Practice 
“animal experiments for cancer research” (Inspection V&W, Zutphen, The Netherlands, 1999) 
and were approved by the Ethical Committee of Utrecht. Daudi-luc and DOHH-2 studies were 
performed with female C.B-17/lcrHan®Hsd-Prkdcscid mice, 7-8 weeks old, obtained from Envigo 
(Huntington, United Kingdom). Mice were housed in a barrier unit of the Central Laboratory 
Animal Research Facility (CLARF) of the Utrecht University (Netherlands) in sterile individually 
ventilated cages (IVC), 5 mice per cage, with sterile food and water provided ad libitum. 
Animals were housed and handled in accordance with good animal practice as defined by the 




In house animal experiments were performed in compliance with the Dutch animal 
protection law (WoD) translated from the directives (2010/63/EU) and, if applicable, 
the Code of Practice “animal experiments for cancer research” (Inspection V&W, Zutphen, 
The Netherlands, 1999) and were approved by the Ethical Committee of Utrecht. Daudi-luc 
and DOHH-2 studies were performed with female C.B-17/lcrHan®Hsd-Prkdcscid mice, 7-8 
weeks old, obtained from Envigo (Huntington, United Kingdom). Mice were housed in 
a barrier unit of the Central Laboratory Animal Research Facility (CLARF) of the Utrecht 
University (Netherlands) in sterile individually ventilated cages (IVC), 5 mice per cage, 
with sterile food and water provided ad libitum. Animals were housed and handled 
in accordance with good animal practice as defined by the Federation of European 
Laboratory Animal Science Associations (FELASA), in an Association for assessment and 
accreditation of laboratory animal care (AAALAC) and ISO 9001:2000 accredited animal 
facility (GDL, Utrecht, Netherlands).
JVM-3 studies were performed with CB17/ICR-PrkdcSCID/IcrlcoCrl mice (Vital River 
Laboratories, Beijing, China) at Crown Bioscience, China. All studies were conducted 
following an approved Institutional Animal Care and Use Committee (IACUC) protocol. All 
experimental data management and reporting procedures were in strict accordance with 
applicable Crown Bioscience, Inc. Guidelines and Standard Operating Procedures. 
NHL patient-derived xenograft (PDX) studies (Supplementary Table 6) were performed 
with CB-17SCID mice (Janvier labs, Le Genest-Saint-Isle, France) at EPO Experimental 
Pharmacology & Oncology Berlin-Buch GmbH, Germany. All animal experiments were 
performed in accordance with the Guidelines for the Welfare and Use of Animals in Cancer 
Research and of the German Animal Protection Law, and approved by the local responsible 
authorities, following standard operating procedures for optimal performance.
Cell line- and patient-derived xenograft studies
Samples sizes of animal models were chosen based on the specific tumor growth 
properties (homogeneous vs heterogeneous tumor growth) and the expected efficacy 
of the drug. Furthermore, our experience has taught us that especially outliers will 
influence the statistical power. Therefore, 10-20% more mice are added to the study 
design in models where heterogeneous tumor growth is expected, such that animals 
with the highest and/or the lowest tumor volumes can be excluded from the study at 
the moment of randomization.
The Daudi-Luc cell line-derived xenograft (CDX) study was performed with 2.5x106 
cells inoculated intravenously (IV) into 7-8 weeks old CB-17 SCID mice. Based on 
bioluminescence imaging on day 0 (obtained within 2 hours post injection of Daudi-luc 
cells), the animals were randomized into groups of 9 animals each. Animals which showed 
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no signal in the lungs at this time point and/or a clear signal at the injection site (tail vein) 
were excluded from randomization. At days 14, 21 and 28 after tumor cell inoculation, mice 
were treated with antibody by intraperitoneal (IP) injection. At weekly intervals, tumor 
growth was assessed using bioluminescence imaging on a Photon Imager (Biospace Lab, 
Nesles-la-Vallée, France). Before imaging, mice were anaesthetized via isoflurane and 
synthetic D-luciferin (BioThema, Handen, Sweden) was injected IP at a dose of 125 mg/kg; 
M3 Vision software (Biospace Lab, Nesles-la-Vallée, France) was used for image analysis. 
The DOHH-2 and JVM-2 CDX studies were performed with 1x106 and 1x107 cells inoculated 
subcutaneously (SC) into the flanks of 8-10 and 7-8 weeks old individual CB-17 SCID mice, 
respectively. Mice were randomized into groups (n=10) with equal tumor size distribution 
when tumors reached 100 and 200 mm3 respectively, and treated IP (DOHH-2) or IV 
(JVM-3) with 3 weekly doses (QWx3) of antibody. Tumor volume was measured at least 
twice per week using caliper measurements and calculated as 0.52 x (length) x (width)2. 
Animals were euthanized when tumors reached 1 500/2 000 mm3. During all CDX studies, 
heparinized blood samples were taken for determination of IgG levels in plasma. All CDX 
studies were performed using a blinded assessment of outcome measures.
NHL PDX models were performed with human tumor tissue implanted subcutaneously 
into the flanks of 6-7 weeks old CB17-SCID mice, and tumors were allowed to reach 
100-250 mm3. Mice were randomized into groups (n=8) according to their tumor 
volume and treated IV with 2 weekly doses (QWx2) of antibody. Tumor volume was 
measured thrice weekly. 
The PDX screening was performed as described above for regular PDX models, 
only using one mouse per group design. The relative tumor growth was defined as 
the ratio between the tumor growth in the DuoHexaBody-CD37-treated mouse (ΔT) 
and the control mouse (ΔC), specifically ΔT/ΔC. Tumor growth was calculated as 
the difference in tumor volume between day of first treatment and day of analysis, ideally 
between 7 and 25 days after initiation of treatment. Models in which the control mouse 
tumor volume did not increase 2-fold after start treatment were excluded from analysis. 
Models were categorized according to the following criteria: responders = ΔT/ΔC <10%; 
intermediates = 10% ≤ ΔT/ΔC ≤ 70%; non-responders = ΔT/ΔC > 70%. All PDX studies were 
performed using a blinded assessment of outcome measures. 
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S U P P L E M E N TA L  TA B L E S
Table 1. The (origin of) cell lines used in this study
Cell line Origin Company Cat. No.
Daudi Burkitt’s lymphoma ATCC CCL-213
DOHH-2 Diffuse large B-cell lymphoma DSMZ ACC-47
Jeko-1 Mantle cell lymphoma DSMZ ACC-553
JVM-2 Mantle cell lymphoma DSMZ ACC-12
JVM-13 Mantle cell lymphoma ATCC CRL-3003
OCI-Ly7 Diffuse large B-cell lymphoma DSMZ ACC-688
OCI-Ly19 Diffuse large B-cell lymphoma DSMZ ACC-528
Raji Burkitt’s lymphoma ATCC CCL-86
Ramos Burkitt’s lymphoma ATCC CRL-1596
RC-K8 Diffuse large B-cell lymphoma DSMZ ACC-561
RI-1 Diffuse large B-cell lymphoma DSMZ ACC 585
SU-DHL-4 Diffuse large B-cell lymphoma ATCC CRL-2957
SU-DHL-8 Diffuse large B-cell lymphoma DSMZ ACC-573
U-2932 Diffuse large B-cell lymphoma DSMZ ACC-633
Wien-133 Burkitt’s lymphoma BioAnaLab, Oxford, UK
WIL2-S EBV-positive B lymphoblastic cell line ATCC CRL-8885
WSU-DLCL2 Diffuse large B-cell lymphoma DSMZ ACC-575
Z-138 Mantle cell lymphoma ATCC CRL-3001
Table 2. Antibodies used for identification of cell subsets in primary patient sample CDC assays
Target Label Target expression Company Cat. No.
CD45 BV785 Leukocytes BioLegend 304048
CD45 KO Leukocytes Beckman Coulter B36294
CD19 PE B cells Beckman Coulter A07769
CD19 PC7 B cells Beckman Coulter IM3628
CD3 T cells BD 560365
CD5 APC Expressed on most T cells and some B cell 
subsets, including some malignant B cells
BD 345783
CD5 PE See CD5-APC DAKO R084201
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Table 3. Antibodies used for h-MDM characterization
Target Label Target expression Company Clone Cat. No.
CD14 PE-Cy7 Maturation and lineage marker for 
monocytes/macrophages
BD Pharmingen M5E2 557742
CD11b PE General myeloid cell lineage and 
maturation marker 
BD Pharmingen ICRF44 555388
CD64 FITC FcgRI (IgG1), expressed on  
mature antigen-presenting cells 
including macrophages
Biolegend 10.1 305006
CD80 APC B7-1, expressed on  




CD163 BV421 Macrophage  
sub lineage/maturity marker
Biolegend GHI/61 333612
CD206 BV711 Mannose receptor, macrophage 
maturity/sub lineage marker 
Biolegend 15-2 321136
FVS eFluor660 Staining of dead cells BD Biosciences 565694
Table 4. Antibodies used for identification of cell subsets in ADCP assays
Target Label Target expression Company Clone Cat. No.
CD11b PE h-MDM BD Pharmingen ICRF44 555388
CD19 BV711 Tumor B cells (Daudi) Biolegend SJ25C1 363026
FVS eFluor660 Staining of dead cells eBioscience 65-0864-14
Table 5. Lineage-specific antibodies for identification of leukocyte subsets in human whole blood
Target Label Target expression Company Clone Cat. No.
CD19 BV711 B cells Biolegend HIB19 302245
CD3 eFluor450 T cells e-Biosciences OKT3 48-0037
CD56 PE-CF594 NK cells BD NCAM16.2 564849
CD16 BV785 Neutrophils Biolegend 3G8 302046
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Over the last decades, several surface antigens have been identified and validated for 
treatment of B-cell malignancies. CD20-targeting antibodies have emerged as an effective 
therapy for patients with B-cell malignancies and are now broadly used in clinical practice. 
Nonetheless, many patients develop resistance against CD20-targeting therapies, 
with little or no further treatment options (1). Tetraspanin CD37 is expressed almost 
exclusively on hematopoietic cells with high expression on mature B-cells, including 
their malignant counterparts (2, 3), and is a well described and validated target for B-cell 
malignancies. A number of CD37 targeting agents are in (pre)clinical development, 
including antibody-drug conjugates (IMGN529 and AGS67E), an Fc-engineered 
antibody (BI836826) a homodimeric therapeutic protein (otlertuzumab/TRU-016), 
a radioimmunoconjugate (177Lu-lilotomab) and chimeric antigen receptor T-cells (4-6). 
We recently reported on the development of DuoHexaBody-CD37, a novel biparatopic 
CD37-bispecific IgG1 antibody with an E430G hexamerization-enhancing single point 
mutation in the Fc-domain (7). In contrast to all other newly developed CD37 targeting 
agents, DuoHexaBody-CD37  mediates potent complement-dependent cytotoxicity 
(CDC), a powerful anti-tumor effector mechanism (8, 9),  in addition to its FcγR-mediated 
tumor cell kill mechanisms including antibody-dependent cellular cytotoxicity (ADCC) 
and cellular phagocytosis (ADCP). DuoHexaBody-CD37 was designed based on recent 
discoveries that (i) initation of CDC is dependent on Fc-mediated hexamer-formation 
of IgG1 antibodies after target engagement on the cell surface (10), (ii) antibody Fc-Fc 
interactions and hexamer formation can significantly be improved by introducing an 
E430G single point mutation in the Fc domain (10, 11), and (iii) dual-epitope targeting of 
CD37 can potentiate or further enhance CDC (7). 
Here, we investigated the ex vivo therapeutic potential of DuoHexaBody-CD37 by 
evaluating its unique CDC-inducing capacity in primary tumor cell samples from a large 
cohort of newly diagnosed (ND) and relapsed/refractory (RR) patients with a broad 
range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and B-cell 
non-hodgkin lymphoma (B-NHL), including diffuse large B-Cell lymphoma (DLBCL), 
follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma 
(MZL) (Supplemental Material and Methods). DuoHexaBody-CD37 induced potent, 
dose-dependent CDC of malignant primary B-cells  in 45 minute complement assays 
with a median maximal lysis of 86% (n=51, range: 0%-99%) and a median half maximal 
effective concentration (EC
50
) of 0.10 µg/mL (range 0.004-15.21 µg/mL) (Figure 1A). 
Strikingly, sensitivity of the patient samples to DuoHexaBody-CD37-induced CDC was 
highly homogeneous. Only in 8 out of 51 patient samples maximal lysis was lower than 
60%, of which three samples demonstrated responses below 20% lysis. The CDC activity 
of DuoHexaBody-CD37 was comparable in samples from ND patients (n=33) (median 





of 89%; range CDC 5%-99%). Furthermore, DuoHexaBody-CD37 was significantly more 
potent than the CD20-targeting antibody rituximab in samples from ND patients, i.e. 
CD20 antibody treatment naïve patients (Figure 1B), even though CD37 expression was 
generally lower than expression of CD20 (Supplemental Figure 1). 
Potent cytotoxicity was also observed in samples from patients who relapsed from 
(Figure 1B blue symbols; n=7) or were refractory to treatment regimens containing CD20-
targeted antibodies (defined by progression of the disease within 6 months post treatment; 
Figure 1B red symbols; n=5), with the exception of one CD20-refractory FL patient. CD37 
expression analysis (Figure 1C) revealed that this patient lacked CD37 expression on tumor 
B-cells. Since it has been reported that anti-CD20 therapy may induce CD20 antigen loss 
(12), and CD20 colocalizes with CD37 on the cell surface (13), we evaluated the possibility 
that CD37 expression levels were reduced on tumor B-cells derived from patients that had 
been exposed to anti-CD20. However, all anti-CD20 treated patient samples in our cohort 
showed high CD37 expression levels and no significant differences were observed in CD37 
expression levels between samples from ND and RR patients (Figure 1C).
In addition, CD37 was expressed homogeneously in all B-cell malignancy subtypes 
(Figure 1D), which is in alignment with several other reports (2, 6) except for a recent study 
Figure 1. DuoHexaBody-CD37 induced potent CDC in samples obtained from newly diagnosed 
and relapsed/refractory patients with various B-cell malignancies. (A) Dose-dependent CDC 
induced by DuoHexaBody-CD37 in tumor B-cells (n=51) derived from patients with various B-cell 
malignancy subtypes grouped together, in the presence of 20% normal human serum (NHS) 
and in comparison to IgG1-ctrl (10 µg/mL). Levels of CDC-mediated tumor cell kill (% CDC) were 
determined by 7AAD-positive tumor cell staining, relative to a no antibody control sample. (B) 
Comparison of CDC activity of 10 µg/mL DuoHexaBody-CD37 in samples from newly diagnosed 
(ND; n=33) and relapsed/refractory (RR; n=18) patients (not significant (ns); Mann Whitney U test), 
and comparison of Rituximab (10 µg/mL) and DuoHexaBody-CD37 in ND patients (****p<0.0001; 
Wilcoxon matched-pairs signed rank test). RR patients include CD20 therapy-refractory patients 
(n=5; ), defined by progression of the disease within 6 months post therapy, and CD20 therapy-
relapse patients (n=6; ). (C) CD37 expression levels (defined as the number of CD37 molecules on 
the cell surface, assessed by quantitative flow cytometry), on tumor B-cells in ND and RR patient 
samples (ns; Mann Whitney U test). (D) Quantified CD37 expression levels (antibody molecules 
per cell) on tumor B-cells stratified according to B-cell malignancy subtype (ns, non-parametric 
Kruskal-Wallis test). All data are shown as the median and interquartile range. (E) CDC activity of 
DuoHexaBody-CD37 (10 µg/mL) stratified according to B-cell malignancy subtype, including CLL 
(n=10), FL (n=12), MCL (n=7), DLBCL (n=18) and MZL (n=4) (*p=0.0321, non-parametric Kruskal-Wallis 
test with Dunn’s multiple comparisons (ns)). Green symbols ( ) indicate patient samples with poor 
prognosis: ibrutinib-refractory CLL (n=2) and double-hit DLBCL (n=3). 7-AAD = 7-Aminoactinomycin 
D, CDC = complement-dependent cytotoxicity, CLL = chronic lymphocytic leukemia, DLBCL = 
diffuse large B-cell lymphoma, FL = follicular lymphoma, IgG1 = immunoglobulin G1, MCL = mantle 
cell lymphoma, MZL = marginal zone lymphoma, ND = newly diagnosed, NHS = normal human 
serum, NS = not significant, RR = relapsed/refractory.
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that suggested variable CD37 expression in DLBCL (14). This study-related discrepancy 
could be due to differences in assay-dependent detection limits in our study (flow 
cytometry) versus the other (immunohistochemistry) study. DuoHexaBody-CD37 
induced an effective and homogeneous CDC response in all samples from CLL (n=10; 
median max lysis 93%; range; 80%-99%), MCL (n=7; 91%; 69%-98%) and MZL (n=4; 
88%; 75%-90%), and 11 out of 12 FL patient samples (n=12; 86%; 5%-98%), while a more 
heterogeneous response was observed in DLBCL patient samples (n=18; 74%; 0%-96%) 
(Figure 1E) (Kruskal-Wallis one-way analysis of variance (ANOVA), p=0.0321). There were 
no differences in sensitivity between activated B-cell (ABC) and germinal center B-cell 
(GCB) subtypes of DLBCL (Supplemental Figure 2). Of note, also samples from ibrutinib-
refractory CLL (n=2) and double-hit DLBCL (n=3) patients with poor prognosis were highly 
susceptible to DuoHexaBody-CD37-induced CDC (maximum lysis > 60%) (Figure 1E). 
Complement activation and CDC-mediated tumor cell lysis is not only dependent on 
antigen density, but also on expression levels of complement regulatory proteins (CRPs) 
CD46 and CD55 that inhibit complement convertases, and CD59 that inhibits the formation 
of the membrane attack complex (15). Expression of CRPs was not associated with B-cell 
malignancy subtype (Figure 2A) or treatment status (Supplemental Figure 3). 
Furthermore, no correlation was observed between DuoHexaBody-CD37-induced 
CDC and expression of CD37 or CRPs (Supplemental figure 4). A weak, but statistically 
significant correlation was observed between sensitivity to DuoHexaBody-CD37 and 
the ratio of CD37 and CD59 expression levels (Figure 2B). However, in DLBCL patient 
samples, differences in (the ratio of) CD37 and CD59 expression could not explain 
the heterogeneous response to DuoHexaBody-CD37 ex vivo (Figure 2B orange symbols). 
We therefore conclude that there is a limited impact of CRP expression on DuoHexaBody-
CD37-mediated CDC. This was in contrast to rituximab-induced CDC, which already 
showed a strong correlation with CD20 expression but an even stronger correlation with 
the ratio of CD20 and CD55 (Supplemental Figure 5).
The first step of complement activation is the binding of C1q to membrane-bound 
antibodies, that together with C1r and C1s forms the C1 complex, the first component 
of the classical complement pathway. Towards understanding the heterogeneity in 
CDC responses observed in DLBCL patient samples, we investigated the C1q binding 
capacity of membrane-bound DuoHexaBody-CD37 in DLBCL patient samples for which 
DuoHexaBody-CD37-mediated CDC levels were lower than 60% (N=6). The C1q binding 
capacity in low CDC responders was comparable to that of two patient samples highly 
susceptible to DuoHexaBody-CD37-induced CDC (Figure 2C), indicating that the first 
step of complement activation is not impaired. Whether other steps in the complement 
activation pathway, such as membrane attack complex assembly and stability, or cell 
intrinsic mechanisms, play a role in resistance to CDC induction remains to be elucidated. 
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Figure 2. Low sensitivity to DuoHexaBody-CD37-mediated CDC is not associated with 
expression of CD37 and CRPs and can be improved by combination with CD20 mAbs. (A) 
Quantified expression levels (antibody molecules per cell) of complement regulatory proteins 
CD46, CD55 and CD59 on tumor B-cells in specific B-cell malignancy subtypes; CLL (n=10), FL (n=12), 
MCL (n=7), DLBCL (n=18) and MZL (n=4) (ns; non-parametric Kruskal-Wallis test). Data shown are 
CDC in individual patient samples, in addition to the median and interquartile range. (B) CDC 
activity of DuoHexaBody-CD37 (10 µg/mL) correlated with the ratio of CD37/CD59 expression levels 
for all B-cell malignancy subtypes grouped together, for DLBCL patient samples specifically ( ) and 
for B-cell malignancy subtypes other than DLBCL (Spearman’s correlation r=0.4423, **p=0.0013; 
r=0.2843, p=0.2678 and r=0.5158, **p=0.0025, respectively). Data are shown relative to a no 
antibody control sample. (C) Expression levels of CD37 (antibody molecules per cell) correlated 
with C1q binding (ΔMFI) for 6 samples with low CDC response (CDC < 60%) ( ), 1 CD37-negative 
sample as negative control ( ) and 2 high responding samples as positive control ( ) (Spearman’s 
correlation r=0.7833, *p=0.0172). (D) CDC induced by a combination of DuoHexaBody-CD37 and 
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Finally we also evaluated whether combination with rituximab and/or ofatumumab 
could further enhance the CDC activity of DuoHexaBody-CD37, as we have previously 
reported enhanced CDC in CLL and B-NHL primary patient cells with combinations of 
CD20 and CD37 antibodies (13). Indeed, in 10 patient samples including samples with 
intermediate to low sensitivy to DuoHexabody-CD37-mediated CDC (<80% CDC), 
the combination of DuoHexaBody-CD37 with  ofatumumab significantly enhanced 
the tumor cell kill in an additive manner (Figure 2D). In contrast to ofatumumab, rituximab 
as single antibody could generally not induce CDC in these samples and the CDC-effects 
of the combination with DuoHexaBody-CD37 are less striking.  
In conclusion, this preclinical study indicates high therapeutic potential for DuoHexaBody-
CD37 in a broad spectrum of B-cell malignancies either as single agent or in combination 
with CD20-targeting antibodies, and supports the recently initiated first-in-human 
clinical trial of DuoHexaBody-CD37 for patients with relapsed or refractory B-cell NHL 
(NCT04358458). 
AC K N OW L E D G E M E N T S
The authors would like to thank Henk Lokhorst for his contribution in the early stage of 
the study. 
This work was supported by research funding from Genmab (Utrecht, the Netherlands). 
The graphical abstract was created using BioRender.com.
A U T H O R S H I P
Contribution: H.J.H. and A.T.G. performed experiments, H.J.H., S.C.O., A.T.G., M.B.O., 
I.S.N., S.Z., M.E.D.C., E.C.W.B. and T.M. designed experiments and discussed results. 
S.C.O., S.A.G.M.C., M.B.O., and E.C.W.B. provided essential materials. H.J.H. wrote 
the manuscript. All authors critically revised and modified the manuscript, and approved 
the final version.  
rituximab or ofatumumab (10 µg/mL+10 µg/mL) versus single antibody (10 µg/mL) (n=10) (*p<0.05, 
***p<0.001 ; Friedman test with Dunn multiple comparison test) relative to a no antibody control 
sample. All data are shown as the median and interquartile range. CDC = complement-dependent 
cytotoxicity, CLL = chronic lymphocytic leukemia, CRP = complement regulatory protein, 
DLBCL = diffuse large B-cell lymphoma, FL = follicular lymphoma, mAbs = monoclonal antibodies, 
MCL = mantle cell lymphoma, MFI = median fluoresence intensity, MZL = marginal zone lymphoma. 
139
4
C O M P E T I N G  I N T E R E S T
S.C.O., M.B.O. and E.C.W.B. are Genmab employees and own Genmab warrants and/or 
stock. H.J.H., S.C.O., M.B.O., M.E.D.C., E.C.W.B. and T.M. are inventors on Genmab patent 
applications. M.E.D.C. has received research support from Gilead, Genmab and Celgene. 
S.Z. has received research support from Celgene, Janssen Pharmaceuticals and Takeda; 
and serves in advisory boards for Celgene, Janssen Pharmaceuticals, Takeda, Amgen, 
and Sanofi. T.M. has received research support from Janssen Pharmaceuticals, Genmab, 
Takeda, Onkimmune, and Gadeta.
140
4
R E F E R E N C E S
1. Salles G, Barrett M, Foà R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-Cell 
Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in 
therapy. 2017 Oct;34(10):2232-73.
2. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody-drug 
conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. 
Blood. 2013 Nov 14;122(20):3500-10.
3. Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen 
(gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. 
Journal of immunology (Baltimore, Md : 1950). 1988 Feb 1;140(3):905-14.
4. Witkowska M, Smolewski P, Robak T. Investigational therapies targeting CD37 for the treatment 
of B-cell lymphoid malignancies. Expert opinion on investigational drugs. 2018 Feb;27(2):171-7.
5. Scarfo I, Ormhoj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, et al. Anti-CD37 
chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018 
Oct 4;132(14):1495-506.
6. Koksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fane A, et al. Preclinical 
development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood advances. 
2019 Apr 23;3(8):1230-43.
7. Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, et al. 
DuoHexaBody-CD37((R)), a novel biparatopic CD37 antibody with enhanced Fc-mediated 
hexamerization as a potential therapy for B-cell malignancies. Blood Cancer J. 2020 
Apr 28;10(3):30.
8. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation 
determines the therapeutic activity of rituximab in vivo. Journal of immunology (Baltimore, 
Md : 1950). 2003 Aug 1;171(3):1581-7.
9. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, 
a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma 
and other hematological tumors. Journal of immunology (Baltimore, Md : 1950). 2011 
Feb 1;186(3):1840-8.
10. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. 
Complement is activated by IgG hexamers assembled at the cell surface. Science (New York, 
NY). 2014 Mar 14;343(6176):1260-3.
11. de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, et al. 
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent 
Formation of IgG Hexamers at the Cell Surface. PLoS biology. 2016 Jan;14(1):e1002344.
12. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion 
promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. 
Journal of immunology (Baltimore, Md : 1950). 2004 Mar 1;172(5):3280-8.
141
4
13. Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, et al. CD20 
and CD37 antibodies synergize to activate complement by Fc-mediated clustering. 
Haematologica. 2019 Sep;104(9):1841-52.
14. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, et al. Assessment 
of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large 
B-cell lymphoma. Blood. 2016 Dec 29;128(26):3083-100.
15. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement 
regulatory proteins. Immunology today. 1999 Dec;20(12):576-82.
142
4
S U P P L E M E N TA L  M AT E R I A L  A N D  M E T H O D S
Therapeutic Antibodies
DuoHexaBody-CD37 and the negative control anti-HIV-1 gp120 antibody IgG1-b12 
(mentioned in manuscript as IgG1-ctrl) were  generated by Genmab (Utrecht, 
The Netherlands) as previously described (S.C. Oostindie et al., 2019). Rituximab 
(MabThera®) and ofatumumab (Arzerra®) were obtained from Genmab.
Patient samples
According to the Dutch Central Committee on Research involving Human Subjects 
(CCMO), this type of study does not require approval from an ethics committee. Primary 
patient samples wereh collected at Amsterdam University Medical Center, location 
VUmc, according to the code of conduct for medical research. Tissues from lymph 
node biopsies were mechanically disrupted, cultured overnight in a fully humidified 
incubator and the cells in suspension were collected and cryopreserved in liquid nitrogen 
until further use. For 7 CLL samples and 1 MCL sample tumor cells were isolated from 
mononuclear cells of the bone marrow (BMNCs) or peripheral blood (PBMCs) by density-
gradient centrifugation (Ficoll-Paque PLUS, Cytiva, MA, USA) according to manufacturer’s 
instructions, and were either used directly or cryopreserved in liquid nitrogen until 
further use. 
Tumor-specific surface markers
B cells were identified using flow cytometry by gating for CD3-CD19+ cells within the CD45+ 
population and made up 20-80% of the total lymph node cell population. Malignant B 
cells were identified by kappa/lambda staining to screen for clonality and if possible 
also by the tumor-specific markers CD10+ (FL and DLBCL), CD5+ (CLL), CD5+CD23- (MCL). 
The following antibodies were used: CD45-KO and CD19-PC7 (Beckman Coulter, CA, USA), 
CD3-V450, CD5-APC, CD10-APC-H7 and kappa-APC-H7 (BD, NJ, USA), CD5-PE, CD10-PE 
and kappa-PE (DAKO, Agilent Technologies, CA, USA), CD23-FITC (BioLegend, CA, USA) 
and lambda-FITC (Emelca Bioscience, Clinge, Netherlands). 
Quantitated expression assays
Target cells were incubated with purified mouse anti-human IgG1 antibodies against CD37, 
CD46, CD55, CD59 and CD20 (BioLegend) and expression levels were quantified by flow 
cytometry using an indirect immunofluorescence assay (QIFIKIT®, Agilent Technologies) 
according to manufacturers protocol, followed by a staining for tumor specific 




Complement-dependent cytotoxicity assays were performed by incubation of single 
cell suspensions (1x105 cells/well) with serial dilutions (0.01-10 µg/mL) of DuoHexaBody-
CD37 for 45 minutes at 37°C in the presence of 20% normal human serum (NHS; 
pooled from 8 healthy donors) as a source of complement. Cells were analysed by flow 
cytometry and viability (%) and lysis (%) of malignant B cells was determined according to 
the following formulas: 
C1q binding assays
Target cells were incubated with DuoHexaBody-CD37 (10 µg/mL) and purified human 
complement component C1q (2.5 µg/mL; Quidel, San Diego, CA) for 45 min at 37°C. After 
washing, purified C1q was labeled with a fluorescein isothiocyanate (FITC)-conjugated 
rabbit anti-human C1q antibody (Dako, Glostrup, Denmark). Binding was detected by flow 
cytometry and expressed as the median fluorescent intensity (MFI). MFI values of purified 
C1q labeled with FITC anti-human C1q were subtracted by MFI values of negative control 
(FITC-anti-human C1q only). 
Statistical analysis
Flow cytometry data were analyzed using FACS DIVA software. Graphs were plotted 
using GraphPad Prism 8.2. for Windows. Statistical analysis was performed with 
the appropriate parametric or non-parametric test, as indicated in the figure legends. 
Two-sided P values < .05 were considered statistically significant.
13 
 
PE (DAKO, Agilent Technologies, CA, USA), CD23-FITC (BioLegend, CA, USA) and lambda-
FITC (Emelca Bioscience, Clinge, Netherlands).  
Quantitated expression assays 
Target cells were incubated with purified mouse anti-human IgG1 antibodies against CD37, 
CD46, CD55, CD59 and CD20 (BioLegend) and expression levels were quantified by flow 
cytometry using an indirect immunofluorescence assay (QIFIKIT®, Agilent Technologies) 
according to manufacturers protocol, followed by a staining for tumor specific cell surface 
markers.  
Complement-dependent cytotoxicity assays 
l ent-dependent cytot xicity assays were perfo med by incubation of single cell 
suspensions (1x105 cells/well) with serial dilutions (0.01-10 µg/mL) of DuoHexaBody-CD37 for 
45 minutes at 37°C in the presence of 20% normal human serum (NHS; pooled from 8 healthy 
donors) as  source of complement. Cells were a alysed by flow cytometry and viability (%)
and lysis (%) of malignant B cells was determined according to the following formulas:  
%��𝑠𝑠��𝑐𝑐�𝑡𝑡� � 100 ∗ � %7��� � 𝑐𝑐𝑐𝑐�𝑠𝑠𝑡𝑡��𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜 𝑡𝑡𝑐𝑐𝑐𝑐𝑡𝑡 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐%7��� � 𝑐𝑐𝑐𝑐�𝑠𝑠𝑡𝑡��𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜 𝑐𝑐𝑜𝑜𝑐𝑐𝑡𝑡𝑐𝑐𝑜𝑜𝑐𝑐 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐� 
%𝑐𝑐�𝑐𝑐�𝑐𝑐 � �100 � %��𝑠𝑠��𝑐𝑐�𝑡𝑡�� 
C1q binding assays 
Target cells were incubated with DuoHexaBody-CD37 (10 µg/mL) and purified human 
complement component C1q (2.5 µg/mL; Quidel, San Diego, CA) for 45 min at 37°C. After 
washing, purified C1q was labeled with a fluorescein isothiocyanate (FITC)-conjugated rabbit 
anti-human C1q antibody (Dako, Glostrup, Denmark). Binding was detected by flow cytometry 
and expressed as the median fluorescent intensity (MFI). MFI values of purified C1q labeled 
with FITC anti-human C1q were subtracted by MFI values of negative control (FITC-anti-
human C1q only).  
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S U P P L E M E N TA L  F I G U R E S
Supplemental Figure 1. Expression levels (antibody molecules per cell) of CD37 and CD20 on tumor 
B cells in samples from ND patients (****p<0.0001; Wilcoxon matched-pairs signed rank test). Data 
are shown as the median and interquartile range.
Supplemental Figure 2. CDC activity of DuoHexaBody-CD37 (10 µg/mL) in DLBCL patient samples 
of ABC (n=5) and GCB subtype (n=11) (ns; Mann-Whitney U-test). Data are shown as the median and 
interquartile range.
Supplemental Figure 3. Expression levels (antibody molecules per cell) of complement regulatory 
proteins CD46, CD55 and CD59 on tumor B cells, according to treatment status; ND versus RR (not 
significant; Mann-Whitney U test). Data are shown as the median and interquartile range.
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Supplemental Figure 4. CDC activity of DuoHexaBody-CD37 (10 µg/mL) correlated with quantified 
expression levels (antibody molecules per cell) of (A) CD37 and (B-D) complement regulatory 
proteins CD46, CD55 and CD59 (Spearman’s correlation r=0.1408, p=0.3243; r=0.1929, p=0.1751; 
r=0.1901, p=0.1814; r=-0.2024, p=0.1542, respectively). Data are shown relative to a no antibody 
control sample.
Supplemental Figure 5. CDC activity of rituximab (10µg/mL) correlated with (A) quantified 
CD20 expression (antibody molecules per cell; Spearman’s correlation r=0.5488, **p=0.0011) and 
(B) the ratio of expression levels of CD20 to complement regulatory protein CD55 (Spearman’s 
correlation r=0.5957, ***p=0.0003). Data are shown relative to a no antibody control sample.
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A B S T R AC T
Apoptosis induction by death receptor (DR)-specific agonistic antibodies is 
a potentially effective anti-tumor therapy. Nonetheless, to date, all conventional 
DR-targeting antibodies, which induce apoptosis via Fcγ-receptor (FcγR)-
dependent DR clustering, failed to show clinical efficacy. HexaBody-DR5/DR5 
has been developed to overcome full FcγR-dependence. HexaBody-DR5/DR5 
is a mixture of two non-competing DR5-specific IgG1 antibodies, each with an 
E430G mutation in the Fc-domain. This mutation enhances Fc-Fc interactions, 
hereby resulting in antibody hexamerization, followed by FcγR-independent 
clustering of DR5 molecules. This unique combination of dual epitope targeting 
and increased IgG hexamerization resulted in potent preclinical anti-tumor activity 
in various solid cancers. We now explored the preclinical activity of HexaBody-
DR5/DR5 in multiple myeloma (MM) as MM cells are known to express DR5. In 
bone marrow samples of 48 MM patients, HexaBody-DR5/DR5 induced potent 
cytotoxicity of primary MM cells. Importantly, HexaBody-DR5/DR5 mediated 
the highest cytotoxic activity in samples from relapsed/refractory MM patients, 
including those who are refractory to daratumumab. This improved cytotoxic 
activity was observed only in patients who received their last anti-MM treatment 
less than a month ago, suggesting that anti-MM drugs sensitized MM cells to 
HexaBody-DR5/DR5. Supporting this, bortezomib combined with HexaBody-
DR5/DR5 synergistically increased cytotoxicity in MM cells in seven out of eleven 
newly-diagnosed patients. Lenalidomide also synergized with HexaBody-DR5/DR5, 
but only via its immunomodulatory effects, presumably by enhancing the ADCC 
activity of HexaBody-DR5/DR5. Daratumumab showed additive effects when 
combined with HexaBody-DR5/DR5. In conclusion, the results of this preclinical 
study indicate therapeutic potential of HexaBody-DR5/DR5, especially in recently 
treated relapsed/refractory MM patients. 
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I N T R O D U C T I O N
Over the past 20 years, the landscape of treatment modalities for multiple myeloma (MM), 
the malignant disease of antibody-producing plasma cells in the bone marrow (BM), has 
expanded rapidly. Starting with the introduction of immunomodulatory drugs (IMiDs) 
and proteasome inhibitors (PIs), and followed by the implementation of monoclonal 
antibodies (mAbs), the overall survival of MM patients has improved significantly (1). 
Nonetheless, MM remains difficult to cure. Few patients achieve long-term remissions 
and most of them eventually develop refractory disease, requiring alternative and more 
effective therapies. Various attempts have been undertaken to develop an effective 
therapy for MM and several solid malignancies by targeting Death Receptors-4 and 
-5 (DR4/TRAIL-R1 and DR5/TRAIL-R2). Triggering of these receptors via TRAIL (tumor 
necrosis factor related apoptosis inducing ligand) or agonistic antibodies selectively 
induced apoptosis in malignant cells derived from a variety of tumors, including MM 
(2-4). Despite promising preclinical studies, recombinant TRAIL (rhTRAIL) as well as DR-
targeting antibodies failed to show a therapeutic benefit in clinical trials (5, 6). Primary 
resistance of cancer cells, but also unfavorable pharmacokinetics or insufficient agonist 
activity have been considered accountable for the limited clinical efficacy of these 
agents. Importantly, it was shown that death receptor di- or trimerization requires 
subsequent higher order clustering for proper activation of the death receptor pathway 
(7). The agonist activity of conventional DR-targeting IgG antibodies is largely dependent 
on Fc tail-mediated antibody crosslinking via Fc gamma receptor (FcγR)-positive cells to 
provide sufficient target clustering (8). This is most probably a substantial limitation for 
their potency in clinical settings, as the frequency of intratumoral FcγR positive cells may 
be too low to achieve efficient DR crosslinking. 
To overcome this limitation, HexaBody-DR5/DR5 was developed through 
the application of the novel HexaBody® platform to DR5-targeting antibodies. This 
platform is based on the natural concept that, upon binding to antigens on a cell surface, 
immunoglobulin G (IgG) molecules can organize into ordered hexamers through 
intermolecular Fc-Fc interactions (9). HexaBody molecules are IgG1 molecules with a single 
point mutation in the Fc domain that facilitates intermolecular Fc-Fc interactions, hereby 
improving hexamer formation upon binding to the target antigen (9, 10). HexaBody-
DR5/DR5 is a 1:1 mixture of two non-competing DR5 antibodies (clone 01 and 05) both 
harboring the specific E430G mutation for hexamerization, since it was established that 
in addition to hexamerization, agonist activity of DR5 antibodies was further enhanced 
by dual-epitope targeting of DR5 (11). HexaBody-DR5/DR5 effectively induced apoptosis 
in a variety of preclinical solid tumor models, which could be achieved independent of 
FcγR-mediated antibody crosslinking (11). Encouraged by these results, we investigated 
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the preclinical efficacy of HexaBody-DR5/DR5 in MM since MM cells are known to express 
DR5 (12). To this end we tested a large set of primary BM samples (n=48), derived from 
both newly diagnosed (ND) (n=13) and relapsed/refractory (RR) (n=35) MM patients. 
M AT E R I A L  A N D  M E T H O D S
Antibodies
IgG1-DR5/DR5 is a 1:1 mixture of two non-competing DR5-specific humanized wild type 
IgG1 antibodies: IgG1-DR5-01 and IgG1-DR5-05. HexaBody-DR5/DR5 (GEN1029) is a 1:1 
mixture of the same two non-competing DR5-specific humanized IgG1 antibodies with 
an E430G hexamerization enhancing mutation in their Fc domains: Hx-DR5-01 and Hx-
DR5-05. Further technical details are described by Overdijk et al. (11). The anti-HIV-1 gp120 
antibody IgG1-b12 with E430G mutation was used as an IgG1 isotype control (IgG1-Ctrl). 
Cell lines
The indicated MM cell lines were cultured in RPMI 1640 medium (Invitrogen Life 
Technologies), supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Invitrogen) and 1% penicillin-streptomycin (pen/strep; Life Technologies) at 37°C in 
5% CO
2
. All MM cell lines were authenticated by STR profiling, at most three months 
before testing.
Bone marrow and peripheral blood mononuclear cells 
According to the Dutch Central Committee on Research involving Human Subjects 
(CCMO), this type of study does not require approval from an ethics committee. Hence, 
all patient material and clinical data used in this project have been collected according 
to the code of conduct for medical research developed by The Council of the Federation 
of Medical Scientific Societies (FEDERA), the Netherlands in 1995, which was revised in 
2002-2003 on the basis of the European Data Protection Directive and its implementation 
in the Dutch Act on the Protection of Personal Data. Bone marrow-derived mononuclear 
cells (BMMCs) or peripheral blood mononuclear cells (PBMCs) were isolated by density-
gradient centrifugation (Ficoll-Paque Plus, Cytiva) from BM aspirates or peripheral blood 
samples of patients with MM. Cells were either used directly or cryopreserved in liquid 
nitrogen until further use. 
IncuCyte Zoom Imaging
NCI-H929 cells incubated with caspase-3/7 green detection reagent (Essen Bioscience) 
were pelleted by centrifugation in a microplate image lock (IncuCyte®) (2x103 cells/well) 
and incubated with HexaBody-DR5/DR5 and IgG1-Ctrl (20 µg/mL), in triplicates. Images 
were obtained by Incucyte Zoom Imaging with a 10x objective for 24 hour every 5 min, 
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and every 30 min once a decrease in signal was detected. Apoptosis was detected by total 
green object area (µm/image). 
Western Blotting
Cells were incubated with indicated concentrations of HexaBody-DR5/DR5 or IgG1-DR5/
DR5 or with medium (negative control) for 6 hours in 12-well plates. To prepare cell lysates, 
cells were washed with ice-cold PBS and incubated for 45 minutes with ice-cold 1% NP40 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 0,5% sodium deoxycholate, 0,1% SDS) 
containing complete protease inhibitor cocktail (Roche). Total cell lysates were loaded on 
a 4-20% gradient polyacrylamide gel (Bio-Rad) for electrophoresis and were then blotted 
onto polyvinylidene difluoride (PVDF) membranes (MerckMillipore). Membranes were 
incubated with primary antibodies rabbit anti-caspase-3, rabbit anti–PARP and mouse 
anti-caspase 8 (Cell Signaling Technology) and mouse anti-actin (MerckMillipore) and 
bands were detected with infrared dye labeled antibodies p680 Goat anti-Rabbit IgG or 
800Cw Goat anti-Mouse IgG (LI-COR Biosciences) and visualized by Odyssey (LI-COR 
Biosciences). Actin was used as protein loading control. 
Flow Cytometry based cytotoxicity assays 
Cryopreserved BMMCs of MM patients containing plasma cells (range 2-80%) and other 
mononuclear immune cells were incubated at a concentration of 1x106 total BMMCs/
mL in 96-well U bottom plates with serial dilutions of HexaBody-DR5/DR5 or IgG1-DR5/
DR5 or with a fixed concentration of IgG1-Ctrl in RPMI 1640 medium supplemented with 
10% heat-inactivated FBS and 1% pen/strep at 37°C for 24hr. Optimum length of the assay 
was determined as 24 h. In the samples, quantitative Flow Cytometry (BD LSRFortessa or 
Celesta) was used to enumerate viable (7AADneg) plasma cells (CD38+CD138+) monocytes 
(CD14+), T-cells (CD3+), B-cells (CD19+/CD20+) and natural killer (NK) cells (CD3-CD56+ 
lymphocytes). Absolute live cell counts in the samples were normalized to untreated 
negative control to calculate % viability = 100 × (plasma cell counts in the test sample / 
average plasma cell counts in the negative control samples) and % kill = (100 - % viable). 
An overview of antibodies used in these flow cytometry-based cytotoxicity assays is 
shown in Table 1. 
Cell surface expression of DR5 was determined using an anti-human DR5 antibody 
(BioLegend) and normalized by MFI subtraction with an isotype control antibody. MM and 
immune cell populations were included for analysis only if more than 500 events were 
counted in untreated samples. A similar procedure was followed for cytotoxicity assays 
with cell lines. Where indicated violet tracer (Thermo Fisher) labeled PBMCs were added 
at an effector to target cell ratio (E:T) of 40:1. 
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Table 1. Antibodies used for flow cytometry-based cytotoxicity assays
Target Label Company
CD38 V450 BD Biosciences
CD138 PE Beckman Coulter
CD56 PC7 Beckman Coulter
CD45 KO Beckman Coulter
CD20 FITC BD Biosciences
CD3 APC BD Biosciences
CD14 APC-H7 BD Biosciences
dsDNA (7-AAD) PerCp BD Biosciences
To explore the direct effect of lenalidomide, bortezomib or daratumumab combined 
with HexaBody-DR5/DR5 on primary patient samples, all agents were simultaneously 
added to the 96-well plates. Given that in preliminary assays the immunomodulatory and 
tumor sensitizing effects of lenalidomide were optimally detectable after an incubation 
period of 5 days which typically exceeds the survival time of primary MM cells ex vivo, we 
explored the combinatorial effects of lenalidomide with HexaBody-DR5/DR5 on MM cell 
lines. Either the MM cell line or the effector PBMCs were preincubated with lenalidomide 
for 5 days, hereafter the effector cells and MM cells were co-incubated in the presence 
of HexaBody-DR5/DR5 for an additional 24 hours. The combination with daratumumab 
was tested in the presence of 20% pooled normal human serum (NHS) that contains 
active complement. When daratumumab was used as a control for ADCC, heat inactivated 
human serum was used. 
Statistical analysis
Flow cytometry data were analyzed using FACS DIVA software. Graphs were plotted using 
GraphPad Prism 8.2. for Windows. Statistical analysis was performed with the appropriate 
parametric or non-parametric test, as indicated in the figure legends. Two-sided P 
values < .05 were considered statistically significant. Synergy was calculated according to 
the Bliss synergy model, whereby combination treatment is considered “synergistic” if 
the observed effect significantly exceeded the expected effect. 
R E S U LT S
HexaBody-DR5/DR5 induces high and specific MM cell kill in bone marrow samples 
of MM patients 
We tested the capacity of HexaBody-DR5/DR5 to kill malignant MM cells using BMMCs 
of MM patients (n=48), which contained 2-80% MM cells. The clinical characteristics 
of the MM patients are shown in Table 2. HexaBody-DR5/DR5 induced cytotoxicity of 
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primary MM cells with a median cell kill of 36% (range 0-86%). A 1:1 mixture of the same 
DR5-antibodies without the hexamerization enhancing E430G mutation (IgG1-DR5/
DR5) induced significantly lower cytotoxicity compared to HexaBody-DR5/DR5 
(Figure 1A). Cytotoxic activity of IgG1-DR5/DR5 may at least partly be attributed to 
the presence of FcγR-positive cells (eg. NK cells) in the bone marrow cell suspensions that 
can induce FcγR-dependent ADCC and/or crosslinking of membrane bound antibodies. 
However, enhanced tumor cytotoxicity in the presence of HexaBody-DR5/DR5 supports 
the relevance of enhanced hexamerization in addition to dual epitope targeting for DR5 
agonist activity.
DR5 expression, which was determined in 46 samples, was heterogeneous, and 
showed a weak but significant correlation with HexaBody-DR5/DR5 induced cytotoxicity 
(r=0.33, p=0.02) (Figure 1B). In 35 of these samples, we also evaluated the cytotoxicity 
of HexaBody-DR5/DR5 on monocytes, T-, NK- and B-cells (Figure 1C). HexaBody-DR5/
DR5 induced little or no cytotoxicity in all these non-malignant immune cell subsets. 
The heterogeneity observed for monocytes was likely due to the tendency of monocytes 
to adhere to the bottom of plates, which affected their harvesting in automated 
flow measurements. 
Relapsed/Refractory MM patient samples are more sensitive to HexaBody-DR5/DR5 
The stratification of all tested samples into newly-diagnosed (ND, n=13) versus relapsed/
refractory (RR, n=35) patients, revealed a significantly better efficacy of HexaBody-
Table 2. MM Patient characteristics
Parameter MM patients (n=48)
Median age, years (range) 69 (25-92)
Sex, male, n (%) 25 (52%)
Disease stage, n (%)
ND, no prior therapy 13 (27%)
RR, ≤3 lines of therapy 14 (29%)
RR, >3 lines of therapy 20 (42%)
RR, unclassifiable 1 (2%)
Last exposure to therapy, n (%)
ND, no prior therapy 13 (27%)
Last exposure >1 month 14 (29%)





Last exposure date unknown 4 (8%)
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Figure 1. HexaBody-DR5/DR5 induces selective MM cell kill in bone marrow samples of 
MM patients. (A) Kill (%) of 20 µg/mL HexaBody-DR5/DR5 (n=48) and IgG1-DR5/DR5 (n=39) in 
a 24-hour assay with BMMCs of MM patients. A Wilcoxon matched-pairs signed rank test was used 
to compare the cytotoxicity of HexaBody-DR5/DR5 with IgG1-DR5/DR5 for the matched samples 
(n=39) (****p<0.0001). Tumor cells were identified by CD38+CD138+. (B) Pearson’s correlation of 
DR5 surface expression level on MM cells with HexaBody-DR5/DR5-induced cytotoxicity (*p=0.02; 
n=46). (C) MM cell kill (%) by HexaBody-DR5/DR5 compared to kill of immune cell populations 
present in the BM of MM patients: natural killer cells (NK), T-cells (T), monocytes (Mono) and 
B-cells (B) (n=35). Data are shown as median; error bars indicate the interquartile range. Statistical 
analysis was performed with a Wilcoxon matched-pairs signed rank test to compare kill of MM cells 
with that of the healthy immune subsets (****p<0.0001 for all subsets). 
DR5/DR5 in the RR group (median kill; range RR 43%; 0-86% vs ND 19%; 3-69%) 
(Figure 2A), which also included eight patients who had become refractory to 
daratumumab monotherapy. Importantly, the MM cells of these daratumumab refractory 
patients were equally susceptible to HexaBody-DR5/DR5 as MM cells from other RR 
patients (median kill 63% versus 43%; ns). A similar differentiation between ND and RR 
patients was not observed for IgG1-DR5/DR5 (Supplemental figure 1).
Further analyses of the RR group, remarkably demonstrated that the cytotoxic activity 
of HexaBody-DR5/DR5 was significantly higher in samples that had been obtained from 
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5 Figure 2. Relapsed/refractory MM patients who received anti-MM treatment shorter than 1 month prior to BM biopsy are most sensitive to HexaBody-DR5/DR5. (A) MM cell kill (%) by 
HexaBody-DR5/DR5 (20µg/mL) of BM samples from newly diagnosed (ND) (n=13) compared to 
relapsed/refractory (RR) (n=35) patients (*p=0.0246), including daratumumab-refractory (Dara-R) 
patients (n=8). (B) MM cell kill (%) by HexaBody-DR5/DR5 (20 µg/mL) of BM samples from RR 
patients who had received their last exposure to therapy >1 month (n=14) and ≤1 month (n=17) prior 
to their BM biopsy (*p=0.0116). Data are shown as median; error bars indicate the interquartile 
range. Statistical analysis was performed with a Mann-Whitney U test. 
patients who were still receiving an anti-MM treatment or had received their last therapy 
less than 1 month ago, as compared to samples obtained from patients who received their 
last therapy longer than 1 month ago (median kill 62% versus 23%; p=0.0116 (Figure 2B). 
This difference was not associated with DR5 surface expression levels of the MM cells 
(Supplemental Figure 2).
Combination of HexaBody-DR5/DR5 with standard of care MM treatments increases 
tumor cell kill
The superior activity of HexaBody-DR5/DR5 in samples from recently treated RR patients 
prompted us to explore whether the combination of HexaBody-DR5/DR5 with standard of 
care MM treatments could improve cytotoxicity in MM cells. We tested the BM samples 
of ND patients in 24h-cytotoxicity assays without supplementing with additional FcγR-
positive effector cells (Figure 3A). Combination of HexaBody-DR5/DR5 with bortezomib 
(3nM; n=11) increased the MM cell kill in modest synergistic manner in 7 out of 11 samples 
according to the Bliss synergy model. Daratumumab (10 µg/mL; n=6), in the presence 
of normal human serum (NHS) with complement activity, did not show synergy with 
HexaBody-DR5/DR5. Lenalidomide (3 µM; n=7) showed strong synergism with HexaBody-
DR5/DR5 in only 1/7 BM samples, however lenalidomide exerted limited single drug 
activity in these ex vivo assays. Since activity of lenalidomide may be more evident after 
prolonged incubation, which precludes ex vivo experiments with primary MM cells, we 
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also performed cytotoxicity assays with MM cell lines NCI-H929 and RPMI8226. Either 
cell lines or the effector PBMCs were separately incubated with lenalidomide for up 
to 5 days, before addition of HexaBody-DR5/DR5. The longer exposure of NCI-H929 
and RPMI8226 to lenalidomide had no effect on HexaBody-DR5/DR5 mediated kill 
(Supplemental figure 3), indicating that lenalidomide did not sensitize the tumor cells for 
HexaBody-DR5/DR5 mediated kill. However preincubation of PBMCs with lenalidomide 
for 5 days synergistically increased the HexaBody-DR5/DR5 mediated kill of NCI-H929 
(n=7 donor PBMCs) and RPMI8226 (n=5 donor PBMCs) (Figure 3B). These results indicated 
that lenalidomide may contribute to HexaBody-DR5/DR5-mediated cytotoxicity by its 
immunomodulatory effects on PBMCs, presumably via the increase in the total number 
of NK cells and the fraction of cytotoxic CD16+ NK cells (Supplemental figure 4). We also 
tested the combination of HexaBody-DR5/DR5 and daratumumab in the presence of 
healthy donor PBMCs at a 40:1 effector to target ratio and pooled NHS (20%), to allow 
the most optimal conditions for ADCC and complement-dependent cytotoxicity (CDC). 
Results demonstrated enhanced tumor cell kill of the combination, although effects were 
additive rather than synergistic (Figure 3C).
HexaBody-DR5/DR5 mediates cytotoxicity via extrinsic apoptotic pathway 
activation and induction of FcγR-mediated ADCC 
The beneficial effect of combining HexaBody-DR5/DR5 with lenalidomide-treated PBMC 
suggested effector mechanisms of HexaBody-DR5/DR5 in addition to FcγR-independent 
DR5 agonism (11), such as ADCC or FcγR-mediated crosslinking. To dissect these possible 
effector mechanisms, we further investigated Hexabody-DR5/DR5-mediated kill using 
the MM cell lines RPMI8226, NCI-H929 and MM.1s. As expected, HexaBody-DR5/DR5 
activated the extrinsic apoptotic pathway in these cell lines in absence of any accessory 
cells (Figure 4A-C). Interestingly, when PBMCs from healthy donors were added in 
the assay, the cytotoxic activity of HexaBody-DR5/DR5 was significantly increased in 
MM.1s. A similar trend was seen for NCI-H929 in 5 out of 6 donors in NCI-H929, although 
statistical significance was not reached (Figure 4D). These data suggest that HexaBody-
DR5/DR5 is capable of inducing FcγR-independent apoptosis as well as FcγR-mediated 
cytotoxicity in vitro. To confirm the ADCC activity of HexaBody-DR5/DR5 ex vivo, we 
tested 4 MM patient samples with the HexaBody-DR5/DR5 variant carrying the L234F/
L235E/D265A (FEA) triple mutation, which abrogates FcγR binding (11). In line with the cell 
line data, the FEA-variant could still induce cytotoxicity but at a reduced level compared 
to HexaBody-DR5/DR5 (Supplemental figure 5). To discriminate whether the increase 
in HexaBody-DR5/DR5-mediated cytotoxicity in presence of PBMC was due to ADCC or 
additional FcγR-mediated crosslinking, we fixated PBMCs with 1% paraformaldehyde 





crosslinking of membrane-bound antibodies (13). The anti-CD38 antibody daratumumab 
was used as control antibody for ADCC, and the wild type IgG1-DR5/DR5 mixture was 
used as a control for FcγR-mediated crosslinking. Indeed, IgG1-DR5/DR5 could still 
induce some cytotoxicity, especially on NCI-H929, suggesting fixed-PBMCs could still 
mediate DR5 agonism by crosslinking membrane-bound antibody, while fixation of 
PBMCs completely abolished the daratumumab-mediated ADCC, as expected. Fixation 
of PBMC also largely neutralized the increased cytotoxic activity of HexaBody-DR5/DR5, 
revealing that ADCC rather than FcγR-mediated clustering of DR5 antibodies is the main 
mechanism of the additional increase in MM cell kill by HexaBody-DR5/DR5 in the presence 
of PBMCs (Figure 4E).   
D I S C U S S I O N
Over the past decade, several conventional monoclonal antibodies targeting death 
receptors have failed to induce a therapeutic response in clinical trials. These conventional 
antibodies require FcγR-mediated crosslinking to induce apoptosis in tumor cells, posing 
a potential and important limitation for the induction of DR5 agonist activity in the clinical 
setting (6, 14). HexaBody-DR5/DR5 is an equimolar mixture of two DR5-specific IgG1 
antibodies with an Fc-domain mutation that augments antibody hexamerization after 
cell surface target binding (11). Here, we explored the preclinical efficacy of HexaBody-
DR5/DR5 in MM. We demonstrate that HexaBody-DR5/DR5 induced potent MM cell 
cytotoxicity in bone marrow samples obtained from MM patients. HexaBody-DR5/DR5 is 
effective in samples obtained from both ND patients and RR patients, including PI- and 
IMiD- but also daratumumab-refractory patients, which were used for these patients as 
end-stage of disease therapy. Remarkably, samples from RR patients recently treated with 
these anti-MM treatments showed significantly increased sensitivity to HexaBody-DR5/
DR5 compared to samples from ND and RR MM patients who had not received treatment 
in the month prior to the BM biopsy. This difference in HexaBody-DR5/DR5 sensitivity was 
Figure 3. HexaBody-DR5/DR5 combined with standard of care MM treatments increases tumor 
cell kill. (A) Observed versus expected MM cell kill (%) of BM samples of newly diagnosed MM 
patients treated with HexaBody-DR5/DR5 (20 µg/mL) in combination with lenalidomide (3 µM; n=7) 
bortezomib (3 nM; n=11) and daratumumab (10 µg/mL; n=6). (B) Observed versus expected MM 
cell kill (%) of the MM cell lines RPMI8226 and NCI-H929 by HexaBody-DR5/DR5 (20 and 0,2 µg/mL) 
and lenalidomide-pretreated healthy donor PBMCs (5 days; 3 µM) at a 40:1 effector to target ratio. 
Each symbol represent a single donor. (C) Observed versus expected MM cell kill (%) of the MM 
cell lines RPMI8226 and NCI-H929 by HexaBody-DR5/DR5 (20 and 0,2 µg/mL) and daratumumab 
(10 and 1 µg/mL) in the presence of healthy donor PBMCs at a 40:1 effector to target ratio and NHS 





not related to expression levels of DR5 on these patient MM cells. The lack of a strong 
correlation between DR5 expression and tumor cytotoxicity has also been observed in 
a previous study with HexaBody-DR5/DR5 in solid cancers and in other studies of DR-
targeting antibodies and TRAIL-based therapeutics (11, 15, 16). 
The increased HexaBody-DR5/DR5 sensitivity in recently-treated RR patients suggested 
that several standard anti-MM treatments could sensitize MM cells to HexaBody-DR5/
DR5. To investigate this possibility in our preclinical setting, we tested the efficacy of 
HexaBody-DR5/DR5 combined with standard of care anti-MM agents using samples of 
ND patients and MM cell lines. The anti-MM activity of HexaBody-DR5/DR5 was readily 
enhanced by bortezomib, in line with previous studies which described bortezomib as 
a potent enhancer of TRAIL-based therapeutics (16-18). Interestingly, we also observed 
increased activity of HexaBody-DR5/DR5 in combination with lenalidomide, which only 
occurred in the presence of PBMCs which were pre-incubated with lenalidomide for 
5 days. Based on the findings that HexaBody-DR5/DR5 can mediate ADCC in MM cells 
these results suggest that lenalidomide synergizes with HexaBody-DR5/DR5 by improving 
its FcγR-mediated ADCC activity. This is in agreement with the well-known activating 
effects of lenalidomide on NK cells, the main cell population mediating the ADCC (19, 20). 
Although more research is needed to elucidate the exact contribution of NK cells or other 
FcγR positive cells, such as monocytes, in Hexabody-DR5/DR5 mediated cytotoxicity, 
the observation that lenalidomide, and possibly other immunomodulatory drugs can 
Figure 4. HexaBody-DR5/DR5 mediates extrinsic apoptotic pathway activation and induces 
low levels of ADCC in MM cell lines. (A) Representative dose-response curve of HexaBody-DR5/
DR5 in RPMI8226, NCI-H929 and MM.1s after a 24 hour incubation compared to IgG1-Ctrl (20 µg/
mL) (n=3-4). (B) Time-lapse of apoptosis induction in NCI-H929 cells by HexaBody-DR5/DR5 and 
IgG1-Ctrl (20 µg/mL). NCI-H929 cells were labeled with caspase 3 green label and pictures were 
taken by Incucyte for a 24 hour time period. Each symbol represents the average total green object 
area per image of 3 replicates. (C) Expression of extrinsic apoptotic pathway related (cleaved) 
proteins for RPMI8226, NCI-H929, and MM.1s, detected by Western Blot after a 6 hour incubation 
with HexaBody-DR5/DR5 (Hx; 1 and 4 µg/mL). Actin was incorporated as loading control. 
A representative image is shown of 2 independent experiments. (D) Kill (%) of RPMI8226, NCI-H929, 
and MM.1s with HexaBody-DR5/DR5 (20 µg/mL) after a 24-hour incubation in the presence of 
healthy donor PBMCs in a 40:1 effector to target ratio. Each symbol represent a single donor. Data 
is shown as mean and SD. Statistical analysis was performed with a paired t-test (**p=0.009). (E) 
Kill (%) of NCI-H929 and MM.1s by HexaBody-DR5/DR5 and IgG1-Ctrl in the absence of PBMCs, 
and in the presence of paraformaldehyde-fixed or non-fixed PBMCs in a 40:1 effector to target 
ratio. IgG1-DR5/DR5 and the anti-CD38 antibody daratumumab are incorporated to control for 
cytotoxicity dependent on FcγR-mediated crosslinking and cytotoxicity dependent on ADCC, 
respectively. Data is shown as mean and SD of two (NCI-H929) or three (MM.1s) independent 
experiments. Statistical analysis was performed with a one-way ANOVA and Tukey’s multiple 
comparisons test to compare the experimental conditions per antibody (*p<0.05 and **p<0.01). 
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enhance HexaBody-DR5/DR5 mediated cytotoxicity is highly relevant for the design 
of future clinical trials. In this respect, it is also worth mentioning the additive effects 
of daratumumab, which also has immunomodulatory effects by activating NK cells (21), 
and HexaBody-DR5/DR5 in our ex vivo assays. Thus, taken together, our results indicate 
that HexaBody-DR5/DR5 can be an excellent partner for PI’s as well as IMiDs and perhaps 
also for daratumumab. These findings will be of great importance in the design of future 
clinical treatment strategies for MM patients.
In conclusion, HexaBody-DR5/DR5 represents a promising therapeutic option for MM 
patients with relapsed/refractory disease, including daratumumab-refractory patients. 
Furthermore, our data suggest that HexaBody-DR5/DR5 benefits from effects of prior 
anti-myeloma agents or in combination with other anti-myeloma agents. 
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Supplemental Figure 2. Comparable DR5 expression levels on MM cells of RR patients 
who received their last anti-MM therapy shorter or longer than 1 month before BM 
biopsy. DR5 surface expression levels (ΔMFI) on tumor cells of BM samples from RR 
patients who had received their last treatment line within 1 month prior to their BM biopsy 
(last exposure to therapy ≤1 month; n=17) to samples from RR patients who received their 
last treatment line longer ago (last exposure to therapy >1month; n=14). Data are shown as 
median; error bars indicate the interquartile range. Statistical analysis was performed with a 
Mann-Whitney U test (ns= non-significant).  
  
S U P P L E M E N TA L  F I G U R E S
Supplemental Figure 1. Similar activity of IgG-DR5/DR5 in newly diagnosed and relapsed/
refractory MM patient samples. MM cell kill (%) by IgG1-DR5/DR5 (20µg/mL) of BM samples 
from newly diagnosed (ND) (n=9) compared to relapsed/refractory (RR) (n=24) patients, 
including daratumumab-refractory (Dara-R) patients (n=4). Data are shown as median; error bars 
indicate the interquartile range. Statistical analysis was performed with a Mann-Whitney U test 
(not significant).
Supplemental Figure 2. Comparable DR5 expression levels on MM cells of RR patients who 
received their last anti-MM therapy shorter or longer than 1 month before BM biopsy. DR5 
surface expression levels (ΔMFI) on tumor cells of BM samples from RR patients who had received 
their last treatment line within 1 month prior to their BM biopsy (last exposure to therapy ≤1 month; 
n=17) to samples from RR patients who received their last treatment line longer ago (last exposure 
to therapy >1month; n=14). Data are shown as median; error bars indicate the interquartile range. 
Statistical analysis was performed with a Mann-Whitney U test (ns= non-significant). 
166
5
Supplemental Figure 3. In the absence of PBMCs a 5-day incubation of MM cells with 
lenalidomide does not increase sensitivity to HexaBody-DR5/DR5. Kill (%) of the MM cell 
lines RPMI8226 and NCI-H929 by HexaBody-DR5/DR5 (circles), lenalidomide (Len, squares) and 
the combination (triangles). Cells were incubated for 5 days with lenalidomide and an additional 




values were determined prior to the experiment. An EC
50 
of 0.4µM lenalidomide was used for both 
cell lines, and EC
50 
values of 0.2 and 0.4 µg/mL HexaBody-DR5/DR5 were used for NCI-H929 and 
RPMI8226 respectively. Graphs show a representative experiment of n=2 (RPMI8226) or n=3 (NCI-
H929) (mean +/- SD of duplicate measurements).
Supplemental Figure 4. Lenalidomide induces NK cell proliferation and the frequency of 
cytotoxic CD16+ NK cells after a 5 day incubation. (A) Fold increase of NK cell numbers (CD3-
CD56+) after a 5 day incubation of healthy donor PBMCs with lenalidomide (3µM). (B) Fraction of 
CD16+ NK cells of total NK cells (CD3-CD56+) after a 5 day incubation of healthy donor PBMCs with 
lenalidomide (3µM). Statistical analysis was performed with a paired t-test (**p=0.0089). 
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5Supplemental Figure 5. The Fc-inert variant of HexaBody-DR5/DR5 is lowered in cytotoxic capacity but can still kill primary MM cells in patient BM samples. MM cell kill (%) by HexaBody-
DR5/DR5 and the Fc-inert variant (FAE mutant) of HexaBody-DR5/DR5 (20µg/mL) of BM samples of 
MM patients (n=4). Statistical analysis was performed with a Wilcoxon matched-pairs signed rank 
test (ns).
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The human immune system possesses natural defenses to fight cancers. These defenses 
are however not always effective at eliminating the tumor cells. Cancer immunotherapy 
uses different approaches to augment tumor immunity and attack tumor cells. In the past 
decades, cancer immunotherapy has become a pillar of cancer therapy, in addition to 
radiation and chemotherapy. An important field of immunotherapy is antibody-based 
therapy. Antibodies naturally have a high specificity for their target antigen and can 
elicit various anti-tumor responses. In the 1970s the hybridoma technology in addition 
to design technologies such as antibody-gene expression libraries allowed large-scale 
production of monoclonal antibodies, which laid the foundation for the field of antibody-
based therapy. 
A N T I B O DY  E N G I N E E R I N G :  U N P R E C E D E N T E D 
T H E R A P E U T I C  A P P L I C AT I O N S 
The first monoclonal antibody was registered for therapeutic use in 1986 to prevent 
kidney transplant rejection, and the first monoclonal antibody for use in cancer therapy in 
1997. Ever since, a plethora of antibody engineering strategies have been developed that 
exploit and/or improve the antigen-binding properties or the antibody effector functions. 
The field of monoclonal antibody therapy thereby evolved into a field of antibody-
based therapeutics, which encompasses different classes of antibody-based formats 
including antibody-drug conjugates, antibody fragments, bispecific antibodies and Fc-
engineered antibodies. The developmental platforms and strategies driving each class 
have developed rapidly and various engineering approaches are available. Combining 
multiple engineering approaches for the desired therapeutic further provides antibody-
based therapy with unprecedented therapeutic applications. In chapter 1 we review 
the different bispecific and Fc-engineering strategies, and introduce two relatively novel 
engineering platforms: the DuoBody and HexaBody technology. The aim of this thesis was 
to evaluate the preclinical efficacy of several antibodies that were developed according 
to these technologies, for the treatment of B-cell malignancies. Novel therapies are 
warranted especially for patients with high risk and relapsed or refractory disease. 
The DuoBody technology is based on a controlled-fab arm exchange, which is 
mimicked from IgG4 antibodies that can dynamically exchange half-molecules and applied 
to IgG1 antibodies via single matched point mutations at the Fc-tail of the antibodies. With 
the HexaBody technology specific point mutations are introduced in the Fc-tail of IgG1 
antibodies that stimulate Fc:Fc interactions upon target binding and induce antibody-
hexamerization, thereby facilitating C1q binding and inducing complement-dependent 
cytotoxicity (CDC). In addition, the HexaBody technology can be employed for antibodies 
that target proteins or receptors that could benefit from antibody clustering. 
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In this thesis we employ these two technologies in four different approaches, which 
illustrates the possibilities of antibody engineering. In chapter 2, we demonstrate 
the preclinical efficacy of epcoritamab, a bispecific antibody designed by the DuoBody 
technology to redirect CD3+-T-cells to CD20+ B-cell lymphoma’s. In other chapters we 
specifically focus on different fundamental and preclinical aspects of HexaBodies targeting 
important B-cell malignancy-associated molecules. In chapter 3 we evaluated HexaBodies 
specific for CD20 and CD37, important B-cell lymphoma and B-CLL-associated molecules. 
We demonstrated that CD20 and CD37 are co-localized on the cell membrane, and that 
HexaBodies targeting CD20 and CD37 synergistically induce CDC. This observation 
prompted us to investigate whether complement activation can also be enhanced by 
dual-targeting of single antigens. In chapter 4 part I we combined the DuoBody and 
HexaBody technology to design a biparatopic CD37-bispecific IgG1 antibody with an E430G 
hexamerization-enhancing single point mutation in the Fc-domain: DuoHexaBody-CD37, 
which indeed demonstrated superior CDC activities. In chapter 4 part II we evaluated 
the preclinical efficacy of DuoHexaBody-CD37 across CLL and various B-cell lymphoma 
patient samples. In chapter 5 we explored the efficacy of the death receptor 5 targeting 
antibody mixture HexaBody-DR5/DR5, which employs the HexaBody technology not to 
enhance CDC but to induce receptor clustering via antibody hexamerization and activate 
the extrinsic apoptotic pathway. 
E X  V I V O  P R E C L I N I C A L  E VA L U AT I O N  O F 
A N T I B O DY  T H E R A P Y 
Before proceeding to clinical trials, antibodies or other novel agents naturally need to 
have an indication of efficacy in preclinical studies. However, the extend of the preclinical 
studies is at times limited to just the indication of efficacy (and safety) on cell line or 
mouse models, to allow rapid progression to phase 1 trials. We advocate for preclinical 
ex vivo evaluation using primary malignant cells isolated from patients as prerequisite 
or at least routine procedure before proceeding to phase 2 and 3 clinical trials. Ex vivo 
preclinical studies can be highly predictive for clinical outcome, as demonstrated by 
the predictive value of the preclinical studies of daratumumab, the mAb directed against 
CD38 for multiple myeloma (1-5). Ex vivo studies also allow for investigation of efficacy 
based on specific patient cohorts, including newly diagnosed and relapsed/refractory, 
and could already lead to the identification of possible responders and biomarkers, which 
demonstrates the added translational value over preclinical studies using only cell lines 
and/or mouse models. If performed in conjunction with clinical dose-finding studies, ex 
vivo studies should not have to delay clinical development. On the contrary: proper ex 
vivo preclinical evaluation can increase the probability of clinical success. If antibodies 
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lack clinical efficacy this is often presumed to be multifactorial, and the most adopted 
explanations include weak direct or Fc-mediated effects and primary resistance of cancer 
cells. However, there are also explanations for a lack of efficacy that are more directly 
linked to the setup of the clinical trial, and include selection of the incorrect patient 
cohort eligible for clinical trial participation and an inefficacious combination therapy. 
Ex vivo preclinical evaluation of antibodies could provide valuable information for 
the correct design of clinical trials. To provide future ex vivo studies with larger patient 
cohorts, as we admit that our cohorts are relatively small, and increase the value of ex vivo 
preclinical evaluation, collecting a large number of diverse patient samples via biobanking 
is becoming increasingly important. 
The data presented in this thesis strongly confirm the added value of ex vivo preclinical 
evaluation, as our findings could inform the clinical trial design of the antibodies that we 
studied. In our preclinical studies of epcoritamab (chapter 2) we found that the tumor 
expression of the immune checkpoint molecule Herpes Virus Entry Mediator (HVEM) 
inhibits the epcoritamab-mediated level of T-cell activation. The negative impact of HVEM 
on the overall-and progression-free survival of B-NHL has previously been described (6), 
however, the negative impact of HVEM on the T-cell activation of T-cell engagers such 
as epcoritamab has not been reported before. While the high HVEM expression levels in 
our study did not directly correlate with epcoritamab-mediated kill, the effect of tumor 
HVEM expression on T-cell activation may have important consequences in the outcome 
of the treatment by epcoritamab and by other T-cell- engagers in B-NHL. Therefore, we 
suggest to include HVEM expression analysis as potential biomarker in clinical studies. 
The development of agents that block HVEM could also be appealing strategies to 
combine with T-cell engagers. The complex role of HVEM as both ligand and receptor 
for immune checkpoint proteins BTLA and CD160, however, warrants caution in such 
therapeutic applications (7).
The findings of our preclinical evaluation of HexaBody-DR5/DR5 for treatment of MM 
(chapter 5) also provided valuable information that could inform the design of clinical 
trials with HexaBody-DR5/DR5 or of other DR5-targeting therapies. This is especially 
relevant in light of the disappointing clinical trial data of TRAIL-based therapeutics 
up to date. First, we have shown that Hexabody-DR5/DR5 is especially effective in 
relapsed/refractory MM patients who had recently received therapy. Next, we confirmed 
the synergistic combination of HexaBody-DR5/DR5 with the proteasome inhibitor 
bortezomib, which has been a well-studied combination in case of other DR5-targeting 
therapies (8-10), demonstrate additivity of HexaBody-DR5/DR5 in combination with 
daratumumab, and most importantly, we found a novel synergistic partner for HexaBody-
DR5/DR5-combination therapy in the class of immunomodulatory drugs (IMiDs), such as 
lenalidomide. These findings may be highly relevant for clinical testing of DR5-targeting 
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therapies. Even more, of the many different formats of TRAIL-based therapeutics that 
have been developed, only one format (circularly permuted TRAIL; CPT) that was tested 
in combination with an IMiD (thalidomide), demonstrated some efficacy in clinical trials 
(11, 12). It remains to be elucidated whether the clinical efficacy observed for CPT is due to 
the combination with an IMiD. Nonetheless, anticipating on the CPT-trial and on the data 
presented in this thesis, we would suggest to select relapsed/refractory MM patients who 
recently received therapy for clinical trial enrollment of DR5-targeting therapies, and 
focus on combination therapy with IMiDs. 
E N H A N C I N G  C O M P L E M E N T- D E P E N D E N T 
C Y TOTOX I C I T Y  F O R  E F F E C T I V E  A N T I -T U M O R 
C Y TOTOX I C I T Y
Multiple Fc-engineered antibodies have reached the stage of clinical testing or 
clinical development. Most of these antibodies are designed to enhance FcγR-binding 
and increase ADCC and/or ADCP levels. The HexaBody technology has therefore 
revolutionized the field of antibody therapy. The clinical trial of DuoHexaBody-CD37 for 
patients with relapsed or refractory B-NHL, which has recently been initiated and which 
was based on the data presented in this thesis (chapter 4), is the first clinical trial of an 
antibody specifically Fc-engineered to enhance CDC. This clinical trial will provide valuable 
information regarding the contribution of CDC to in vivo antibody efficacy. Currently, it is 
difficult to dissect the exact contribution of a specific mAb effector function (CDC, ADCC, 
ADCP) to clinical efficacy. Most antibodies induce a combination of effector functions, and 
it is not (yet) possible to evaluate the contribution of mAb effector functions to tumor kill 
in patients undergoing antibody therapy. There are recent studies that focus on answering 
these questions in light of the CD20-targeting mAbs (13-15), but CD37 as target might be 
a less complicated model. Conventional CD37-targeting antibodies do not induce CDC, 
and the efficacy of two CD37-targeting antibody-based agents, otlertuzumab (TRU‐016) 
and BI 836826, that reached phase I clinical trials (and were subsequently discontinued) 
is primarily based on ADCC induction (16, 17). Hence, comparing the results of these 
trials with the results of the upcoming clinical trial of DuoHexaBody-CD37, if performed 
in similar patient groups, could contribute to estimating antibody-mediated CDC 
effects in vivo. 
C E L L  I N T R I N S I C  R E S I S TA N C E  TO  A N T I B O DY-
M E D I AT E D  C D C
In addition to moving DuoHexaBody-CD37 to clinical studies, our preclinical investigation 
also provided important fundamental insights regarding CDC. When we correlated 
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DuoHexaBody-CD37 mediated CDC with the tumor expression levels of complement 
regulatory proteins (CRPs) CD46, CD55 and CD59, we observed very limited inhibitory 
effects of the CRPs. In contrast, the efficacy of two other CDC-inducing antibodies, 
the CD20-targeting antibody ofatumumab and the CD38-targeting antibody 
daratumumab, has been described to be significantly hampered by the expression of 
CRPs (2, 18). Despite the efficiency of DuoHexaBody-CD37 to activate the complement 
pathway and overcome CRP expression, we could still observe a (partial) resistance to 
DuoHexaBody-CD37 mediated CDC in 6 out of 17 (35%) DLBCL samples that expressed 
CD37 at sufficiently high and CRP at sufficiently low levels. We also demonstrate that 
the complement pathway was activated on these samples, as we detected C1q binding, 
and have indications that the membrane-attack complex (MAC; C5b-C9) is formed on 
the cell membranes (unpublished data). Thus, these preclinical studies revealed that cell-
intrinsic resistance might play a role in resistance to DuoHexaBody-CD37 mediated CDC. 
After completion of the complement pathway, upon sufficient insertion of MACs into 
the cell membrane, cells undergo regulated necrotic cell death. The specific intracellular 
signaling pathways of CDC and the factors involved in this necrotic cell death however 
are yet to be unraveled (19). Moreover, the capacity of tumor cells to inhibit the necrotic 
cell death once sufficient MACs have been formed has not been described before. 
The observation that DLBCL cells can resist CDC despite full complement activation is 
therefore highly relevant, and further studies are warranted to elucidate the intracellular 
pathways of CDC as well as the specific mechanisms of resistance. As first step in 
deciphering the intracellular CDC pathways we would suggest the use of genome-wide 
CRISPR-Cas9 library screening. This unbiased screening method could identify key genes 
involved in in CDC to enable a reconstruction of the intracellular CDC pathways. 
T H E  C L I N I C A L  P R O S P E C T  O F  T H E  D U O B O DY  A N D 
H E X A B O DY  T E C H N O LO G I E S  F O R  T R E ATM E N T  O F 
B - C E L L  M A L I G N A N C I E S 
Clinical trials of epcoritamab and  DuoHexabody-CD37 are currently ongoing for 
patients with relapsed or refractory B-cell lymphoma. As demonstrated in chapter 2 and 
chapter 4, both therapies are effective in samples from relapsed and from newly 
diagnosed patients and might therefore also be evaluated as therapy in early lines of 
treatment. DuoHexaBody-CD37 could also be combined with rituximab therapy, as our 
ex vivo studies indicated an increase in cytotoxicity by this combination. Furthermore, if 
DuoHexaBody-CD37 shows a significant effect in clinical trials, the HexaBody technology 
will probably be employed for more antibodies to enhance CDC-activities. In succession 
of the clinical trial with DuoHexaBody-CD37, a trial with a CD38-targeting HexaBody has 
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also recently been initiated, as it showed promising preclinical activity in MM (20). In 
addition, the HexaBody technology applied to Death Receptor 5 (chapter 5) illustrates 
that this technology can be employed not solely for CDC-enhancing purposes, but 
for target clustering in general. We therefore expect that more receptors or proteins 
that could benefit from this antibody-mediated clustering, will be evaluated for 
targeting by HexaBodies. 
F R O M  M O N O - ,  TO  D U A L- ,  TO  M U LT I -TA R G E T I N G 
A N T I B O D I E S
Antibodies are naturally monospecific: they bind to one target. The development 
of bispecific antibody technologies enabled dual-targeting of antigens or epitopes 
by a single drug. The concept of dual-targeting is mostly applied to redirect T-cells or 
other effector cells to tumor cells, similar to epcoritamab as described in chapter 2, 
but can also be employed to increase tumor selectivity by targeting different tumor-
associated antigens, or to modulate two functional pathways simultaneously. In 
chapter 3 we discovered a potential alternative application for dual-targeting. We 
observed that antibodies targeting CD20 and CD37 co-localized on the cell membrane, 
and synergistically activated the complement pathway. In this thesis we elaborated on this 
finding by developing the dual-epitope targeting hexamerization-enhancing antibody 
DuoHexaBody-CD37 (chapter 4). For future studies, it would be interesting to explore 
the CDC activity of bispecific antibodies that target antigens that are expressed at close 
proximity on the cell surface. Furthermore, taken all the possibilities of dual-targeting 
into account it, many more opportunities will arise now that recently trispecific antibody 
formats have been developed (21, 22).
T H E  F U T U R E  O F  F C - E N G I N E E R E D  A N T I B O D I E S
We hypothesize that in the near-future Fc-engineered antibodies will evolve into 
a therapy that is tailor-made for specific target and disease (-subtype). This hypothesis 
is based on two important developments in the field of antibody therapy. The first 
development concerns the advances in antibody manufacturing, which currently have 
no integrated methods for efficient Fc-sequence engineering. Instead, they apply 
site-directed mutagenesis either directly once heavy and light chain sequences are 
available (for structure-based sequence engineering), or to generate phage or yeast 
display libraries to screen for the most optimal Fc variant out of single-mutated variants 
(empirical-based sequence engineering). Recent efforts focused on generating high-
throughput Fc-engineering platforms that harbor (combinations of) different sequencing 
approaches (23), which will enable fast and large screenings of different antibody 
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engineering strategies. Such large empirical in vitro screenings of different approaches 
could determine the most favorable approach for a specific target, before continuing to 
(pre)clinical evaluation. Currently, the decision to choose a specific antibody format or 
engineering approach for a target is quite arbitrary, and often based on prior successes.
The second development is the exponential increase in antibody-based formats 
that reach clinical testing, leading to greater clinical knowledge of engineered antibody 
formats for hematological malignancies. This could provide us with valuable information 
regarding i) potential biomarkers that could predict response to a specific antibody format 
or antibody effector function, ii) the exact clinical effect of the different engineering 
strategies, and iii) the specific contribution of ADCC, ADCP and CDC to clinical efficacy 
of mAbs. These insights could drive future decision-making in antibody therapy, to an 
extent in which an antibody engineering strategy is chosen not only by in vitro efficacy, 
but also by understanding what specific effector function and engineering strategy is 
most beneficial for a specific patient (group).
C O N C L U S I O N
Antibodies have emerged as an important part of cancer therapy due to their specificity 
for their target and their capacity to induce various anti-tumor effector mechanisms. 
The possibility of engineering different elements of antibodies has led to many different 
antibody-engineering approaches, and antibody-based therapy is one of the most 
rapidly growing classes of therapeutics. Adopting extensive preclinical investigation 
of antibody-based formats can provide the tools for successful clinical application 
to move cancer therapy forward. In this thesis we present the preclinical evaluation of 
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E N G L I S H  S U M M A RY
B-cell malignancies define a subset of hematological cancers, including the B-cell 
proliferative disorders B-cell chronic lymphocytic leukemia (B-CLL) and B-cell non 
Hodgkin lymphoma’s (B-NHL) and the plasma cell proliferative disorder multiple myeloma 
(MM). Survival rates can vary widely for the various (sub)types as well as the stage of 
the disease. 
The cornerstone of therapy for B-CLL and B-NHL is the CD20-targeting antibody 
rituximab. Ever since rituximab was first approved by the FDA in 1997, survival rates 
of B-CLL and B-NHL have improved drastically. However, patients with relapsed or 
refractory disease still have a very poor prognosis, and novel therapies are warranted. 
The application of antibodies for treatment of MM succeeded not until recent years. 
The first antibody to enter the clinic for treatment of MM was the CD38-targeting 
antibody daratumumab in 2016. In addition to other recent advances in the treatment 
of MM, including the development of immunomodulatory agents and proteasome 
inhibitors, daratumumab significantly improved the prognosis of MM patients. Still, MM 
generally remains an incurable disease. 
The advances in antibody engineering over the last decades has allowed 
the development of different antibody-based therapies, including antibody-drug 
conjugates, bispecific T-cell engagers, and Fc-engineered antibodies, which are currently 
being investigated for the treatment of B-cell malignancies in addition to other targeted 
approaches such as small molecule inhibitors and chimeric antigen receptor (CAR) T-cells. 
In chapter 1 we describe the various Fc-engineering strategies and bispecific antibody 
formats, and introduce two novel and promising antibody technologies: the DuoBody 
and HexaBody. The DuoBody technology is based on a controlled-fab arm exchange, 
which is mimicked from IgG4 antibodies that can dynamically exchange half-molecules 
and applied to IgG1 antibodies via single matched point mutations at the Fc-tail of 
the antibodies. With the HexaBody technology specific point mutations are introduced 
in the Fc-tail of IgG1 antibodies that stimulate Fc:Fc interactions upon target binding 
and induce antibody-hexamerization, thereby facilitating C1q binding and inducing 
complement-dependent cytotoxicity (CDC). 
In this thesis we focused on the application and preclinical evaluation of several 
antibodies that were developed according to the DuoBody and HexaBody platforms, for 
the treatment of B-cell malignancies.  
In chapter 2 we explored the possibility of redirecting CD3+ T-cells to CD20+ B-cell 
lymphoma cells using epcoritamab (DuoBody-CD3xCD20, GEN3013), a novel bispecific 
IgG1 antibody created using the DuoBody platform. We demonstrate that targeting 
CD20 with a bispecific antibody can be effective even in samples from patients who had 
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(recently) become refractory to previous CD20-targeting therapies. In addition, we found 
that the expression of the immune checkpoint molecule herpesvirus entry mediator 
(HVEM) can negatively impact epcoritamab-mediated T-cell activation.
In chapter 3 we introduced the E430G HexaBody-mutation in naked CD20- and CD37-
targeting antibodies and found that antibody hexamerization significantly enhanced CDC 
levels against B-NHL and CLL tumorcells, even for CD37-targeting antibodies that do not 
naturally have the capacity to activate the complement pathway. In addition, we observed 
that CD20- and CD37-targeting HexaBodies co-localize on the cell surface, form hetero-
hexamers and thereby synergistically activate the complement pathway and induce CDC. 
The efficacy of introducing E430G in CD37-targeting antibodies and the observation 
that combining HexaBodies enhances CDC activity, prompted us to further explore 
HexaBodies applied to CD37 as target for B-cell malignancies in chapter 4. In part I we 
evaluated various CD37-antibody variants harboring the E430G mutation, and found that 
a combination of dual-epitope targeting and antibody hexamerization most potently 
induces CDC. We therefore combined the DuoBody and HexaBody antibody platform 
technologies to develop DuoHexaBody-CD37, a biparatopic bispecific hexamerization-
enhancing IgG1 antibody. In part II of chapter 4 we evaluated the preclinical ex vivo 
efficacy of DuoHexaBody-CD37 in samples from patients with B-CLL and various types of 
B-NHL. We observed high cytotoxicity across the different B-cell malignancy subtypes, 
even when tumor cells highly expressed complement regulatory proteins. In concordance 
with the data presented in chapter 2, we found that simultaneous targeting of CD37 and 
CD20, here by DuoHexaBody-CD37 and rituximab, enhanced CDC. 
In addition to CDC induction, the HexaBody technology can be employed to induce 
receptor clustering. In chapter 5 we applied the E430G HexaBody mutations to a mixture 
of two non-competing death receptor 5 (DR5) targeting IgG1 antibodies, termed 
HexaBody-DR5/DR5. Receptor (hyper) clustering of DR5 is required to induce extrinsic 
apoptotic pathway activation. We explored the preclinical activity of HexaBody-DR5/DR5 
in MM, and found that HexaBody-DR5/DR5 was especially effective in recently treated 
relapsed/refractory patients. Important for future clinical trial design is our observation 
that HexaBody-DR5/DR5 can be an excellent partner for combination therapy for both 
immunomodulatory drugs as well as proteasome inhibitors, presumably due to the fact 
that HexaBody-DR5/DR5 can induce direct activation of the apoptotic pathway as well as 
antibody-dependent cellular cytotoxicity (ADCC).
C O N C L U S I O N 
In this thesis we demonstrate the potential of DuoBody-CD3xCD20, DuoHexaBody-CD37 
and HexaBody-DR5/DR5 for the treatment of B-cell malignancies. We aimed to provide 
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the tools for successful clinical application, to move cancer therapy forward. In chapter 6 





 » B-cel maligniteiten zijn verschillende hematologische kankers, ontstaan vanuit 
de B-cel (een type witte bloedcel), waaronder B-cel non-hodgkin lymfoom 
(B-NHL), B-cel chronische lymfatische leukemie (B-CLL) en multiple myeloom 
(MM).
 » Antilichamen zijn onderdeel van ons immuunsysteem en kunnen specifieke 
moleculen (antigenen) op ziekteverwekkers herkennen waardoor ze deze 
kunnen opruimen, onder ander door het perforeren van de celwand van 
de ziekteverwekker. Dit heet complement-gemedieerde celdood (CDC). 
 » Antilichamen kunnen buiten het lichaam worden geproduceerd tegen 
antigenen op tumorcellen en zo worden ingezet als behandeling voor kanker.
 » Antilichamen kunnen worden gemodificeerd om hun effectiviteit te verhogen. 
In hoofdstuk 1 geven we een overzicht van verschillende antilichaam-
modificatietechnieken.
Antilichaam-technologieën gebruikt in dit proefschrift
 » Met de DuoBody technologie worden antilichamen geproduceerd die aan 2 
verschillende cellen kunnen binden (bispecifiek), waardoor ze een celdood-
inducerende cel bij de tumorcel kunnen brengen.
 » De HexaBody technologie is een platform ontwikkeld om verhoogde CDC in 
de tumorcel te kunnen induceren. Er worden veranderingen (puntmutaties) 
in het antilichaam aangebracht waardoor de antilichamen 6-potige structuren 
vormen als ze aan de tumorcel binden. Hierdoor kunnen ze efficiënt de reactie 
opstarten die uiteindelijk tot CDC leidt.   
Proefschrift 
 » In dit proefschrift doen we preklinisch onderzoek naar verschillende nieuw-
ontwikkelde antilichamen voor de behandeling van B-cel maligniteiten. 
We gebruiken zo veel mogelijk tumor- en immuuncellen afkomstig van 
patiënten om de effectiviteit en werkingsmechanismen van de antilichamen 
te testen, resistentiemechanismen van de tumorcel te onderzoeken, 
N E D E R L A N D S E  S A M E N VAT T I N G  VO O R  
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biomarkers te identificeren die kunnen voorspellen welke patiënten zullen 
reageren en combinatietherapieën te testen. 
 » In hoofdstuk 2 onderzoeken we de effectiviteit van epcoritamab (DuoBody-
CD3xCD20), een bispecifiek IgG1 antilichaam ontwikkeld met de DuoBody 
technologie dat CD3-positieve cytotoxische T-cellen bij de CD20-positieve 
tumorcellen kan binden. 
 » In hoofdstuk 3 gebruiken we antilichamen ontwikkeld met de HexaBody 
technologie om CDC te induceren tegen twee B-NHL en CLL-geassocieerde 
antigenen: CD20 en CD37. 
 » In hoofdstuk 4 combineren we de HexaBody en DuoBody technologie in een 
antilichaam tegen CD37 dat hierdoor twee verschillende delen van het CD37 
antigeen kan binden en antilichaam-clustering kan induceren: DuoHexaBody-CD37. 
 » In hoofdstuk 5 gebruiken we de HexaBody-technologie om via antilichaam-
clustering ook clustering van de death receptor 5 in MM cellen te 





Het aantal kankergevallen is de afgelopen decennia sterk toegenomen en 
is de nummer één doodsoorzaak geworden in de westerse wereld. Volgens 
de Wereldgezondheidsorganisatie (World Health Organization; WHO) komt 1 van 
de 6 sterfgevallen wereldwijd door kanker en volgens het Centraal Bureau voor Statistiek 
(CBS) was kanker in Nederland in 2019 zelfs in 30% van de sterfgevallen de oorzaak. 
Hoewel kanker al werd beschreven door de oude Egyptenaren en de term kanker voor 
het eerst werd gebruikt door de Griekse arts Hippocrates, zo’n 400 jaar v.Chr., wordt 
kanker vaak aangeduid als een moderne ziekte. Dit komt omdat de enorme toename in 
kankergevallen te wijten valt aan onze moderne levensstijl en de hoge levensverwachting. 
Kanker betekent dat cellen ongecontroleerd delen. Alle cellen in het lichaam hebben 
een bepaalde houdbaarheid en moeten op den duur vervangen worden. Een cel kan zich 
delen om een nieuwe cel te maken en kopieert daarbij ook het erfelijk materiaal (DNA). 
Dit proces is foutgevoelig: er kunnen veranderingen (mutaties) in het DNA ontstaan. 
Mutaties zorgen voor genetische variatie en spelen een belangrijke rol bij evolutie, maar 
als mutaties voorkomen in het DNA dat betrokken is bij celdeling kan dit proces verstoord 
worden waardoor ongecontroleerde celdeling ontstaat. Mutaties in het DNA kunnen ook 
ontstaan door externe factoren zoals roken, voeding en zonlicht (UV straling).
B-cel maligniteiten
Kanker kan onderverdeeld worden in solide (vaste) tumoren en niet-solide ofwel 
hematologische kanker. B-cel maligniteiten is een verzamelnaam voor verschillende 
soorten hematologische kankers die zijn ontstaan vanuit de B-cel, een specifiek type 
witte bloedcel. Hieronder valt B-cel non-hodgkin lymfoom (B-NHL), B-cel chronische 
lymfatische leukemie (B-CLL), en multiple myeloom (MM). B-NHL is kanker in het 
lymfatisch stelsel. Het omvat veel verschillende subtypes, volgens de WHO zelfs zo 
rond de 100, waarvan de meest voorkomende diffuus grootcellig B-cellymfoom 
(DLBCL), folliculair lymfoom (FL), mantelcellymfoom (MCL), marginale zone lymfoom 
(MZL) en burkitt lymfoom (BL) zijn. Bij B-CLL zijn ook de B-cellen aangetast, maar 
wordt er gesproken over leukemie omdat de tumorcellen zich voornamelijk in het 
bloed en beenmerg bevinden. CLL en de subtypen B-NHL verschillen in uiterlijke 
kenmerken, genetische opmaak en agressiviteit en vereisen daarom ook om een 
aangepaste behandelingsstrategie. MM, ook wel ziekte van Kahler genoemd, is een 





De moderne geneeswijze zorgt voor steeds meer mogelijkheden om kanker 
te behandelen of zelfs te genezen. De meest gebruikte behandelingen voor kanker zijn 
chemo- en radiotherapie en het operatief verwijderen van de tumor. Bij chemotherapie 
krijgt de patiënt een geneesmiddel toegediend dat de celdeling remt, terwijl bij 
radiotherapie DNA schade wordt toegebracht door gamma- of röntgenstraling. Bij beide 
behandelingen worden vooral de snelgroeiende cellen ofwel de tumorcellen beschadigd, 
maar ook gezonde cellen ondervinden schade. Zowel chemo- als radiotherapie hebben 
daardoor vaak nog ernstig schadelijke bijwerkingen. Daarnaast is kanker met deze 
behandelingsmethoden niet altijd te genezen. Er is de afgelopen decennia daarom veel 
onderzoek geweest naar het ontwikkelen van effectieve therapieën die tumorcellen 
kunnen doden zonder veel schade aan gezonde cellen toe te brengen. Een van de meest 
revolutionaire ontwikkelingen is immuuntherapie. Er zijn verschillende vormen van 
immuuntherapie, die kunnen worden onderverdeeld in passieve en actieve therapie. 
Bij actieve immuuntherapie wordt ons eigen immuunsysteem actief ingeschakeld door 
geheugen op te bouwen, zoals bij een vaccinatie. Bij passieve immuuntherapie krijgt 
de patiënt ‘externe’ immuuncellen of kunstmatig gemaakte lichaamseigen eiwitten, zoals 
antilichamen, die een direct effect op de kankercellen hebben. In dit proefschrift hebben 
wij ons gericht op antilichaamtherapie. 
Antilichamen: structuur en functie
Antilichamen, ofwel antistoffen of immunoglobulinen (Ig), worden geproduceerd 
door (gezonde) B-cellen en spelen een belangrijke rol in ons afweersysteem. Op het 
moment dat een ziekteverwekker het lichaam binnen dringt, kunnen unieke moleculen 
(antigenen) van de ziekteverwekker herkend worden door een passend antilichaam. 
De B-cellen die dit antilichaam produceren differentiëren dan deels naar plasmacellen, 
die de antilichaamproductie verder op gang brengen en deels naar geheugen cellen. 
De antilichamen kunnen een afweerreactie inzetten om de ziekteverwekker op te ruimen. 
Antilichamen zijn opgebouwd uit vier eiwitketens die samen een Y-structuur vormen. De 
twee ‘armen’ van het antilichaam bevatten een variabel gedeelte dat bepaalt wat voor 
antigeen het antilichaam kan herkennen en binden. De staart van het antilichaam, de 
fragment-crystallizable (Fc-regio), bepaalt wat voor afweerreactie het antilichaam kan 
oproepen (Figuur 1). De specifieke afweerreactie is afhankelijk van het type antilichaam. 
De meeste therapeutische antilichamen voor kanker, inclusief de antilichamen die 
gebruikt zijn in dit proefschrift, zijn van het isotype IgG subtype 1 (IgG1). Met de Fc-staart 
kan een antilichaam op verschillende manieren een afweerreactie oproepen om de 
ziekteverwekker op te ruimen (Figuur 1). In dit proefschrift focussen wij ons op een 
specifieke reactie: de complement-gemedieerde celdood (complement-dependent 
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cytotoxicity; CDC). Het complement systeem is een onderdeel van ons immuunsysteem 
en bestaat uit verschillende eiwitten. Een IgG1 antilichaam kan het complement systeem 
activeren door met de Fc-staart aan het complement eiwit C1q te binden. Complement 
activatie via C1q resulteert in het perforeren van de cel via de formatie van ringstructuren 
op het oppervlak van de cel (membraanaanval complex; MAC), waardoor de cel 
dood gaat. 
Antilichamen als therapie voor kanker
Tumorcellen brengen net zoals gezonde cellen eiwitten tot expressie. De eiwitten op 
de tumorcel zijn vaak lichaamseigen, waardoor ze geen immuunreactie oproepen. Door 
het extern produceren van antilichamen tegen tumorgeassocieerde eiwitten zijn we 
Figure 1. De structuur en Fc-gemedieerde functies van IgG1 antilichamen. IgG1 antilichamen 
hebben een antigeenbindend fragment (Fab) en een constante regio (Fc) die een specifiek type 
afweerreactie kan initiëren. IgG1-antilichamen kunnen als ze aan het specifieke antigeen op het 
celmembraan zijn gebonden via de Fc-staart binden aan verschillende Fc-receptoren, die bij 
activatie de tumorcel kunnen doden via het uitscheiden van gifstoffen (antibody-dependent cellular 
cytotoxicity; ADCC) of door de tumorcel op te eten (antibody-dependent cellular phagocytosis; 
ADCP). De Fc-staart kan ook binden aan het plasma-eiwit C1q en daarmee de complement route 
activeren. Hierbij worden verschillende plasma-eiwitten gesplitst en geactiveerd die uiteindelijk 
een membraanaanval complex (MAC) op het celoppervlak vormen wat celdood kan induceren 
(complement-dependent cytotoxicity; CDC). 
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toch in staat een immuunreactie op te roepen. Het extern produceren van antilichamen 
op een kunstmatige manier, identiek (monoklonaal) en in grote hoeveelheden is sinds 
enkele decennia door geavanceerde technologieën mogelijk gemaakt. In 1997 werd 
het IgG1 antilichaam rituximab als eerste antilichaam door de FDA (US Food and Drug 
Administration) geaccepteerd als behandeling voor kanker. Rituximab bindt het antigeen 
CD20, wat tot expressie komt op bijna alle B-cellen, inclusief de tumor B-cellen. Rituximab 
is geregistreerd als behandeling voor CLL en B-NHL. Na het klinische succes van rituximab 
zijn er veel meer antilichamen ontwikkeld en goedgekeurd voor de behandeling van 
verschillende soorten kanker.  
Voor CLL en B-NHL vormt rituximab jaren nadat het op de markt is gekomen nog steeds 
de basis voor de meeste behandelingsplannen, vaak in combinatie met chemotherapie 
en andere drugs. Voor MM werd antilichaamtherapie pas veel later gerealiseerd. Het 
CD38-bindend antilichaam daratumumab was in 2016 het eerste antilichaam dat voor 
de behandeling van MM werd goedgekeurd. In de afgelopen decennia is de prognose 
van patiënten met B-cel maligniteiten, door onder andere deze antilichaamtherapieën, 
sterk verbeterd. Voor patiënten met terugkerende ziekte (recidief) of patiënten die 
niet op therapie reageren (refractair) zijn er echter nog vaak weinig mogelijkheden qua 
behandeling. Nieuwe therapieën zijn daarom dringend nodig. 
Antilichamen kunnen op verschillende manieren worden gemodificeerd om een 
betere of een alternatieve behandeling te kunnen bieden. De Fc-regio van het antilichaam 
kan worden aangepast om de reactie tegen de tumorcellen te vergroten. Ook kan een 
antilichaam zo gemodificeerd worden dat het kan binden aan twee verschillende cellen, 
een zogenaamd bispecifiek antilichaam, waardoor het een cytotoxie-inducerende 
cel bij de tumorcel kan brengen. In hoofdstuk 1 hebben we een overzicht gegeven 
van de verschillende bispecifieken formats en Fc-engineering strategieën. Twee 
veelbelovende en recent ontwikkelde technologieën zijn de DuoBody en de HexaBody 
technologie, respectievelijk een bispecifiek format en een Fc-engineering strategie.
DuoBody en HexaBody technologie
Bij de DuoBody technologie worden gekoppelde mutaties aangebracht in de Fc-staarten 
van twee verschillende IgG1 antilichamen. Als de antilichamen in specifieke condities 
worden samengebracht vormen ze halve IgG moleculen, die door de gekoppelde 
mutaties weer volledige IgG1 antilichamen vormen die bestaan uit twee verschillende 
helften. Hierdoor ontstaat een bispecifiek antilichaam dat aan twee verschillende cellen 
kan binden.  
Bij de HexaBody technologie wordt de Fc-staart aangepast om een betere reactie 
tegen de tumorcel te krijgen. Er wordt een gerichte aanpassing (E430G puntmutatie) 
in de Fc-staart van het IgG1 antilichaam gebracht wat ervoor zorgt dat antilichamen 
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nadat ze aan het antigeen binden clusteren in groepjes van zes (hexameren). Door deze 
hexamerisatie kan het zeskoppige eiwit C1q, dat de complement reactie opstart, efficiënt 
binden en wordt complement-gemedieerde celdood (CDC) geïnduceerd. 
In dit proefschrift:
Preklinische evaluatie van antilichamen ontwikkeld met de DuoBody en Hexabody 
technologie voor de behandeling van B-cel maligniteiten
In dit proefschrift hebben we in een preklinische evaluatie het potentieel onderzocht 
van verschillende antilichamen die zijn ontwikkeld met de DuoBody en HexaBody 
technologie voor de behandeling van verschillende B-cel maligniteiten. We testen 
zoveel mogelijk op materiaal (lymfeklier, bloed en beenmerg) afkomstig van patiënten 
om de stap naar klinische toepassing te verkleinen. We onderzoeken de effectiviteit en 
werkingsmechanismen van de antilichamen en de mogelijke resistentie mechanismen 
van de tumorcel. Met het oog op de klinische toepassing van de antilichamen proberen 
we biomarkers te identificeren, die kunnen voorspellen welke patiënten (groepen) zullen 
reageren op therapie, en zoeken we naar mogelijke combinatie therapieën. 
In hoofdstuk 2 hebben gekeken naar de mogelijkheid om CD3-positieve T-cellen, 
een cytotoxische lymfocytenpopulatie, bij de CD20-positieve tumorcellen (subtype 
DLBCL, FL en MCL) te brengen met epcoritamab (DuoBody-CD3xCD20, GEN3013), een 
nieuw bispecifiek IgG1 antilichaam ontwikkeld met de DuoBody technologie. We laten 
zien dat dit bispecifieke antilichaam tumordood kan induceren in verschillende B-NHL 
subtypes (DLBCL, FL en MCL), zelfs als de samples afkomstig zijn van patiënten die recent 
andere CD20-targeting therapieën hebben gehad. We constateren ook dat T-cellen 
afkomstig van de patiënten even capabel zijn als T-cellen van een gezonde donor om 
epcoritamab-gemedieerde celdood te induceren. Verder ontdekken we dat tumorcellen 
die het molecuul herpesvirus-ingangsmediator (HVEM) hoog tot expressie brengen, een 
significant lagere T-cel activatie hebben. 
In hoofdstuk 3 introduceren we de E430G HexaBody-mutaties in antilichamen 
tegen CD20 en tegen CD37, een antigeen dat net zoals CD20 voornamelijk op volwassen 
B-cellen tot expressie komt. De hexameriserende CD20 en CD37-targeting antilichamen 
induceren sterke celdood via CDC in B-NHL en CLL cellijnen of patiënten samples, zelfs 
in het geval van CD37-targeting antilichamen die zonder HexaBody-mutatie helemaal 
geen complement activeren. Als we de CD20- en CD37-targeting HexaBodies combineren 
zien we dat de antilichamen colokaliseren op het celoppervlak en vermoedelijk 
heterohexameren vormen, waardoor ze synergistisch (versterkend) CDC induceren. 
In hoofdstuk 4 gaan we dieper in op de mogelijkheden van CD37-targeting 
HexaBodies. In deel I testten we verschillende CD37 antilichaam varianten met de E430G 
mutatie. We zien dat de CDC effecten worden vergroot wanneer we twee CD37-targeting 
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HexaBodies combineren die twee niet-overlappende epitopen (bindingsplekken) op 
het CD37 antigeen targeten. Gebaseerd op deze bevinding combineren we de DuoBody 
en HexaBody technologieën om een nieuw antilichaam te ontwikkelen: DuoHexabody-
CD37, een biparatopic (dubbel-epitoop-targeting) bispecifiek hexamerisatie-verhogend 
IgG1 antilichaam. In deel 2 onderzoeken we de effectiviteit van DuoHexaBody-CD37 op 
samples van patiënten met CLL en B-NHL. We demonstreren een hoge CDC inductie in 
alle verschillende subtypes en in samples van zowel onbehandelde patiënten als patiënten 
met een recidief of refractair ziektebeeld. Zelfs als tumorcellen een hoge expressie 
hebben van complement-remmende eiwitten induceert DuoHexaBody-CD37 een hoge 
mate van celdood. In navolging van de synergie tussen CD20- en CD37- antilichamen die 
we in hoofdstuk 2 observeren zien we ook dat DuoHexaBody-CD37 gecombineerd kan 
worden met rituximab om de CDC te verhogen. 
In hoofdstuk 5 gebruiken we de HexaBody technologie niet voor complement 
activatie, maar om via de antilichaam clustering ook receptor clustering te induceren. 
Death receptor 5 (DR5) reguleert celdood (apoptose) en wordt geactiveerd wanneer 
de receptoren op het celoppervlak clusteren. We introduceren de E430G HexaBody-
mutaties in twee DR5-targeting IgG1 antilichamen, die we in combinatie HexaBody-DR5/
DR5 noemen, om apoptose in MM cellen te induceren. Onze preklinische evaluatie toont 
een goede effectiviteit van HexaBody-DR5/DR5 vooral in samples van MM patiënten met 
een recidief of refractair ziekteverloop die recente behandeling hebben gehad, zelfs 
patiënten die refractair zijn tegen daratumumab. Belangrijk voor klinische toepassing is 
de bevinding dat HexaBody-DR5/DR5 goed gecombineerd kan worden met proteasoom 
remmers en immunomodulatoire drugs, twee klasse geneesmiddelen die worden gebruikt 
bij MM. Dit is waarschijnlijk te verklaren door de verschillende werkingsmechanismen van 
HexaBody-DR5/DR5: HexaBody-DR5/DR5 kan zowel direct apoptose van de cel induceren 
als indirecte celdood via ADCC. 
C O N C L U S I E
In dit proefschrift hebben we het potentieel laten zien van DuoBody-CD3xCD20, 
DuoHexaBody-CD37 en HexaBody-DR5/DR5 voor de behandeling van B-cel maligniteiten. 
In hoofdstuk 6 worden de belangrijkst resultaten van dit proefschrift bediscussieerd. 
Met onze uitgebreide preklinische analyse hopen we een klinische toepassing van deze 
antilichamen te realiseren.  
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DA N K WO O R D
Een cliché maar waar: een PhD periode is een achtbaan van emoties. Het is een tijd van 
vele pieken maar ook dalen, die elkaar vaak razendsnel afwisselen. Ik heb ervan genoten, 
soms een beetje van gebaald, maar bovenal veel kennis en vriendschappen op gedaan. Er 
zijn enkele mensen die ik persoonlijk wil bedanken. 
Als eerst mijn promotoren en copromotoren. Tuna, jij was de afgelopen jaren mijn mentor. 
Je hebt mij begeleid en opgeleid. Met jouw kritische blik en creatieve geest leerde je mij 
hoe ik mijn naïeve en wilde onderzoeksplannen om kan zetten tot gestructureerde en 
haalbare projecten. Ik zal je adviezen nog lang bij me dragen. Ik vind het bijzonder dat ik 
ondanks je drukke agenda altijd bij je kon aankloppen als ik advies nodig had, maar ook 
als ik even wat stoom af moest blazen of gewoon even wilde kletsen. Sonja, jij weet altijd 
op bewonderingswaardige wijze de kritische met de vrolijke noot te combineren. Bij onze 
meeting, die iets minder frequent plaatsvond dan de werkbespreking, overlaadde ik je 
soms met data. Jij was hierdoor nooit uit het veld geslagen, sterker nog; je kwam altijd 
met nieuwe inzichten en invalshoeken. Martine en Inger, copromotoren; jullie klinische 
input tijdens de werkbesprekingen was van onschatbare waarde waar ik jullie nooit eerder 
voor heb bedankt. Martine, jij bracht balans in onze werkbesprekingen. Als we tijdens 
discussies afdwaalden van de hoofdzaken bracht jij ons daar weer naar terug. Inger, je 
raakte pas later als copromotor betrokken maar dat was nergens aan te merken, je was 
direct overal van op de hoogte en wist precies wat er nog moest gebeuren. 
Iedereen bij Genmab met wie ik de afgelopen jaren zo’n fijne samenwerking heb gehad. 
Frank, jouw enthousiasme voor het onderzoek, antilichamen en het complement 
systeem zorgde ervoor dat ik uiteindelijk deze promotie ben gaan doen. Esther (Breij), jij 
hebt een alles overziende blik waar ik jaloers op ben; met een scala aan projecten onder 
jouw hoede kun je alsnog bij elk project binnen 2 seconden de diepte induiken. Ida, 
Kristin, Marije, Simone, bedankt voor jullie enthousiasme en jullie onvermoeibaarheid 
met betrekking tot het kritisch nalopen van alle experimenten en manuscripten. Simone, 
ik kan niet wachten om ook jouw boekje te zien! 
Henk, jij was betrokken bij het begin van de promotie en bij het opzetten van alle plannen. 
Jouw rust, betrokkenheid en kennis zorgden voor een heel fijne start van mijn promotie. 
Anne en Margot, mijn twee paranimfen met wie ik een groot deel van mijn PhD heb 
doorgebracht. Anne, toen je solliciteerde als analist voor deze projecten zei ik direct: haar 
moeten we hebben. Ik vond het fijn om met je samen te werken en ben ervan overtuigd 
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dat iedereen die ooit met jou heeft gewerkt hetzelfde vindt. Je bent scherp, nauwkeurig, 
slim, weet met een vage omschrijving van mij precies wat te doen en hebt enorm veel 
experimenten uitgevoerd. Ik hoop dat jij je ook trots voelt op dit boekje! Margot, in mijn 
eerste jaar vonden wij elkaar tijdens een congres op de dansvloer en sindsdien is onze 
vriendschap een feit. We hebben de afgelopen jaren zoveel gedaan en besproken – soms 
belden we elkaar ’s avonds op omdat we na een werkdag samen nog niet uitgepraat 
waren – dat het voelt alsof ik je al langer ken. Ik ben blij dat ik jullie beide aan mijn zijde 
heb tijdens mijn promotie!
Anneke en Vera, allebei een extra steun in het lab. Anneke, we hebben maar kort 
samengewerkt maar ik was onder de indruk van jouw zelfstandigheid en creativiteit in het 
lab, zelfs in een voor jou heftige periode. Vera, als student heb je bergen met werk verzet 
voor het epcoritamab-project. Die bergen ben je blijven verzetten, maar nu voor je eigen 
promotie. Je bent gedisciplineerd en gedreven (en grappig); het spreekwoord ‘waar een 
wil is, is een weg’ is jou op het lijf geschreven. 
Alle analisten, post docs, PIs en het secretariaat van de hematologie afdeling. Velen 
hebben direct of indirect bijgedragen aan dit proefschrift. Het liefst zou ik iedereen 
persoonlijk noemen, maar ik zal ongetwijfeld iemand vergeten dus ik hoop dat iedereen 
zich aangesproken voelt als ik zeg: bedankt! Een aantal analisten wil ik specifiek bedanken 
omdat zij de pech hadden dat ik ze standaard benaderde als ik een vraag had en niet wist 
waar of bij wie ik precies moest zijn: Renée, Fedor, Adri, Sander en Floortje. Daarnaast wil 
ik ook iedereen bedanken die aandachtig heeft geluisterd of kritische vragen heeft gesteld 
tijdens mijn presentaties. Onderzoek is geen onderzoek zonder hoor en wederhoor. 
Naast de kritische blik van mijn eigen promotieteam kwamen er bij de lymfoïde research 
bespreking altijd interessante vragen van oa Richard, Maria, Henk-Jan, Tamás en Niels. 
Bedankt dat jullie altijd meedenken!  
Iedereen die heeft meegewerkt aan het verzamelen en verwerken van alle patiënten 
samples, zonder jullie zijn dit soort studies niet mogelijk. Voor het verzamelen van 
de lymfeklieren wil ik pathologie bedanken. Marit en Daphne, fijn dat we onze krachten 
van pathologie en hematologie konden bundelen voor het epcoritamab project. Saskia, 
bedankt voor de samenwerking voor het DuoHexaBody-CD37 stuk. 
Mijn collega AIO’s, met wie ik al die jaren lief en leed heb gedeeld. Alle oud-PhD-
studenten die voor mij al het CCA hebben verlaten; Rocco, Jakub, Anna, Nathalie, Han, 
Kris, Inge, Ittai, maar vooral Esther (Drent), de senior AIO die deze toen-nog-junior 
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overal op sleeptouw nam en mij zelfs wakker belde voor een vlucht uit de (reële) angst dat 
ik me zou verslapen. Ik mis je gezelligheid! 
Diana, Lisa, Margot en Noortje, de door onszelf benoemde ‘supportgroep’ waarbij 
de groepsactiviteiten vooral bestonden uit wandelen en wijn drinken; ik vond het zo fijn 
om met jullie het grootste gedeelte van mijn PhD door te brengen! Carolien en David, 
jullie zijn een geestig duo, ik hoop dat we onze spelletjesavonden nog lang voort zullen 
zetten. Afroditi, I love your caring and crazy personality. Your wedding was definitely 
one of the highlights of my PhD. Alexandros, second ball is for you! Can’t wait to be 
with you on the dancefloor again. Jiaxian, I was always amazed by your ability to explain 
the most difficult things with such ease. If you ever consider teaching then I want to 
join your class! Christie, jouw optimisme en relativerend vermogen maakte een niet zo 
geslaagde werkweek altijd weer wat beter. Wassilis, met zoveel oog voor detail moet er 
wel een mooi boekje komen! Lok Lam, voor een beetje positiviteit kan iedereen altijd bij 
jou terecht. Luca, Margot R, Charlotte, Jesse, George, heel veel succes met het vervolg 
van jullie PhD’s! 
Mijn lieve vrienden (van Woerden, de studie/Utrecht, reizen en iedereen daartussenin); 
jullie kregen misschien niet altijd mee waar ik nu precies mee bezig was, wat vooral te 
wijten is aan het gebrek aan uitleg van mijn kant, maar als ik het nodig had was er altijd 
een luisterend oor of waren er bemoedigende woorden. Bovenal zorgden jullie voor de 
broodnodige ontspanning, bedankt daarvoor! Sommigen kreeg ik zelfs zo ver om de 
werk borrels in de Blauwe Engel of andere kroegen te komen vergezellen. 
Lieve (schoon)familie, wat ben ik blij met jullie allemaal om me heen! Lieve pap en mam, 
bedankt voor de sterke basis, het fijne nest en de onvoorwaardelijke steun. Linda en 
Sylvia, lieve zussen, wij zijn zo verschillend van karakter maar juist daarom heb ik veel van 
jullie geleerd!  
Lieve Jort, de eerste keer dat mijn oog op je viel was toen jij op ons AIO-weekend, na 
je mislukte fjeljerep poging, helemaal besmeurd onder de modder het Friese beekje uit 
kwam strompelen. Ik ben gevallen voor (of ondanks?) je flauwe grapjes en gevatheid maar 
vooral op je open en eerlijke manier van denken. Het was fijn om altijd te met jou kunnen 
sparren over ons onderzoek; er zijn best wat onrealistische plannen van mij gesneuveld 
door jouw kritische blik. Een serieuze relatie die is begonnen in de Blauwe Engel, wie had 
dat ooit verwacht? Ik kan niet wachten om samen meer van de wereld te ontdekken! 

